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 Solid tumors exist as heterogeneous populations comprised not only of malignant cells, 
but various other cell types, including cells that make up the vasculature, that can strongly 
influence tumorgenicity.  Many forms of solid cancers are highly vascularized due to 
dysregulated angiogenesis.  The tumor vasculature is classified by leaky, chaotic blood vessels 
consisting of several components including vascular endothelial cells and pericytes, as well 
vascular progenitors, resulting in vascular permeability and high interstitial pressure.  As a result, 
the tumor vasculature limits the access of immune effector cells to the tumor, and may in part be 
responsible for the modest success observed in many current anti-cancer immunotherapies.  
Current first-line therapeutics in the advanced stage disease setting include anti-angiogenic small 
molecule drugs that have yielded high objective clinical response rates, however these responses 
tend to be transient in nature, with most patients becoming drug-refractory.   Anti-tumor 
vasculature vaccines may promote the reconditioning of the tumor microenvironment by 
coordinately promoting a pro-inflammatory environment and the specific immune targeting of 
tumor-associated stromal cell populations that contribute to vasculature destabilization.  
Implementing a vaccine with these therapeutic effects is a promising treatment option that may 
extend disease-free intervals and overall patient survival.  I show that vaccines specifically 
targeting tumor vasculature populations can “normalize” the tumor microenvironment, as shown 
by upregulation of proinflammatory molecules within the tumor as well as vascular remodeling 
promoting enhanced recruitment of CD8
+
 T cells, resulting in superior anti-tumor efficacy.  
Engaging the Immune Response to Normalize the Tumor Microenvironment 
Nina Chi Sabins, Ph.D. 
University of Pittsburgh, 2013
 
 v 
TABLE OF CONTENTS 
1.0 INTRODUCTION ........................................................................................................ 1 
1.1 IMMUNE TARGETING OF RCC .................................................................... 2 
1.1.1 Cellular vaccines for RCC .............................................................................. 2 
1.1.2 Genetic vaccines for RCC ............................................................................... 4 
1.1.3 Clinical responses to current vaccine treatment for RCC ........................... 5 
1.1.4 Immune responses to current vaccine treatment for RCC. ......................... 7 
1.2 THE TUMOR MICROENVIRONMENT ........................................................ 8 
1.2.1 Adaptive T cell response against tumor ........................................................ 8 
1.2.2 Immune dysfunction within the tumor microenvironment ......................... 9 
1.2.3 Angiogenesis and the vasculature ................................................................ 11 
1.2.4 Abnormalities of the tumor vasculature ...................................................... 13 
1.2.5 Hypoxia in the tumor microenvironment .................................................... 14 
1.3 TARGETING THE TUMOR STROMA ......................................................... 16 
1.3.1 Small molecule drugs targeting angiogenesis and the vasculature ........... 16 
1.3.2 Vaccines targeting tumor stromal antigens................................................. 18 
1.4 NOTCH ............................................................................................................... 21 
1.4.1 Delta-like homolog 1 (DLK1)........................................................................ 21 
1.4.2 Notch signaling ............................................................................................... 22 
 vi 
1.4.3 Notch inhibition ............................................................................................. 25 
1.5 STATEMENT OF THE PROBLEM ............................................................... 27 
2.0 INTRATUMORAL IL-12 GENE THERAPY RESULTS IN CROSSPRIMING 
OF TC1 CELLS REACTIVE AGAINST TUMOR-ASSOCIATED STROMAL 
ANTIGENS .................................................................................................................................. 28 
2.1 ABSTRACT........................................................................................................ 29 
2.2 INTRODUCTION ............................................................................................. 30 
2.3 MATERIALS AND METHODS ...................................................................... 32 
2.3.1 Mice ................................................................................................................. 32 
2.3.2 Cell lines and culture ..................................................................................... 32 
2.3.3 Reverse transcriptase-PCR ........................................................................... 33 
2.3.4 Fluorescence imaging of tumor sections ...................................................... 33 
2.3.5 Synthetic peptides .......................................................................................... 34 
2.3.6 Generation of HHD bone marrow-derived DCs and DC.IL12 ................. 35 
2.3.7 Intratumoral (i.t.) DC.IL12 therapy ............................................................ 36 
2.3.8 Evaluation of murine CD8+ T cell responses in vitro .................................. 37 
2.3.9 In vitro assessment of human CD8+ T cells responses against TASA- or 
TAA-derived peptides ................................................................................................ 38 
2.3.10 Statistical analysis ......................................................................................... 39 
2.4 RESULTS ........................................................................................................... 39 
2.4.1 Analysis of TASA expression in the TME. .................................................. 39 
2.4.2 Selection of TASA peptides for immunologic analyses .............................. 43 
 vii 
2.4.3 Delivery of DC.IL12 into HLA-A2neg B16 tumors promotes the cross-
priming of CD8
+
 T cells reactive against tumor pericytes, VEC and an array of 
TASA-derived peptide epitopes in HHD mice ......................................................... 43 
2.4.4 CD8+ T cells from HLA-A2+ normal donors or HLA-A2+ melanoma 
patients recognize TASA-derived peptides in vitro ................................................. 48 
2.5 DISCUSSION ..................................................................................................... 51 
3.0 VACCINES TARGETING TUMOR BLOOD VESSEL ANTIGENS PROMOTE  
CD8
+ 
T CELL-DEPENDENT TUMOR ERADICATION OR DORMANCY IN  HLA-A2 
TRANSGENIC MICE ................................................................................................................ 56 
3.1 ABSTRACT........................................................................................................ 57 
3.2 INTRODUCTION ............................................................................................. 58 
3.3 MATERIALS AND METHODS ...................................................................... 59 
3.3.1 Mice ................................................................................................................. 59 
3.3.2 Cell lines.......................................................................................................... 59 
3.3.3 Peptides ........................................................................................................... 60 
3.3.4 Production of murine bone marrow-derived DC and DC.IL12 ................ 60 
3.3.5 Vaccine experiments ...................................................................................... 60 
3.3.6 Evaluation of specific CD8+ T cell responses in HHD mice ....................... 61 
3.3.7 Reverse transcriptase-PCR ........................................................................... 62 
3.3.8 Fluorescence imaging of tumor sections ...................................................... 62 
3.3.9 Cutaneous wound healing assays ................................................................. 62 
3.3.10 Statistical analysis ......................................................................................... 62 
3.4 RESULTS ........................................................................................................... 63 
 viii 
3.4.1 Vaccines incorporating peptide epitopes derived from TASA are 
immunogenic and protect HHD mice against HLA-A2
neg
 MC38 tumor challenge
 63 
3.4.2 Protective vaccines incorporating TASA peptides promote enhanced 
infiltration of the TME by CD8
+
 T cells in association with an inhibition of tumor 
vascularity ................................................................................................................... 65 
3.4.3 Therapeutic vaccines incorporating TASA-derived peptide epitopes are 
effective against established HLA-A2
neg
 MC38 colon carcinomas and HLA-
A2
neg
 B16 melanomas in HHD mice ......................................................................... 67 
3.4.4 HHD mice cured of B16 tumors by TASA peptide-based therapeutic 
vaccines exhibit extended survival and durable Tc1 responses against tumor-
associated pericytes and/or VEC and spreading in anti-TASA CD8
+ T cell 
repertoire .................................................................................................................... 69 
3.4.5 HHD mice cured of B16 tumors by TASA peptide-based therapeutic 
vaccines either exhibit true “molecular cures” or a state of CD8+ T cell-mediated 
tumor dormancy ......................................................................................................... 71 
3.5 DISCUSSION ..................................................................................................... 72 
4.0 DLK1: A NOVEL TARGET FOR IMMUNOTHERAPEUTIC REMODELING 
OF THE TUMOR BLOOD VASCULATURE ........................................................................ 76 
4.1 ABSTRACT........................................................................................................ 77 
4.2 INTRODUCTION ............................................................................................. 78 
4.3 MATERIALS AND METHODS ...................................................................... 80 
4.3.1 Mice ................................................................................................................. 80 
 ix 
4.3.2 Tumor cells ..................................................................................................... 80 
4.3.3 Stromal cell isolation ..................................................................................... 80 
4.3.4 Real-time PCR ............................................................................................... 81 
4.3.5 In vitro generation of bone marrow-derived dendritic cells (DC) and 
DC.IL12 ....................................................................................................................... 81 
4.3.6 Synthetic peptides .......................................................................................... 81 
4.3.7 Recombinant lentiviral vector production .................................................. 82 
4.3.8 Animal therapy experiments ........................................................................ 83 
4.3.9 Evaluation of specific CD8
+
 T cell responses in vitro ................................. 83 
4.3.10 Fluorescent imaging of tumors .................................................................... 84 
4.3.11 Hemoglobin quantitation ............................................................................. 85 
4.3.12 Measurement of tumor hypoxia using pimonidazole ................................ 85 
4.3.13 RNA purification and Real-Time PCR array ............................................ 86 
4.3.14 Statistical analysis ......................................................................................... 86 
4.4 RESULTS ........................................................................................................... 87 
4.4.1 RCC-associated pericytes differentially express the DLK1 antigen ......... 87 
4.4.2 Treatment of RENCA tumor-bearing mice with a DLK1 peptide-based 
vaccine is therapeutic and associated with specific Type-1 CD8
+
 T cell (Tc1) 
activation and recruitment into the TME ................................................................ 89 
4.4.3 Vaccination with a recombinant lentivirus encoding murine DLK1 cDNA 
is therapeutic in the RENCA model of RCC ........................................................... 91 
4.4.4 Vaccination with lvDLK1 normalizes the RENCA vasculature ............... 93 
 x 
4.4.5 Therapeutic vaccination with lvDLK1 results in reduced hypoxia and a 
lower incidence of cell populations expressing hypoxia-responsive markers in the 
TME 97 
4.4.6 Loss of DLK1 expression in the TME after therapeutic vaccination with 
lvDLK1 leads to increased locoregional activation of Notch. ................................ 99 
4.5 DISCUSSION ................................................................................................... 101 
5.0 GENERAL DISCUSSION ...................................................................................... 105 
6.0 APPENDIX ............................................................................................................... 117 
7.0 BIBLIOGRAPHY .................................................................................................... 132 
 xi 
 LIST OF TABLES 
 
Table 1. TASA-derived peptides evaluated in this study: Summary of in vitro results. .............. 35 
Table 2. Cells expressing TASA in the TME. .............................................................................. 42 
Table 3. Normal donor and melanoma patient demographics and responsiveness to TASA. ...... 50 
Appendix Table 1. RT-PCR primers used in this study.............................................................. 117 
Appendix Table 2. In vivo immunogenicity and anti-tumor efficacy of TASA-based vaccines in 
HHD models. .............................................................................................................................. 121 
 xii 
LIST OF FIGURES 
 
Figure 1. Trial outcomes based on the clinical and immunologic endpoints.................................. 6 
Figure 2. Notch signaling and its antagonism. .............................................................................. 23 
Figure 3. Expression of TASA in the established B16 TME. ....................................................... 41 
Figure 4. Induction of CD8
+
 T cells reactive against TASA after intratumoral delivery of 
DC.IL12. ....................................................................................................................................... 45 
Figure 5. CD8
+
 TIL from DC.IL12-treated mice are enriched in effector cells reactive against 
tumor pericytes and/or VEC, as well as TASA peptides. ............................................................. 47 
Figure 6. In vitro immunogenicity of TASA-derived peptides in HLA-A2
+
 normal donors and 
patients with melanoma. ............................................................................................................... 49 
Figure 7. Splenic CD8
+
 T cells from HHD mice effectively treated with DC.IL12 gene therapy 
develop HLA-A2-restricted responses against melanoma-associated antigens. ........................... 52 
Figure 8. Induction of specific/protective CD8
+
T cells reactive against TASA as a consequence 
of DC/peptide-based vaccination. ................................................................................................. 64 
Figure 9. MC38 tumors in mice prevaccinated with TASA-derived peptides exhibit differential 
infiltration by CD8
+
 T cells and alterations in vascular density. .................................................. 66 
 xiii 
Figure 10. DC.IL12 vaccines containing TASA-derived peptides are therapeutic against MC38 
colon carcinomas and B16 melanomas in HHD mice: requirement for CD8
+
 T cells and HLA-
A2
+
 host (stromal) cells. ............................................................................................................... 68 
Figure 11. HHD mice cured of B16 melanoma by treatment with DC.IL12/peptide vaccination 
exhibit polyspecific anti-TASA Tc1 responses. ........................................................................... 70 
Figure 12. In vivo depletion of CD8
+
, but not CD4+, T cells from a cohort of HHD mice 
effectively treated with TASA peptide-based vaccines results in recurrence of disease at the site 
of primary tumor inoculation. ....................................................................................................... 72 
Figure 13. DLK1 is differentially expressed by RENCA tumor-associated pericytes. ................ 88 
Figure 14. DC/DLK1 peptide-based vaccines are both immunogenic and therapeutic in the 
murine RENCA model of RCC. ................................................................................................... 90 
Figure 15. Recombinant lvDLK1-based vaccines are therapeutic and promote a Type-1-polarized 
TME. ............................................................................................................................................. 92 
Figure 16. Recombinant lvDLK1-based vaccines promote normalization of the tumor 
vasculature. ................................................................................................................................... 94 
Figure 17. Recombinant lvDLK1-based vaccination reduces tumor vascular permeability 
resulting in the development of apoptotic “dead zones” in the TME distal to residual blood 
vessels. .......................................................................................................................................... 96 
Figure 18. Recombinant lvDLK1-based vaccines promote normoxia in the TME in association 
with the loss of cells bearing stem cell-like phenotypes. .............................................................. 98 
Figure 19. Treatment with lvDLK1 vaccines results in Notch activation in the TME which is 
partially responsible for the anti-tumor effectiveness of this treatment strategy. ....................... 100 
 xiv 
Appendix Figure 1. Synthetic peptides are competent to bind and stabilize HLA-A2 complexes 
by T2 cells. .................................................................................................................................. 118 
Appendix Figure 2. Splenic CD8
+
 T cells isolated from the untreated and DC.ψ5-treated animals 
failed to recognize HLA-A2
+
 pericytes and VEC flow sorted from single-cell digests of B16 
tumors (versus DC.IL12 treatment). ........................................................................................... 119 
Appendix Figure 3. CD8
+
 TIL isolated from untreated or DC.ψ5-treated melanoma had 
decreased recognition of tumor-associated pericytes (versus DC.IL12 treatment). ................... 120 
Appendix Figure 4. Expression of TASA in the established MC38 TME. ................................ 122 
Appendix Figure 5. Correlation of biologic parameters assessed in the MC38 tumor model 
system. ........................................................................................................................................ 123 
Appendix Figure 6. Mice protected against initial MC38 tumor challenge as a consequence of 
TASA-based prophylactic vaccination display durable immunity against a subsequent challenge 
with both MC38 sarcoma and B16 melanoma cells. .................................................................. 124 
Appendix Figure 7. Production of recombinant lvDLK1 and control lvNEG lentiviruses. ....... 125 
Appendix Figure 8. DLK1 is differentially expressed by human RCC-associated pericytes. .... 126 
Appendix Figure 9. Expression of subset of TASA in RENCA tumor pericytes. ...................... 127 
Appendix Figure 10. RGS5 expression in RENCA tumor pericytes. ......................................... 127 
Appendix Figure 11. DC/RGS5 peptide-based vaccine does not impact tumor growth in the 
murine RENCA model of RCC. ................................................................................................. 128 
Appendix Figure 12. Live lentivirus encoding human RGS5 delayed tumor growth in murine 
RENCA tumor model with increased expression of Type 1 proinflammatory genes in the TME.
..................................................................................................................................................... 129 
 xv 
Appendix Figure 13. Vaccination of RENCA tumor-bearing mice with lvRGS5 does not induce 
RGS5-specific T cell responses. ................................................................................................. 130 
Appendix Figure 14. Vaccination of RENCA tumor-bearing mice with lvRGS5 does not confer 
additional therapeutic benefit compared to vaccination with lentivirus encoding irrelevant 
antigen ovalbumin. ...................................................................................................................... 131 
 xvi 
PREFACE 
I must first thank my advisor, Dr. Walter Storkus, for accepting me into his lab and providing me 
knowledge, insight, guidance, and support in all aspects of my life for the past five years.  I want 
to specifically thank Walt for continuing to believe in me when my experiments weren’t 
working, for staying positive throughout my paper submission process, and for encouraging and 
supporting me in my career choices as a scientist.  I would like to thank my Thesis Committee 
for their feedback on my project because it truly helped shape my paper into what it is today.  I 
would also like to thank my friends in the Storkus lab for making the lab such an enjoyable 
place. 
I want to acknowledge my father who defeated Hodkins Lymphoma more than twenty years ago, 
and to my mother who lost her battle to non-small cell lung adenocarcinoma twelve years ago.  
They have been my inspiration in entering the field of cancer research so that one day no one has 
to lose this battle. 
And lastly I want to thank my husband, Erik, who encouraged me to pursue a Ph.D., who moved 
with me to build a life in Pittsburgh, who supported me through all the ups and downs of 
graduate school, and who gave me the greatest treasure of my life, my daughter CeCe.  
To you all, I dedicate this dissertation. 
 
 1 
1.0  INTRODUCTION 
Functional immunity protects the body from a broad span of dangers through different 
processes, from destroying external pathogenic microbes to controlled killing of abnormal cells 
arising from genetic mutation.  Countless studies have been performed showing the adaptive 
response as the dominant mechanism in the rejection of tumors, particularly the activation of 
CD4
+
 helper T cells, CD8
+
 cytotoxic T cells, and antibodies (Ab), thus prompting extensive 
efforts in the development of immunotherapies that can activate T cells against cancers (1).  The 
first cancer antigen (Ag) discovered to be recognized by T cells was MAGE1 found to be 
expressed in melanoma over two decades ago (2).  Since then many more markers have been 
identified to be expressed on solid tumors of various tissue origin that are recognizable by the 
immune system (3).   
While the findings in this thesis are applicable to all forms of vascularized solid cancer, 
we adopted renal cell carcinoma (RCC) as our model due to its intrinsic immunogenic nature (4).  
RCC accounts for approximately 3% of all cancers in adults, with metastases identified in 20-
30% of patients at the time of initial diagnosis.  Metastatic RCC, if left untreated, has a 5-year 
disease-free survival rate of only 2-11% (5).  Following nephrectomy, conventional treatments 
with standard chemotherapeutic agents, hormones, and radiotherapy have exhibited minimal 
success. This has prompted extensive evaluation of alternate treatment strategies, including 
immunotherapies, in advanced stage disease settings.   
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1.1 IMMUNE TARGETING OF RCC 
Although administration of high-dose interleukin-2 (IL-2) has yielded durable complete 
responses in a small minority of treated patients with metastatic RCC, severe toxicities have also 
been observed with this approach (5), suggesting the need to identify more specific and focused 
immunotherapy approaches.   
1.1.1 Cellular vaccines for RCC 
Reports have shown that Type-2 T cell responses (typically characterized by IL-4 and IL-
5 production and associated with humoral immunity and allergic reactivity) may be repolarized 
towards Type-1 [i.e., producing interferon-γ (IFN-γ) and capable of mediating the cytotoxic 
death of tumor cells] immunity in vitro by stimulation with antigen-pulsed dendritic cells (DC) 
that were pre-conditioned with pro-inflammatory cytokines, toll-receptor ligands (TLR), and 
other costimulatory adjuvants (6-8).  In humans, Type-1 effector T cells have exhibited extended 
survival, function and conversion into the memory cells when provided signals from CD16
+
 
monocyte-derived DC (9).  Furthermore, Type-1 polarized DC appear superior to alternate 
antigen presenting cell (APC) types in their capacity to activate and drive naïve T cell 
differentiation into Type-1 CD4
+
 and CD8
+
 T effector cells in vitro and in vivo (8, 10, 11).  
While much of this data has been developed clinically in the context of cell (i.e., DC)-based 
therapeutics, it would also be predicted that cell-free vaccine formulations including the 
appropriate tumor antigens and conditioning adjuvants would activate APC in situ with similar 
Type-1-polarizing potential (12-14). 
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Several vaccine formats have been designed to promote specific adaptive immunity 
against RCC.  One format of vaccine is the RCC cells themselves (either autologous or allogenic 
cells that express unique and shared tumor-associated antigenic proteins).  The first attempt was 
made over twenty years ago when one group trialed autologous RCC tumor cells using C. 
parvum as adjuvant (15).  Later, other investigators modified the autologous tumor cell vaccine 
by using granulocyte macrophage-colony stimulating factor (GM-CSF) or other inflammatory 
cytokines as adjuvant (16).  Soon thereafter, others used genetically modified patient tumor cells 
that expressed inflammatory cytokines including GM-CSF, IFN-γ, and IL-2 (17).  Another tumor 
vaccine formulation is represented by RCC-APC fusion hybrids, which generate APC that are 
capable of expressing RCC gene products and presenting their derivative peptide epitopes to T 
cells.  Using serial electrical pulses, autologous RCC tumor cells could be fused to DC from 
normal donors (18).  Another approach involves RCC-derived total mRNA or cDNA (encoding 
the complete repertoire of RCC-associated antigens).  While most published work using these 
vaccines has been limited to preclinical models (19, 20), there has been one clinical report using 
autologous DC transfected with total RCC RNA (21).    
More recently, several labs have been moving towards a more specified vaccine format 
using peptides, protein, mRNA or cDNA derived from or encoding one or more molecularly-
defined RCC-associated antigens (RCCAA).  In one trial, RCC patients were vaccinated with 
autologous DC loaded with carbonic anhydrase-IX (CA-IX) peptides, and while the treatment 
was well tolerated, patients did not show CA-IX specific immunity and there was no observable 
clinical response (22).  In another RCC trial, however, where patients received MUC1 pulsed-
DC, several patients exhibited MUC1-specific T cell reactivity along with objective responses 
(23).  Just last year, it was reported that patients receiving a vaccine consisting of multiple 
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RCCAA peptides, administered intradermally with GM-CSF, exhibited immune responses to 
multiple RCCAA with decreased regulatory T cells, correlating with improved disease control 
and overall survival (24).  These mixed results indicate the therapeutic potential of DC-peptide 
based vaccines in RCC, but also highlights the need for fine-tuning of antigen selection and 
vaccine formulation.  In general, vaccines based on specific RCCAA or their derivative peptides 
that can be presented on major histocompatibility complexes (MHC) have lagged behind due to 
the comparatively recent molecular identification of these antigens.   
1.1.2 Genetic vaccines for RCC 
An alternative approach to cellular-based vaccines is in situ genetic vaccination using 
recombinant viral-based deliver systems.  Various reports have shown virus-based vaccinations 
possess therapeutic advantages over protein antigen/adjuvant-based approaches (25, 26), 
presumably due to the intrinsic pro-inflammatory properties of viruses (i.e., via activation of 
TLR expressed by APC) and their ability to infect professional APC, allowing for ectopic 
expression of the vaccine antigen within patient dendritic cells (27-29).  Additionally, high-titer 
recombinant viruses are easy to produce and when compared to cell-based therapies that require 
costly time-consuming methods due to their patient-specific nature, viral vectors can be 
administered to any given patient as an “off-the-shelf” treatment modality.  Thus, despite minor 
concerns for replication-competent contaminant virus or for insertional mutagenesis in the case 
of retroviruses (30), genetic vaccines remain attractive treatment options in the cancer setting.   
The recombinant modified vaccinia virus Ankara (MVA) encoding RCC antigen 5T4, 
(TroVax®) has been tested in several clinical trials.  Initial trials in RCC patients showed some 
objective clinical responses after administration of the TroVax® vaccine (31, 32), however in 
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phase III trials employing TroVax® with or without cytokines (IFN-α and IL-2) in combination 
with the approved first-line treatment tyrosine kinase inhibitor, sunitinib, no significant 
difference in survival between the experimental and control groups could be demonstrated (33).  
A second MVA vaccine was developed containing the recombinant MUC1 and IL-2 transgenes, 
administered with or without cytokines. Although some RCC patients exhibited anti-MUC1 T 
cell responses, treatment with this vaccine formulation did not result in objective clinical 
responses based on RECIST criteria (34). 
It is important to note there are non-viral molecular vaccines under development for 
RCC.  One such approach a direct intradermal injection of multi-antigen mRNA-based vaccine 
encoding MUC1, CEA, Her-2/neu, telomerase, survivin, and MAGE-A1 has been evaluated in a 
phase I/II clinical trial involving 30 RCC patients. The reported results were promising, with 
some vaccinated patients exhibiting stable disease and coordinately increased tumor antigen-
specific T cell responses (35). 
1.1.3 Clinical responses to current vaccine treatment for RCC 
Despite recent discussions that immunotherapies should not be evaluated based on the 
“acute” RECIST criteria defined for chemotherapeutic agents because immunotherapies may 
depend on the gradual build up of adaptive immunity over a protracted period of time (36, 37), 
virtually all reported RCC vaccine trials currently still do so.  Therefore, I have depicted 
objective clinical response frequencies based on partial responses (PR), complete responses (CR) 
or stabilization of disease (SD) per RECIST criteria as reported by the primary investigators 
(Figure 1).  The consensus of such information suggests that current RCC vaccines are generally 
safe and well-tolerated (38), but are curative in only a very minor subset of treated patients.  
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While partial responses increase somewhat after vaccine treatment, the major benefit of these 
cancer vaccines is reflected in the many patients that exhibit stable disease, translating into 
increased progression-free and overall survival when compared to control groups (38-41).  
Notably, each of the various vaccine formulation categories listed yielded similar clinical impact 
based on RECIST criteria (Figure. 1) with roughly 50% of treated patients exhibiting stable 
disease, 20% showing partial response and <20% developing complete responses.  
 
Figure 1. Trial outcomes based on the clinical and immunologic endpoints.   
Objective clinical response frequencies based on partial responses (PR), complete responses 
(CR) or stabilization of disease (SD) per RECIST criteria and patient tumor-specific T cell 
responses in vitro (TRIV) and delayed-type hypersensitivity (DTH) responses to vaccine 
components in vivo as reported by the primary investigators. 
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1.1.4 Immune responses to current vaccine treatment for RCC.  
Since these represent immunotherapies rather than chemo- or radiotherapies, 
immunologic endpoint analyses are critical in determining the biologic efficacy of these 
approaches and how such strategies may be improved based on our current understanding of 
RCC immunobiology.  In this regard, the diverse array of RCC vaccine trials performed over the 
past 15 years has implemented a number of immune assessment assays to determine specific 
immune response to active vaccination; including analyses of patient tumor-specific T cell 
responses in vitro (TRIV) and delayed-type hypersensitivity (DTH) responses to vaccine 
components in vivo.  Assays for TRIV have dramatically evolved over the past decade, with 
established proliferation (i.e., 
3
H-thymidine incorporation) and cytokine (i.e., ELISA) assays 
now being supplemented by additional methods capable of discerning the frequency and/or 
functionality of clonal T cell responses [i.e., cytokine ELISPOT assays, intracellular staining of 
T cells for cytokines (predominantly IFN-γ) production and reactivity of T cells with 
fluorescently-labeled, recombinant MHC-tumor peptide multimers]. The merits and perceived 
weaknesses of these various methods have been well discussed in the past (42-44).   
In Figure 1, I include a sampling of the reported clinical trial data that supports the 
capacity of RCC vaccines to promote an increase in RCC-specific T cell responsiveness.  
Although the frequency of immunologically-responsive patients was highly variable within a 
given treatment format, in many cases the majority of treated patients exhibited detectable 
increases in TRIV at some point post-vaccination.  Similarly, DTH analyses suggest that RCC 
vaccines have been generally competent to promote tissue inflammation at sites of vaccination 
(mediated by Type-1 T cells).  Unfortunately, detectable TRIV and DTH as determined by 
current methods, even at high percentages, do not appear to directly correlate with clinical 
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outcome (Figure 1), implying that other factors within the TME may inhibit vaccine efficacy 
and that tumor cells (and their associated antigens) may not serve as the most effective targets for 
immunotherapy, thus reinforcing the need for improved treatments against RCC.       
1.2 THE TUMOR MICROENVIRONMENT 
Within the tumor microenvironment (TME) is a heterogeneous population of various cell 
types that are distinct from the tumor cells themselves.  Among the non-tumor (i.e., stromal) 
cells of the TME are fibroblasts, mesenchymal stem cells (or cancer stem cells), vascular cells, 
such as neutrophils, myeloid-derived suppressor cells, mast cells, and lymphocytes (45). These 
cells serve various functions that could be either pro- or anti-tumor, depending on signals that are 
systemic or within the TME. 
1.2.1 Adaptive T cell response against tumor 
To activate potent anti-tumor immunity, APC, particularly DC, are required to undergo 
several processes.  Dendritic cells are a professional type of APC specialized in the detection of 
tissue damage, pathogen entry, and inflammation (46), and the first step involves their capture 
and processing of tumor protein antigens.  DC can acquire antigens by various endocytic routes 
such as phagocytosis, macro/micro-pinocytosis, and receptor-mediated endocytosis (e.g., Ab-Ag 
complexes via Fc receptors or C-type lectins.)  These antigens are then processed through the 
MHC class II pathway for presentation to CD4
+
 T cells, or translocated to the cytosol to enter the 
MHC class I pathway for “cross-presentation” to CD8+ T cells (47).  Immature DC present the 
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antigenic peptides, and are activated by pro-inflammatory cytokines, such as IFN- and TNF-, 
to express costimulatory molecules, such as CD80/86, as well as increased expression of MHC 
on their surface.  The next step is for tumor-specific naïve T cells to differentiate into effector T 
cells.  This event occurs as a result of the combination of signaling from T cell receptor (TCR) 
binding to the antigen peptide-loaded MHC on the DC and the binding of costimulatory 
molecules expressed by the T cells and the DC, such as CD28 and CD80/86, respectively.  
Activated cytotoxic T lymphocytes (CTL) will then recognize cells expressing the specific 
antigens to which they were primed against and induce target cell lysis.  However, despite the 
comprehensive list of tumor-associated antigens found to be immunogenic, solid tumors continue 
to progress and metastasize in generally immune-competent individuals (Figure 1) (48).  Tumor 
cells possess the ability to adapt and evade the immune response by down-regulating MHC 
molecules on their surface, abrogating the ability for T cell recognition and inducing T cell 
anergy.  Additionally, solid tumors can secrete immunosuppressive factors [i.e., tumor growth 
factor-β (TGF-β), IL-10] into their local environment or systemically that can thwart the immune 
response.  
1.2.2 Immune dysfunction within the tumor microenvironment 
Optimism for the use of biologic response modifiers and vaccines has been buoyed by 
past findings suggesting that RCC progression/regression may be regulated by immunologic 
mechanisms (49).  Patients with RCC exhibited a low but significant incidence of spontaneous 
regression (50), and patients under chronic immunosuppression regimens to retain kidney 
allografts displayed an increased risk of developing RCC (51). The degree of tumor infiltration 
by lymphocytes has been used as a prognostic indicator for patient survival (52).  In particular, T 
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cells with a Type-1 polarization profile and high proliferative potential (53), have proven to 
represent primary immunologic mediators of objective clinical responses.  
However, patients with RCC are frequently characterized with a state of “immune 
dysfunction” (53-56), where Type-1 responses directed against RCCAA are muted in 
comparison to Type-2 and/or T-regulatory (Treg) responses, which favor humoral responses in 
nature (57-60).  Furthermore, when they can be identified, Type-1 anti-RCCAA T cells may be 
pro-apoptotic given a chronic state of stimulation with specific tumor antigens in the cancer-
bearing patient (61, 62).       
Additional factors in solid tumors can lead to impaired effector T cell and DC function, 
including hypoxia (63). Upregulated hypoxia inducible factor (HIF) expression leads to 
increased vascular endothelial growth factor (VEGF) expression, which can generate 
regulatory/tolerogenic DC and/or attenuate DC differentiation.  VEGF can also increase STAT3 
activation via VEGF receptor-2 (VEGFR2)-mediated signaling, thus promoting the intrinsic 
expression of immunosuppressive factors including IL-10 and TGF-β in these regulatory DC 
(64).  In many cancer patients, Type-1 pro-inflammatory responses required for tumor 
destruction are inhibited or functionally dysregulated by the suppressive influence of Treg or 
myeloid-derived suppressor cells (MDSC) with or without the addition of Type-2 inflammatory 
molecules (59-62).    
It has recently been shown that tumors can inhibit the Notch pathway in T cells through 
reductions of Delta like ligand (DLL)-1 and -4 expression, thereby suppressing their function and 
allowing for tumor immune escape (65).  Additionally, reduced Notch activation within the TME 
has been reported to promote accumulation of IL-10 producing M2 macrophages in tumors and 
reducing the number of IL-12 producing M1 anti-tumor macrophages (66, 67).  Such immune-
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evasion tactics assumed by the tumor serve to limit the protective host immunological responses 
and allow for tumor survival and progression.  In addition, the destabilized vasculature in 
progressively growing tumors can further abrogate effective immune responses by preventing 
circulating Type-1 anti-tumor T effector cells to traffic efficiently to sites of tumor (68).  These 
limitations observed in anti-tumor immunotherapy alert the need for alternative approaches 
towards solid cancer treatments, including targeting of the vasculature within the tumor 
microenvironment. 
1.2.3 Angiogenesis and the vasculature 
The cancerous features of tumor cells cannot manifest without the important interplay 
between cancer cells and their environment.  Various cell populations reside within the TME 
including the cancer cells themselves and self-renewing cancer stem cells (CSC), as well as cells 
the make up the vasculature (i.e., VEC and pericytes).  Blood vessels in the TME support cancer 
progression by: i.) delivering oxygen and nutrients, ii.) providing a conduit by which primary 
tumors can metastasize, iii.) recruiting/supporting cancer stem cells and vascular cell precursors 
that promote tumor neovascularization, and iv.) recruiting immune regulatory cell populations 
(i.e., Treg, MDSC, M2 macrophages).  Solid tumors of various tissue types, including renal, 
ovarian, and lung, are typically highly-vascularized, with dysregulated angiogenesis resulting 
from excessive growth-promoting signals and a lack of sufficient cues to spatially and 
temporally coordinate vessel growth, remodeling, maturation, and stabilization.  Under 
physiological conditions, angiogenesis is a vital process that supplies normal organs and tissue 
with oxygen and nutrients while disposing of catabolic products (69).  Multiple steps are 
necessary for functional angiogenesis, the first being the partial degradation of the extracellular 
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matrix (ECM) and opening and migration of existing capillaries, allowing for migration of 
endothelial cells towards avascular areas.  VEC are guided by VEGFA, which is induced by 
hypoxia, via their expression of VEGFR2 on their cell surface (70).  A VEGFA gradient 
promotes the infiltration of a subset of VEC, tip cells, toward the avascular, hypoxic region, with 
high VEGFA concentrations inducing stalk cell proliferation to form a new vessel sprout (71).  
These tip cells become proteolytic in function and begin breaking down the vascular basement 
membrane with matrix metalloproteinases (MMP), triggering a series of signaling cascades that 
result in cytoskeleton reorganization and sprouting morphogenesis of VEC.  VEGF also induces 
expression of Notch ligand DLL4 along Notch1 and Notch4 receptors.  DLL4-Notch interactions 
limit excess angiogenesis and promote the orderly development of new blood vessels (72).  This 
resolution step turns off VEC proliferation and signals the recruitment of pericytes and vascular 
smooth muscle cells, which provide stabilization and maturation to the vessel (73).  Pericytes 
originate from arterioles and possibly from bone marrow-derived progenitors and are primarily 
recruited by platelet-derived growth factor (PDGF) that is secreted by endothelial cells, via 
expression of PDGF receptor  (PDGFR).  Pericytes also express angiopoetin-1 (Ang-1) on 
their surface, which binds to Tie2 receptors on VEC.  Contact between VEC and pericytes 
switches off the proteolytic activity of the VEC and leads to the tight junctions and adherens 
junctions that seal the vessel.  Pericytes can also inhibit endothelial cell division via TGF- 
activation (74).  As new capillaries mature, pruning of excess or unnecessary vessels promote 
optimal perfusion.  There is controversy regarding the role of pericytes in tumor vasculature, 
with some reports suggesting preventing pericyte recruitment through PDGFR inhibition may 
have anti-tumor benefits, while other studies have shown that decreased pericyte coverage leads 
to increased metastases (75, 76).  In addition, pericytes are believed to possess pluripotent 
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characteristics of stem cells with the ability to differentiate into various cell types (77, 78).  
These confounding findings emphasize the need for better understanding of the role pericytes 
play is vessel homeostasis and maturation within the TME. 
1.2.4 Abnormalities of the tumor vasculature 
Under normal physiological conditions, the cellular processes that occur during 
angiogenesis are turned off once vascular perfusion is achieved.  However, during tumor 
pathogenesis, the angiogenic cascade of events persists and fails to resolve in a controlled 
manner.  The vasculature in the TME is typically characterized as “abnormal,” here defined as 
tortuous, irregular networks of blood vessels with highly unstable and permeable capillaries 
branching from the main vessel bed.  Instability in the tumor vasculature increases interstitial 
pressure within the tumor, preventing the delivery of tumoricidal drugs and immune effector 
cells into the TME (73, 79).  Many cancers have increased VEGF expression due to various 
environmental cues (i.e., hypoxia, gain of oncogene and/or loss of tumor suppressor function), 
which contribute to the abnormal vasculature observed in solid tumors.  Inhibition of the Ang-
Tie2 interaction between VEC and pericytes has also shown to be a factor contributing to tumor 
angiogenesis (80).  It has been reported that tumor VEC may have genetic abnormalities, 
including aneuploidy, multiple chromosomes and multiple centrosomes (69) leading to irregular 
phenotypes.  These abnormal VEC within the tumor exhibit differential gene expression when 
compared to VEC isolated from healthy tissue, with such transcripts believed to underlie tumor 
blood vessel destabilization.  Silencing these genes using siRNA approaches has been shown to 
block VEC migration and vascular tube formation (81), thus supporting tumor VEC as a highly 
relevant therapeutic target.  Another characteristic of the tumor vasculature is the aberrant 
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pericyte coverage of the blood vessels.  Tumor pericytes are typically immature and loosely 
attached to the capillary, and may even be absent in some areas, leading to vessel destabilization 
(73, 82).  Regulator of G protein-5 (RGS5) has been found to be highly upregulated in PDGFRβ+ 
pericytes isolated from murine tumors (83). These pericytes exhibited an immature phenotype 
and were associated with highly angiogenic vasculature.  RGS5 is transiently expressed 
throughout development, with one of the earliest reports showing RGS5 expression restricted to 
pericytes in mouse embryos (84).  More recently, RGS5 has been found to play a key role in 
vascular maturation and vessel remodeling during tumorigenesis.  In a study where RGS5-
deficient mice were intercrossed with a mouse model for spontaneous insulinoma, tumors 
lacking RGS5 exhibited dramatically altered vessels that appeared more regular and 
homogeneous, with significantly reduced leakiness and hypoxia, similar to vasculature seen in 
normal healthy tissue.  These vascular changes were associated with an increased infiltration of 
adoptively-transferred tumor-specific T cells into the TME, with coordinate prolonged survival 
of treated animals.  On the other hand, the vasculature observed in RGS5-competent insulinomas 
displayed the hallmark characteristics of tumor angiogenesis, as depicted by a disorganized 
network of tortuous and leaky vessels with poor oxygen perfusion (68).   
1.2.5 Hypoxia in the tumor microenvironment 
Hypoxia is associated with various physiological processes, including cell survival and 
proliferation, tissue vasculogenesis and angiogenesis, all of which are necessary for normal 
functions such as wound healing (85).  However, in cancer, these hypoxic events lead to tumor 
development and progression.  Clinically, hypoxia has been shown to cause resistance to 
radiotherapy and chemotherapy, leading to increased risk of tumor recurrence and metastases, 
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with poor patient outcome and lower overall survival (86).  Inadequate blood supply due to 
dysfunctional vessel formation is the major contributor to hypoxia in the TME.  The rapid 
expansion of tumor cells can surpass the rate of angiogenesis leaving large regions within the 
TME without access to oxygen (87).  Given other genetic modifications resulting in adaptation, 
tumor cells have superior survival compared to normal cells in such hostile, hypoxic 
environments, favoring tumor progression.  This adaptation is largely controlled by the 
transcriptional changes in the genome, of which it is estimated that up to 1.5% is responsive to 
hypoxia, with hypoxia-induced factors (HIFs) playing a critical role in transcriptional regulation 
(87).  In addition to hypoxia, aberrations in other pathways can pathologically upregulate HIF1 
(69).  For example, mutations in the tumor suppressor gene Von Hipple Lindau (VHL) is known 
to increase the expression and activity of HIF1, particularly in renal cell carcinoma, by 
preventing its normal process of polyubiquitylation and proteosomal degradation of the HIF1 
protein (88). 
In recent years, there has been increasing evidence of hypoxia playing a role in the 
development and maintenance of cancer stem cells (CSC) and epithelial-to-mesenchymal 
transition (EMT) (86).  CSC are a population of cells within the tumor with the ability of self-
renewal with high resistance to many forms of anti-cancer therapies (89), providing one 
explanation as to why tumor regression may not correlate with patient outcome/survival.  It has 
been shown that under hypoxic conditions, CSC have increased capacity to retain an 
undifferentiated state (90).  Indeed, several reports have shown that upregulation of HIF1 and 
HIF2 promotes expression of HIF-target gene CD133, a CSC marker (86).  EMT was originally 
described in embryonic development when epithelial cells with a cobblestone phenotype become 
mesenchymal cells with a spindle-shaped fibroblast-like morphology (91).  More recently, EMT 
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has been implicated in cancer cell invasion and migration, and promoting CSC phenotype and 
function, leading to chemo- and radiotherapy resistance.  Several studies have demonstrated that 
epithelial cells, when grown under hypoxic conditions, evolve to a more mesenchymal 
phenotype, leading to increased tumor aggressiveness (86).  While the crosstalk between the HIF 
and EMT signaling pathways is not fully understood, it has been proposed that HIFs can 
upregulate EMT-associated transcription factors (63) as well as play a role in certain EMT-
associated signaling pathways such as TGF-, Notch, NF-B, Wnt/-catenin, and Hedgehog (86, 
92).   
1.3 TARGETING THE TUMOR STROMA  
1.3.1 Small molecule drugs targeting angiogenesis and the vasculature 
Over a decade ago, Judah Folkman presented the novel idea of angiogenesis as a 
therapeutic target in cancer (93).  His theory spurred the development of several anti-angiogenic 
therapies including monoclonal antibodies reactive against angiogenic growth factors (and their 
cognate receptors) and small molecule inhibitors of pro-angiogenic receptor tyrosine kinases 
(RTK). Later it was suggested that normalization of the tumor vasculature could be achieved via 
administration of anti-angiogenic agents and that this would actually be a desirable therapeutic 
outcome in cancer therapy (94, 95) as this approach would coordinately allow for the improved 
delivery of co-applied chemotherapeutic agents into the TME.  
The humanized monoclonal antibody bevacizumab (Avastin) been shown to induce a 
transient normalization of the tumor vasculature in treated patients, which when coupled with 
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chemotherapy, promoted enhanced anti-tumor effects (96).  Targeting soluble VEGF increases 
the preponderance of PDGF in the TME, thus inducing pericyte recruitment and activation and 
capillary stabilization (97).  Huang et al. recently reported that at low doses of anti-VEGFR2 
antibody, the tumor vasculature became normalized in mice.  Furthermore, this treatment 
reprogrammed the TME to be more proinflammatory and receptive to T effector cell infiltration 
(98). Alternatively, pharmacological agents targeting VEGF receptors (i.e., VEGFR1-3), as well 
as other pro-angiogenic RTK (i.e., PDGFR), can also inhibit dysregulated angiogenesis leading 
to a temporary normalization of the vasculature. 
Due to the highly-vascularized nature of RCC, several clinical trials have utilized 
tyrosine kinase inhibitors (TKI) that antagonize angiogenesis as a means to treat this disease. 
One such inhibitor is sunitinib malate (Sutent) (99), which has exhibited pronounced (albeit 
temporary) efficacy in phase I/II clinical trials and is approved as a first-line treatment for 
patients with RCC (100-103).  However, a phase III trial showed that while progression-free 
survival early on was higher in patients receiving sunitinib (11 months) compared to interferon 
treatment (5 months), the overall survival benefit associated with this approach was not 
dramatically different between the two groups (26.4 months versus 21.8 months) (100).  Direct 
anti-tumor effects have not been determined for sunitinib, as no somatic mutations in RTK have 
been identified in human RCC (103) and in vitro studies have shown that mechanism of action of 
sunitinib involves the induction of an apoptotic death for tumor-associated endothelial cells 
rather than human RCC cells themselves.  
Although sunitinib was initially developed as an angiostatic agent, recent reports suggest 
that this TKI actually “normalizes” the tumor vasculature, similar as observed with bevacizumab 
(104), by selective pruning of immature and fragile vessels, leaving the more differentiated 
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vessels intact with mature pericyte coverage.  This normalization event leads to a decrease in 
interstitial pressure and improved delivery of chemotherapeutic drugs and effector T cells into 
the TME (105).  Corresponding results from a study by Ganss et al. show that inflammation of 
the TME induced by local radiotherapy, in conjunction with adoptive transfer of tumor-specific 
cells, can induce microvasculature remodeling towards a phenotype resembling normal tissue 
(106).  The normalized endothelium exhibited increased expression of Type 1 chemokines 
CXCL9 and CXCL10 as well as their cognate receptor CXCR3. CXCL10 is an endogenous 
angiogenic inhibitor that acts as a chemoattractant for Type-1 T cells and has been shown to 
induce apoptosis in human CXCR3b
+
 endothelial cells but not tumor cells (107). 
Additionally, patients treated with sunitinib exhibit reductions in MDSC and Treg 
populations with normalized Type-1 T cell responses in vitro (101, 102, 108, 109).  Murine 
tumor models suggest that sunitinib suppresses STAT3 activation and boosts the efficacy of 
immunotherapy by promoting tumor-specific effector T cells while also suppressing MDSC and 
Treg in vivo (102, 108, 110). Sunitinib treatment has been shown to skew expression of 
chemokines and their receptors towards a Type 1 profile (111) as well as increased expression of 
VCAM1 and CXCL9 (MIG) with increased IFN- producing T cells within the TME and tumor 
draining lymph node implying this TKI may represent a potent immune adjuvant.  We anticipate 
that a similar and potentially more durable impact of vascular normalization might result from 
the specific immune targeting of tumor-associated blood vessels and their cell sub-populations.   
1.3.2 Vaccines targeting tumor stromal antigens 
Genetic aberrations can potentially develop within the evolving and heterogeneous RCC 
lesion over many months to years under immune selective pressure (112).  As previously 
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mentioned, vaccines based on whole tumor cells, tumor-APC hybrids, tumor-derived mRNA or 
cDNA, and/or tumor antigens derived from mutated or overexpressed proteins have thus far 
underperformed as therapeutic agents (Figure 1).  These vaccine formulations may merely 
reinforce an existing, yet failing, immune repertoire given the immune dominance of certain 
tumor antigens over others and to immune evasion paradigms assumed by the heterogeneous 
TME. Competition between multiple peptide epitopes for loading on to MHC molecules 
expressed by APCs in vivo could also limit effective immune activation against a broad range of 
otherwise therapeutic tumor antigen targets.  
Recently, several groups (113, 114) have shown that while treatment with anti-
angiogenic agents may lead to the transient normalization of the tumor vasculature and to at least 
a temporary delay in tumor progression, ultimately, upon treatment cessation, the tumors recur 
and may even exhibit more aggressive behavior with regard to their invasiveness and metastatic 
potential.  Since these drugs only limit angiogenesis (i.e., via RTK signaling antagonism) rather 
than eradicating the vasculature outright, it is likely that tumor-associated vascular cells adapt to 
a state of drug-resistance.  A possible means to circumvent this problem is to specifically induce 
immune-targeting of the tumor stroma providing a durable response capable of preferentially 
eliminating tumor-associated stromal cells, such as fibroblasts and vascular cells, while sparing 
the vasculature in normal, healthy organs in the patient.  Indeed, multiple reports have already 
shown that vaccination with endothelial cells could effectively limit tumor growth in vivo (115, 
116).  There has been further evidence of therapeutic benefit with immune targeting of 
specifically defined vascular antigens (on VEC and pericytes) as a means to promote anti-tumor 
responses (117).  However, as shown in Figure 1, while the frequency of antigen-specific T cells 
induced by a vaccine may indicate an active immune response, it is rarely indicative of patient 
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outcome.   Indeed, induction of broad immunity to multiple antigens may confer better anti-
tumor efficacy (118).  By focusing Type-1 immune responses in the tumor vascular niche, one 
may also enhance the uptake of tumor antigens and induce epitope spreading within the TME, 
allowing for activation of tumor-specific T cells along with the tumor-associated antigen-specific 
T cells.  Furthermore, this local Type-1 inflammation could activate the TME (i.e., modulating 
the cytokine millieu and activation state and expression of adhesion molecules) leading to the 
enhanced recruitment and functionality of anti-RCCAA T effector cells. 
We, and others, have recently advocated the implementation of vaccines promoting 
specific Type 1 T cell recognition of tumor vascular cell populations (119-121), however these 
vaccine formulations have been cellular-based, utilizing adoptive transfer of DC presenting 
stromal antigen-derived peptides.  Rosenberg’s group has recently shown that T cells engineered 
to express a chimeric antigen receptor specific for VEGFR2, which is overexpressed in the 
vasculature of many solid cancers, including RCC, were able to limit the growth of 5 different 
types of established, vascularized tumors in mice and to coordinately induce VEGFR2-specific 
host T cell responses (122).  This treatment strategy is currently under investigation in Phase I 
trials for RCC as well as melanoma patients.  It has also been shown that treatment with 
fibroblasts genetically altered to express endostatin, another molecule critical for tumor 
angiogenesis, leads to reduced tumor burden with increased infiltration of CD4
+
, CD8
+
, and 
CD49b/VLA-4
+
 lymphocytes in a metastatic RCC mouse model when combined with rIL-2 
administration, indicating an additive immunomodulatory effect of the vaccine (123).    
Current genetic immunization strategies for RCC have been limited to those using 
recombinant vaccinia viruses encoding tumor antigens, which have thus far met with moderate 
clinical success (Figure 1).  This muted efficacy may be, in part, due to the fact that vaccinia the 
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rapid host development of neutralizing antibodies can limit the booster capacity of repeated 
administrations of this vaccine modality (124).  Given the ability of lentivirus to transduce 
endogenous DC in vivo in the absence of evoking neutralizing anti-viral immunity (125), and 
therefore the potential of reiterated dosing, I have developed a lentiviral-based vaccine designed 
to promote specific immune targeting of the tumor vasculature, and more specifically, an antigen 
our group recently discovered to be expressed specifically on tumor pericytes and 
immunologically relevant in multiple tumor models: Delta-like homolog-1 (DLK1). 
1.4 NOTCH 
1.4.1 Delta-like homolog 1 (DLK1) 
DLK1, also known as Pre-adiposite factor 1 (Pref-1) and Fetal Antigen 1 (FA1), is a 50 
kDa membrane-bound protein containing six tandem EGF-like repeats, a tumor necrosis factor- 
converting enzyme (TACE)-mediated cleavage site, a transmembrane domain, and a cytoplasmic 
tail.  ADAM17 is the TACE that cleaves DLK1 to yield the soluble form of DLK1 (126).  While 
the structure DLK1 is similar to the canonical DLL ligands of Notch, it lacks the conserved Delta 
Serrate Lag (DSL) signaling domain, and is therefore considered a competitive inhibitor and 
negative regulator of Notch signaling (127).  DLK1 has been reported to inhibit several Notch-
dependent differentiation pathways including normal adipogenesis, muscular and neuronal 
differentiation, bone differentiation and hematopoiesis.  DLK1 is widely expressed during 
embryonic development, with high amounts found in the placenta, adipose tissue, liver, skeletal 
muscle, and the pituitary and adrenal glands (127).  In adults, expression is restricted to 
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neuroendocrine tissues, such as the pancreas, testes, prostate, and ovaries.  While the expression 
pattern of DLK1 suggests an important role in tissue development and maturation, Dlk-null mice 
show relatively mild phenotype with increased adiposity, and defects in muscle development and 
B-cell differentiation, suggesting the existence of compensatory mechanisms (128-130).   In 
cancer, DLK1 modulation of Notch activation has been reported to either promote or suppress 
tumor development/progression based on dynamic (temporally and spatially) context in which 
Notch signaling is involved (127, 131, 132). 
1.4.2 Notch signaling 
The Delta-Notch signaling pathway has been highly conserved through evolution, 
covering a broad range of developmental processes including cell differentiation and 
proliferation (133).  Mammals possess four Notch receptors  (Notch1-4) with five activating 
canonical ligands (Jagged1, Jagged2, Dll1, Dll3, and Dll4).  These ligands are characterized by 
their DSL domain (a cryptic EGF-like repeat) and specialized tandem EGF repeats.  Upon 
ligand-binding of the Notch receptor, two enzymatic cleavage events occur.  The TACE, 
ADAM10, cleaves the extracellular portion of the receptor while a -secretase cleaves the Notch 
intracellular domain (NICD) that can then translocate to the nucleus.  Within the nucleus the 
NICD displaces co-repressors bound to the DNA-binding transcriptional repressor CBF1, 
converting it into a transcriptional activator, and recruit co-activators (such as MamL1), thus 
inducing transcription of target genes, including the HES family of transcription factors (134).  
Here I provide a simplified schematic of the key players involved in Notch signaling (Figure 2). 
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Figure 2. Notch signaling and its antagonism.  
Canonical Notch signaling with Delta-like ligands (DLL) and Jagged ligands through Notch 
receptors leads to cleavage of Notch intracellular domain (NICD) and its translocation into the 
nucleus where it induces transcription of Notch target genes by displacing co-repressors of 
transcription factor CBF-1.  Notch activation can be pharmacologically inhibited by anti-DLL 
and anti-Notch antibodies as well as α-secretase inhibitors (ASI) and γ-secretase inhibitors (GSI). 
 
Many studies have shown that Notch signaling plays an important role in tumorigenesis 
through its regulation of cell proliferation, survival, and invasion (135).  Indeed, Notch was first 
observed as an oncogene in T cell acute lymphoblastic leukemia (T-ALL) (136), and later found 
to be implicated in several solid tumors including breast cancer, colorectal cancer, non-small cell 
lung carcinoma, and melanoma (132, 137, 138) and as an activator of tumor invasion (139).  
There has also been evidence of Notch involvement with the induction of EMT and CSC 
maintenance and function (140, 141).  Hypoxia has been shown to promote Notch activation in a 
HIF-1-dependent manner, leading to increased cell survival, Notch-induced EMT, CSC 
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maintenance, and tumor cell invasion and migration (86).  More recently, HIF-2 has also been 
found to induce Notch activation in stem cells (142). 
Although Notch activation can promote tumorigenesis, there has been growing evidence 
of a tumor suppressive role as well, particularly in the skin.  Indeed, it has been reported that loss 
of NOTCH1 resulted in spontaneous basal cell carcinoma, increased sensitivity to chemically 
induced skin carcinogenesis, and defects in the integrity of the skin barrier promoting 
tumorigenesis (143, 144).  Recent studies have revealed Notch to also be a tumor suppressor in 
hepatocellular carcinoma, chronic myelomonocytic leukemia, head and neck squamous cell 
carcinoma, gastrointestinal stromal cancer, endometrial cancer, and B cell malignancies (134, 
145-148). 
As mentioned briefly earlier, Notch also plays a crucial role in the regulation of 
angiogenesis.  It has been shown that Notch signaling during normal physiological conditions 
limits excessive angiogenesis as a negative feedback mechanism and to promote the formation of 
an intact, functional, mature vascular network (149).  Inhibition of DLL4 in the tumor 
vasculature results in a significant increase in the number of new vessel sprouts and branches, 
however these vessels are non-functional resulting in a disrupted vasculature.  In certain models, 
DLL4 inhibition led to reduced tumor growth, while other studies observed severe toxicities and 
development of vascular tumors with chronic DLL4 blockade (150, 151), indicating the delicate 
balance of Notch signaling during angiogenesis.   
Given the role Notch plays in such diverse cellular processes during embryonic 
development and in adult tissues, it may be expected that abnormalities in Notch signaling could 
result in such a wide range of pathologies.  Evidence shows that depending on the cellular 
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context, Notch can promote stem cell maintenance or induce terminal differentiation, and that the 
mechanism behind this duality of Notch signaling in cancer requires further investigation.   
1.4.3 Notch inhibition 
As previously discussed, canonical Notch signaling involves an enzymatic cleavage event 
following ligand binding involving -secretase.  Inhibiting this process has been done in clinical 
trials for Alzheimer’s disease and various cancers using small molecule -secretase inhibitors 
(GSI) (152). Aside from the four Notch receptors, GSIs also target the Notch ligands, Jagged and 
Delta-like ligands.  Most GSIs are hydrophobic compounds that are cell-permeable that can act 
as reversible inhibitors of -secretase.  The most commonly used GSI in the laboratory is N-[N-
(3,5-Difluorophenylacetyl-L-alanyl)]-S-phenylglycine t-Butyl ester (DAPT).  Early clinical trials 
have been testing the Merck GSI MK-0752 in patients with T-cell leukemia/lymphoma as well as 
solid cancers including glioma and breast cancer showing moderate success (152).   
While GSI are the only form of Notch inhibitors available in clinical trials, there are other 
types of Notch inhibitors under development. Targeting the -cleavage of the Notch receptor 
using small molecule inhibitors of ADAM10 and ADAM17 has also been shown to effectively 
shut down Notch signaling with the added advantage of not being required to enter the cell (153).   
Another method of blocking Notch activity is the use of antibody inhibitors that can 
physically block the protein-protein interactions between receptor and ligand.  Studies have 
shown that anti-DLL4 antibodies can effectively inhibit Notch signaling resulting in chaotic, 
dysfunctional vasculature (149-151).  There have also been reports describing antibodies to 
specific Notch family members, and even specific functional regions, such as cleavage sites 
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(152), that allow for fine-tuning of Notch inhibition.  These methods of Notch inhibition are 
depicted in Figure 2. 
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1.5 STATEMENT OF THE PROBLEM 
Despite the recent developments in vaccine therapy for RCC, with the vast majority targeting 
antigens expressed on tumor cells, these treatments have yet to show any prolonged clinical 
benefit.  This is not entirely surprising given the ability of cancer cells to constantly adapt and 
evade immune recognition, thus rendering many of these tumor-specific vaccines ineffectual.  
Additionally, the aberrant vasculature of RCC tumors can further inhibit vaccine efficacy by 
limiting the trafficking of immune effector cells as well as promoting an inhospitable TME that 
abrogates effector cell function and favors tumor cell and CSC growth/maintenance.  Current 
strategies to “normalize” the TME, specifically the vasculature, employ pharmacological agents, 
which have been shown to remodel the vasculature; however, these effects are transient at best, 
indicating a need for alternative therapies that could potentially induce a more durable effect. 
The studies in this thesis were designed to assess the efficacy of anti-vascular/stromal targeted 
vaccines in reconditioning the TME.  My findings show that tumor stroma-associated antigens 
can serve as promising targets for immunotherapy, and that by vaccinating against specific tumor 
stromal populations, the TME becomes “normalized” with corollary reduction in tumorigenesis. 
I believe these findings support a general therapeutic paradigm allowing for the immune 
targeting of various tumor stroma targets (i.e., pericytes and VEC) thus rendering this approach 
versatile for the immunotherapy in most solid forms of cancer, including RCC. 
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+
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manuscript. 
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2.1 ABSTRACT 
HLA-A2 transgenic mice bearing established HLA-A2
neg
 B16 melanomas were 
effectively treated by intratumoral (i.t.) injection of syngeneic DC transduced to express high 
levels of IL-12, resulting in CD8
+
 T cell-dependent antitumor protection.  In this model, HLA-
A2-restricted CD8
+
 T cells do not directly recognize tumor cells and therapeutic benefit was 
associated with the crosspriming of HLA-A2-restricted type-1 CD8
+
 T cells reactive against 
antigens expressed by stromal cells (i.e., pericytes and VEC).  IL-12 gene therapy-induced CD8
+
 
T cells that directly recognized HLA-A2
+
 pericytes and VEC flow-sorted from B16 tumors based 
on IFN-γ secretion and translocation of the lytic granule-associated molecule CD107 to the T cell 
surface after coculture with these target cells.  In contrast, these CD8
+
 T effector cells failed to 
recognize pericytes/VEC isolated from the kidneys of tumor-bearing HHD mice.  The tumor-
associated stromal antigen (TASA)-derived peptides studied are evolutionarily conserved and 
could be recognized by CD8
+
 T cells harvested from the blood of HLA-A2
+
 normal donors or 
melanoma patients after in vitro stimulation.  These TASA and their derivative peptides may 
prove useful in vaccine formulations against solid cancers, as well as, in the immune monitoring 
of HLA-A2
+
 cancer patients receiving therapeutic interventions, such as IL-12 gene therapy. 
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2.2 INTRODUCTION 
T cell-mediated antitumor immunity plays a role in regulating tumor growth, placing 
selective pressure on the heterogeneous cancer cell population throughout disease progression 
(154-156).  To date, most tumor-associated antigens (TAAs) recognized by T cells have proven 
to be non-mutated, “self” antigens that may be quantitatively overexpressed by tumor cells of 
one or more histologic types (157).  Clinical trials implementing vaccines and immunotherapies 
targeting such antigens have exhibited success in promoting increased numbers of specific 
CD4
+
 and/or CD8
+
 T cell populations in the peripheral blood of patients, but they have only 
rarely demonstrated therapeutic efficacy in the advanced disease setting based on RECIST 
criteria (Figure 1) (158-160).  Although transient objective clinical responses have been reported 
in some instances, responding patients may relapse with progressor tumors that fail to express 
elements of the MHC antigen-presenting machinery and/or treatment-targeted antigens. 
The modest success of current therapeutic vaccines targeting TAA suggests that alternate 
target antigens might instead be considered for integration into treatment designs in order to 
improve the efficacy of such approaches.  In particular, a selection of antigens that are both 
crucial to tumor growth and survival, but which cannot be readily disposed of in the face of 
immune attack/selection (i.e., the oncogenes HPV-E6/E7 in cervical carcinoma (161), etc.) 
would appear most prudent.  As an alternative to developing immune-based strategies against 
dominant oncogenes, serious consideration should be given to the targeting of antigens that are 
expressed not by tumor cells themselves, but rather by cells comprising the tumor-associated 
stroma (162, 163).  Treatment-induced, immune-mediated disruption of the tumor stroma would 
be expected to inhibit tumor growth and/or promote disease resolution (164). 
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In this context, we investigated whether the crosspriming of CD8
+
 T cells reactive against 
TASA is a general paradigm for effective immunotherapy. We have previously shown that i.t. 
delivery of syngenic DC engineered to secrete interleukin (IL)-12p70 (i.e., DC.IL12) results in 
potent CD8
+
 T cell-mediated immunity against CMS4 sarcomas in Balb/c mice (121).  Protection 
in this model was at least partially due to therapy-induced crosspriming of type-1 CD8
+
 T (i.e., 
Tc1) cells reactive against an H-2L
d
-presented peptide derived from the β-hemoglobin (HBB) 
protein expressed by pericytes and/or VEC within the sarcoma TME (121).  In the current report, 
we now show that delivery of DC.IL12 into B16 (HLA-A2
neg
) melanomas established in HLA-
A2 transgenic (HHD) mice results in the induction of protective HLA-A2-restricted CD8
+
 T cells 
recognizing tumor-associated HLA-A2
+
 pericytes and VEC, as well as an array of HLA-A2-
presented TASA-derived peptide epitopes.  Murine TASA-derived peptide epitopes share 
sequence identity with their human homologues, and human HLA-A2
+
 normal donors and 
melanoma patients displayed anti-TASA CD8
+
 T cell responses after in vitro stimulation (IVS). 
These data support the therapeutic targeting of TASA as a potential means to treat vascularized 
solid tumors that may be refractory to TAA-based therapeutics based on MHC/TAA expression 
heterogeneity and the progressive selection of immune escape variants. 
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2.3 MATERIALS AND METHODS 
2.3.1 Mice 
HHD mice were obtained from Dr François A. Lemonnier through Dr Pravin T.P. 
Kaumaya (The Ohio State University, Columbus, OH). HHD mice do not express H-2
b
 class I 
molecules, with their cells instead expressing an HLA-A*0201-hβ2 microglobulin single-chain 
(HHD) gene product (165).  Ag-specific CD8
+
 T cell responses in HHD mice recapitulate those 
observed in HLA-A2
+
 human donors.  Female 6–8-week-old mice were used in all experiments 
and were handled in accordance with an Institutional Animal Care and Use Committee-approved 
protocol.  HLA-A2 expression on peripheral blood cells isolated from HHD mice via tail 
venipuncture was confirmed by coordinate positive staining as assessed by flow cytometry using 
two monoclonal antibodies (mAbs) MA2.1 (reactive against HLA-A2 and HLA-B17) and BB7.2 
(reactive against HLA-A2 and HLA-Aw69) (both mAbs from the American Type Culture 
Collection, Manassas, VA). 
2.3.2 Cell lines and culture 
B16 is an HLA-A2
neg
, mMART-1
+
, mgp100
+
 melanoma cell line (syngenic to the H-
2
b
 background of HHD mice) and has been described previously (166).  The T2 cell line is an 
HLA-A2
+
, TAP-deficient human T-cell/B-cell hybridoma (57).  Cell lines were free of 
mycoplasma contamination and were maintained in CM [RPMI 1640 supplemented with 10% 
heat-inactivated fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin, and 10 mmol/l 
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-glutamine (all reagents from Life Technologies, Grand Island, NY)] in a humidified incubator at 
5% CO2 and 37 °C. 
2.3.3 Reverse transcriptase-PCR 
Reverse transcriptase – PCR was performed using the following primer pairs (Appendix 
Table 1). Cycling times and temperatures were as follows: initial denaturation at 94 °C for 2 
minutes (1 cycle), denaturation at 94 °C for 30 seconds, annealing at 60 °C for 30 seconds and 
elongation at 72 °C for 1 minute (30 cycles), final extension at 72 °C for 5 minutes (1 cycle). 
PCR products were identified by image analysis software for gel documentation (LabWorks 4.6 
Software; UVP, Upland, CA) following electrophoresis on 1.2% agarose gels and staining with 
ethidium bromide (Sigma-Aldrich, St Louis, MO). 
2.3.4 Fluorescence imaging of tumor sections 
Tumor tissue samples were prepared and sectioned as previously reported (121).  For 
analysis of T cell subsets, sections were incubated with rabbit anti-mouse NG2 (Millipore, 
Bedford, MA) along with Alexa488-conjugated anti-CD4 or -CD8β antibodies or matching 
isotype controls (all from BD Biosciences, San Jose, CA) for 1 hour. After washing with 0.5% 
bovine serum albumin in phosphate-buffered saline (PBS), sections were stained with donkey 
anti-rabbit Ig Cy5 (Jackson ImmunoResearch, West Grove, PA) secondary pAb for 1 hour at 
room temperature. For analysis of CD31 versus NG2, sections were first incubated with rat anti-
mouse CD31 (BD Biosciences) and rabbit anti-mouse NG2 (Millipore) Abs for 1 hour at room 
temperature and then washed. Sections were then treated with donkey anti-rat Ig Cy3 and donkey 
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anti-rabbit Ig Cy5 (both from Jackson ImmunoResearch) Abs for 1 hour and washed. For the 
analysis of target antigens in B16 tumor lesions, all sections received dilutions of rat anti-mouse 
CD31 (BD Biosciences) and guinea-pig anti-mouse NG2 (kindly provided by Dr. Bill Stallcup, 
The Burnham Institute for Medical Research, La Jolla, CA (167)) Abs. In addition, each slide 
received a pAb reactive against a given TASA: rabbit anti-mouse pAb for DLK1 (R&D Systems, 
Minneapolis, MN), EphA2 (Santa Cruz Biotech., San Diego, CA), PSMA (Thermo Fisher 
Scientific, Rockford, IL), RGS5 (Sigma-Aldrich), VEGFR1 (Thermo Fisher Scientific) or goat 
anti-mouse pAb for HBB (Santa Cruz), NRP1 (R&D Systems), NRP2 (R&D Systems), PDGFRβ 
(R&D Systems), VEGFR2 (Abcam, Cambridge, MA). Sections were then again washed five 
times with 0.5% bovine serum albumin (in PBS), before a 1-hour incubation with dilutions of a 
mixture of secondary antibodies: (i) donkey anti-rat Cy5 pAb, (ii) donkey anti-guinea-pig 
DyLight 488 pAb, and (iii) either donkey anti-rabbit Cy3 pAb or donkey anti-goat Cy3 pAb 
depending on the species of antibody directed against the TASA target (all secondary antibodies 
were purchased from Jackson ImmunoResearch). After secondary Ab staining, sections were 
then washed with three washes of PBS, coverslipped with Gelvatol mounting media (made in-
house) and stored at 4 °C until imaging using an Olympus Fluoview 500 Confocal microscope 
(Olympus America, Center Valley, PA). 
2.3.5 Synthetic peptides 
Peptides (Table 1) were synthesized by 9-fluorenylmethoxycarbonyl (Fmoc) chemistry 
by the University of Pittsburgh Cancer Institute's Peptide Synthesis Facility (a shared resource). 
Peptides were >96% pure based on high-performance liquid chromatography profile and mass 
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spectrometric analysis performed by the University of Pittsburgh Cancer Institute's Protein 
Sequencing Facility (a shared resource). 
 
Table 1. TASA-derived peptides evaluated in this study: Summary of in vitro results.  
CD8
+
 T cell response data is summarized for (i) HHD mice treated with DC.IL12 gene therapy 
(as in Figure 4C) of (ii) HLA-A2
+
 normal human donors and HLA-A2
+
 patients with melanoma 
as displayed pictorially in Figure 6.  Human (ELISA) responses were designated as + if CD8
+
 T 
cell reactivity against T2 cells presenting the indicated peptide (IFN-γ) was >30 pg/ml and more 
than twofold higher than reactivity against T2 cells pulsed with negative control HIV-nef190-198 
peptide (p<0.05).  Peptide sequences were submitted to an online algorithm predicting binding to 
HLA-A2 with the deduced scores provided.  A higher number reflects the prediction of a more 
stable HLA-A2 peptide complex. 
2.3.6 Generation of HHD bone marrow-derived DCs and DC.IL12 
DC were generated from bone marrow precursors isolated from the tibias/femurs of mice 
using in vitro cultures containing 1,000 U/ml recombinant murine granulocyte/macrophage 
colony-stimulating factor and 1,000 U/ml rmIL-4 (both from Peprotech, Rocky Hill, NJ), as 
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previously described (121).  The Ad.mIL-12p70 and Ad.ψ5 (empty) recombinant adenoviral 
vectors were produced and provided by the University of Pittsburgh Cancer Institute's Vector 
Core Facility (a shared resource), as reported previously (121, 168).  Five million (day 5 
cultured) DCs were infected at an multiplicity of infection = 50 with Ad.mIL-12p70 or the 
control, empty vector Ad.ψ5. While control DC produced <62.5 pg IL-12p70/ml/48 
hour/10
6
 cells, DC.IL12 cells produced 1–10 ng IL-12p70/ml/48 hour/106 cells. 
2.3.7 Intratumoral (i.t.) DC.IL12 therapy 
B16 melanoma cells (1 × 10
5
) were injected subcutaneously in the right flank of HHD 
mice and allowed to establish for 7 days. Mice were then randomized into cohorts of five 
animals, with each cohort exhibiting an approximate mean tumor size of 30–50 mm2. On days 7 
and 14, tumor-bearing mice were untreated or treated with i.t. injections of 1 × 10
6
 adenovirus-
infected DCs (DC.ψ5 or DC.IL12) in a total volume of 50 µl PBS. Tumor size was then assessed 
every 3–4 days and recorded in mm2, determined as the product of orthogonal measurements 
taken using vernier calipers. In some experiments, as indicated, in vivo antibody depletions (on 
days 6, 13, and 20 post-tumor injection) of CD4
+
 T cells or CD8
+
 T cells were performed as 
previously described (121).  Data are reported as mean tumor area ± SD. On day 17–19 post-
tumor inoculation, CD8
+
 splenocytes and TIL were magnetic bead cell sorting-isolated from 
three mice/cohort, with cells pooled and assessed for reactivity against peptide epitopes or cell 
targets (pericytes, VEC, tumor cells) as described below. 
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2.3.8 Evaluation of murine CD8+ T cell responses in vitro 
To analyze Ag-specific responses, spleens and TIL were harvested (from two 
mice/group) 3–5 days after the second i.t. injection of control DC or DC.IL12 (i.e., day 17–19 
after tumor inoculation). Splenic lymphocytes were restimulated in vitro for 5 days with 
irradiated (2.5 Gy) naive peptide-pulsed HHD splenocytes at a stimulator:responder cell ratio of 
1:1. Responder CD8
+
 T cells were then isolated using magnetic bead cell sorting (Miltenyi 
Biotec, Auburn, CA) and analyzed for reactivity against unpulsed or peptide-pulsed T2 cells, as 
indicated. To analyze T cell response to stromal cell targets and tumor cells, untreated HHD 
mice bearing established day 17–19 B16 tumors were sacrificed and tumors and kidneys 
removed. Tissues were then minced manually and enzymatically digested as described by 
Crisan et al. (78) using collagenases IA, II, and IV (Sigma-Aldrich) and DNAse I (Sigma-
Aldrich) for 30 minutes at 37 °C, with gentle shaking. Cells were then being passed through a 
70-micron cell strainer (BD Biosciences), washed with PBS, and single-cell suspensions stained 
with anti-mouse CD31 FITC (BD Biosciences), anti-mouse CD140b (PDGFRβ) PE 
(eBioscience, San Jose, CA), and anti-mouse H-2K
b
 APC (BD Biosciences). After washing with 
PBS, cells were sorted into enriched populations containing pericytes (PDGFRβ+CD31negH-
2K
b(neg)
) or VEC (PDGFRβnegCD31+H-2Kb(neg)) using a multicolor fluorescence-activated cell 
sorter (FACSAria; BD Biosciences). In all cases, cells were >95% pure for the stated phenotype. 
CD8
+
 T cells (10
5
) were then co-cultured with 10
4
 pericytes or VEC in U-bottom 96-well plates 
(Sigma-Aldrich). To verify HLA-A2 restricted recognition of target cells by CD8
+
 T cells, 10 µg 
of anti-HLA-A2 mAb BB7.2 or control anti-HLA-class II mAb L243 (both from ATCC) were 
added to replicate coculture wells. Forty-eight hours after initiating splenic CD8
+
 T cell co-
cultures, cell-free supernatants were collected and analyzed for mIFN-γ content using a 
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commercial ELISA (BD Biosciences) with a lower limit of detection of 31.3 pg/ml. Data are 
reported as the mean ± SD of triplicate determinations. Alternatively, freshly sorted CD8
+
 TIL 
were cocultured with pericytes, VEC, T2 cells (±peptides) or B16 tumor cells at a T cell-to-target 
cell ratio of 3:2 for 4–5 hours at 37 °C and analyzed for intracellular levels of IFN-γ or cell-
surface expression of CD107a/b using specific mAbs (APC-labeled anti-mouse CD8α from 
eBioscience; PE-labeled rat anti-mouse IFN-γ and FITC-labeled rat anti-mouse CD107a/b from 
BD Biosciences) and flow cytometry using the manufacturer's suggested protocol and ref. (169), 
respectively. 
2.3.9 In vitro assessment of human CD8+ T cells responses against TASA- or TAA-derived 
peptides 
Peripheral blood mononuclear cells were obtained by venipuncture or leukapheresis from 
HLA-A2
+
 normal donors or HLA-A2
+
 melanoma patients with written consent under 
institutional review board-approved protocols. CD8
+
 T cells were then isolated by magnetic bead 
cell sorting (Miltenyi Biotec) and either not stimulated or stimulated with autologous, TASA 
peptide-pulsed DC as previously described (57).  Normal donor T cells were stimulated with 
TASA peptide-pulsed DC twice on a weekly schedule, with responder T cells harvested for 
analysis of their specificity 5 days after the booster stimulation (i.e., day 12 of T cell-DC 
coculture). Melanoma patient CD8
+
 T cells were analyzed after a single round of stimulation 
with TASA peptide-pulsed, autologous DC (i.e., day 5 of T cell-DC coculture) as indicated in 
text.  For DC-based stimulations, DC were pulsed with an equimolar (1 µmol/l each) pool of the 
TASA peptides (Table 1) for 4 hours at 37 °C at 5% CO2 tension. These antigen-loaded DC 
were then used to stimulate autologous CD8
+
 T cells at a T cell-to-DC ratio of 10:1 to generate a 
 39 
bulk population of responder T cells. T cells were maintained in IMDM media supplemented 
with 10% human AB serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 10 mmol/l -
glutamine and MEM nonessential amino acids (all reagents from Invitrogen, except human AB 
serum that was purchased from Sigma-Aldrich, Carlsbad, CA). Responder CD8
+
 T cells were 
analyzed for reactivity against control (HLA-A2
+
) T2 cells or T2 cells pulsed with individual 
TASA or TAA peptides (1 µmol/l for 4 hours at 37 °C
50
) at a CD8
+
 T cell-to-T2 cell ratio of 5:1 
for 24 hours. Harvested cell-free supernatants were consequently assessed for hIFN-γ content 
using a specific ELISA (BD Biosciences) with a lower detection limit of 4.7 pg/ml. 
 
2.3.10 Statistical analysis 
Student's two-sided t-test and one-way analysis of variance were used to test for overall 
differences between groups (StatMate III; ATMS, Tokyo, Japan), with a P value <0.05 taken as 
significant. 
2.4 RESULTS 
2.4.1 Analysis of TASA expression in the TME. 
We have previously reported that CD8
+
 T cells responses against peptides derived from 
the murine HBB or EphA2 proteins inhibit the establishment and progression of HBB
neg
 or 
EphA2
neg
 tumor cells, respectively, in syngeneic wild-type hosts in vivo (121, 166).  The 
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“antitumor” efficacy of these Tc1 cells appeared to be due to their targeting of HBB+ pericytes 
and/or EphA2
+
 VEC within the TME.  Based on these data, as well as, recent reports by other 
groups (170-173), we hypothesized that TASA might serve as “universal” targets allowing for 
CD8
+
 T cell-mediated restricted growth of solid vascularized tumors.  Among the known TASA 
expressed by pericytes and/or activated VEC (84, 121, 166, 170-178), we selected an initial 
panel of 12 antigens for evaluation in the current studies  (Table 2).  To validate that the chosen 
TASA were indeed expressed in situ by stromal cells in the TME, we performed 
immunohistochemistry analyses using specific pAbs on tissue sections isolated from day 14 
(HLA-A2
neg
) B16 melanomas growing progressively in untreated HLA-A2 Tg (HHD) mice.  
Using immunofluorescence microscopy, we determined coexpression patterns of specific stromal 
target antigens with NG2
+
 pericytes and/or CD31
+
 VEC within the TME. The resulting images 
are depicted in Figure 3A, with a summary of cellular protein expression profiles provided 
in Table 2.  Based on these imaging analyses, we assigned the DLK1, HBB, NG2, PDGFRβ, 
RGS5, and VEGFR2 antigens as predominantly tumor pericyte-associated, and the EphA2 and 
TEM1 antigens as predominantly tumor VEC-associated.  The NRP1, NRP2, PSMA, and 
VEGFR1 antigens appeared to be expressed by multiple cell types including pericytes, VEC, and 
alternate stromal cells and/or tumor cells within the progressive B16 TME. To further 
corroborate TASA expression by NG2
+
 pericytes, CD31
+
 VEC, or H-2K
b+
 tumor cells within the 
TME, these cell populations were flow-sorted from enzymatically digested B16 tumors resected 
from untreated recipient HHD mice.  To gauge potential overexpression of TASA in tumor 
versus normal tissues, pericytes and VEC were also flow-sorted from single-cell digests of 
tumor-uninvolved kidneys harvested from these same animals. Reverse transcriptase (RT)-PCR 
analyses were then performed on cDNA isolated from each of these sorted cell populations. 
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Quality control analyses supported the expression of NG2 transcripts only in pericytes, CD31 
transcripts only in VEC and gp100 transcripts only in B16 cells (Figure 3B).  These analyses 
also support: (i) tumor pericyte expression of all TASA transcripts with the exceptions of EphA2 
and PSMA; (ii) tumor VEC expression of transcripts for DLK1, EphA2, HBB, PSMA, TEM1, 
VEGFR1, and VEGFR2; (iii) B16 expression of transcripts for NRP1, PDGFRβ, VEGFR1, and 
VEGFR2; (iv) higher levels of DLK1, EphA2, HBB, NRP1, NRP2, PDGFRβ, RGS5, TEM1, 
VEGFR1, and VEGFR2 transcript expression in tumor- versus normal kidney-derived stromal 
cells; and (v) comparable or greater levels of NG2, PSMA, and CD31 transcript expression in 
normal kidney- versus tumor-derived stromal cells (Figure 3B). 
 
Figure 3. Expression of TASA in the established B16 TME.  
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(A) B16 melanoma cells were injected s.c. in the right flank of female HHD mice and allowed to 
establish/progress for 14 days at which time tumors were resected and analyzed for expression of 
the indicated antigens using specific Abs and fluorescence microscopy as outlined in Materials 
and Methods section. Specific pAb against NG2 (green), the indicated antigen of interest (red), 
and CD31 (blue) were used to distinguish preferential antigen expression in tumor-associated 
stromal pericytes, VEC, alternate stromal cells and/or tumor cells. (B) B16 melanoma cells, as 
well as, flow-sorted (PDGFRβ+, CD31neg) pericytes and (PDGFRβneg, CD31+) VEC isolated 
from day 19 established B16 tumors and tumor-uninvolved kidneys were analyzed for expression 
of target genes using reverse transcriptase-PCR (RT-PCR) as described in Materials and 
Methods section. All data are reflective of three independent experiments performed for each 
tumor type. 
 
 
 
Table 2. Cells expressing TASA in the TME.  
Progressor B16 tumors (day 14) in untreated HHD mice were resected and analyzed for specific 
TASA expression by fluorescence microsopy, as described in Materials and Methods. Based on 
co-localization of TASA with NG2 and/or CD31 markers in fluorescence microscopy analyses, 
we assigned a pericyte (P) – and/or VEC-association with a given marker, respectively.  In some 
cases, TASA were also expressed by NG2
neg
, CD31
neg
 cells (designated as T/S – tumor/stromal) 
in the TME, which could reflect either tumor cells or alternate stromal cell populations.  Reverse 
transcriptase (RT) – PCR analyses were performed on flow-sorted tumor-derived pericytes and 
VEC and tumor cells as described in Materials and Methods.  Numbers in parentheses reflect the 
fold increase in expression of transcripts in tumor versus normal kidney pericytes or VEC, as 
indicated, after first normalizing densitometry signals against β-actin.  (Hi) indicates the TASA 
transcript is expressed by tumor pericytes/VEC, but not normal kidney pericytes/VEC. 
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2.4.2 Selection of TASA peptides for immunologic analyses 
Of the selected TASA, HLA-A2-presented epitopes recognized by CD8
+
 T cells have 
been previously reported for human EphA2, NG2, PSMA, RGS5, VEGFR1, and VEGFR2 
(Table 1). Notably, these defined human epitopes share 100% sequence identity with their 
murine homologues.  To identify novel HLA-A2-presented epitopes in the alternate six selected 
TASA, a prediction algorithm (http://www.bimas.cit.nih.gov/molbio/hla_bind/) was applied to 
each protein, and nonameric (9-mer) and/or decameric (10-mer) peptides were preferentially 
chosen for synthesis and corollary analyses based on two priority criteria: (i) a high algorithm 
predicted binding score to the HLA-A2.1 class I molecule, and (ii) identity in the human versus 
murine peptide sequences.  This latter restriction was adopted for translational purposes; i.e., to 
insure that specific therapy-induced T cell responses would need to break operational tolerance 
in HLA-A2 Tg recipient mice in order to provide antitumor protection (i.e., as would also need 
to occur for protection in HLA-A2
+
 patients with solid cancers).  After selection, we showed that 
each of the chosen synthetic peptides was competent (to a varying degree) to bind and stabilize 
HLA-A2 complexes expressed by T2 cells (Appendix Figure 1), a prerequisite to their ability to 
be presented to specific, HLA-A2-restricted CD8
+
 T cells. 
2.4.3 Delivery of DC.IL12 into HLA-A2neg B16 tumors promotes the cross-priming of 
CD8
+
 T cells reactive against tumor pericytes, VEC and an array of TASA-derived peptide 
epitopes in HHD mice 
In order to assess the potential in vivo relevance of therapy-induced CD8
+
 T cell 
responses against these TASA in the tumor setting, we strategically built upon our earlier work 
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that identified HBB as tumor pericyte-associated antigen (121).  In that study, i.t. delivery of 
syngenic DC.IL12, but not control DC, was competent to break operational tolerance against 
HBB and to yield protective immunity.  As a consequence, in the current studies, DC.IL12 were 
prepared and injected directly into subcutaneous (HLA-A2
neg
) B16 melanomas growing 
progressively in HLA-A2 Tg HHD mice on days 7 and 14 post-tumor inoculation. On day 19 
post-tumor inoculation, the mice were euthanized and CD8
+
 splenic T cells were analyzed for 
their ability to secrete interferon (IFN)-γ in response to stimulation with TASA-derived peptides 
presented by the HLA-A2
+
 T2 cell line.  I.t. delivery of DC.IL12 resulted in dramatically 
reduced tumor growth (Figure 4A; P < 0.05 versus versus DC.ψ5-treated or untreated controls 
after day 11).  Furthermore, splenic CD8
+
 T cells isolated from the DC.IL12 (but not DC.ψ5)-
treated cohort of animals directly recognized HLA-A2
+
 pericytes and VEC flow sorted from 
single-cell digests of B16 tumors (but not kidneys isolated from these same tumor-bearing 
animals) or HLA-A2
neg
 B16 tumor cells (Figure 4B and C and Appendix Figure 2).  Tc1 
recognition of tumor-derived pericytes and VEC was completely blocked in the presence of the 
anti-HLA-A2 mAb BB7.2 (but not an anti-MHC II mAb L243), supporting the HLA-A2-
restricted nature of T cell reactivity.  Splenic CD8
+
 T cells from DC.IL12- (but not control DC-) 
treated animals also responded against an array of TASA-derived peptides when presented by 
HLA-A2
+
 T2 cells in vitro (Figure 4C).  The ability of these murine (HHD) CD8
+
 T cells to 
recognize TASA-derived peptides in the context of the human T2 cell line suggests these Tc1 
effector cells exhibit moderate-to-high avidity for specific epitopes, since the murine CD8 
coreceptor interacts inefficiently with the human HLA class I α3 domain (179) expressed by T2 
cells.   
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Figure 4. Induction of CD8+ T cells reactive against TASA after intratumoral delivery of 
DC.IL12.  
(A) HLA-A2neg B16 melanoma cells were injected s.c. in the right flank of female HLA-A2 Tg 
(HHD) mice and allowed to establish for 7 days upon which mice were randomized into three 
groups (n = 5 mice each) receiving no treatment (control), i.t. injection of DC.ψ5, or i.t. injection 
of DC.IL12. Animals were retreated using the same therapy on day 14 post-tumor inoculation. In 
replicate cohorts of animals receiving DC.IL12, depleting mAbs against CD4 or CD8 were 
provided as described in Materials and Methods section. Tumor sizes were assessed every 3–4 
days and are reported as mean ± SD in mm2. *P < 0.05 versus control or DC.ψ5-treated mice on 
days ≥14. (B) On day 19 post-tumor inoculation, the mice were euthanized and CD8+ splenocytes 
isolated and cultured with flow-sorted pericytes or VEC as described in Materials and Methods. 
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After coculture ± anti-HLA-A2 mAb BB7.2 or anti-major histocompatibility complex (MHC) 
class II mAb L243, supernatants were analyzed for mIFN-γ content by ELISA. Data are mean ± 
SD for triplicate determinations, and are representative of two independent experiments 
performed. *P < 0.05 versus kidney cells (pericytes or VEC) and tumor pericytes/VEC in the 
presence of anti-HLA-A2 mAb BB7.2. (c) On day 19 post-tumor inoculation, the mice were 
euthanized and splenocytes and stimulated with stromal peptides as outlined in the Materials and 
Methods. On day 5, CD8+ splenocytes were co-cultured with HLA-A2+ T2 cells loaded with the 
indicated TASA-derived peptides or HLA-A2neg B16 tumor cells and analyzed for mIFN-γ 
production by specific ELISA. Data are mean ± SD for triplicate ELISA determinations. *P < 
0.05 versus FluM1 control peptide responses. All presented data are representative of three 
independent experiments performed. 
 
We next analyzed the impact of therapy on the ability of CD8
+
 TIL freshly isolated from 
day 17 tumors to recognize flow-sorted pericytes and VEC, as well as, TASA peptides presented 
by T2 cells.  Using both intracellular IFN-γ staining (Figure 5A) and CD107 translocation 
(Figure 5B) assays, we observed that 3–12% of CD8+ TIL isolated from animals treated with 
DC.IL12 mediated effector Tc1 responses against tumor (but not kidney)-derived pericytes and 
VEC. Similar frequencies of CD8
+
 TIL from the DC.IL12-treated cohort of mice recognized 
TASA peptides presented by T2 cells (Figure 5A and B). The ability of target cells to elicit 
effector responses from CD8
+
 TIL isolated from DC.IL12-treated mice was blocked by anti-
HLA-A2 (but not anti-class II) mAb and these T cells display only background reactivity against 
HLA-A2
neg
 B16 tumor cells (Appendix Figure 3).  In contrast, the frequency of TASA-specific 
CD8
+
 TIL isolated from untreated or DC.ψ5-treated melanoma was lower (versus DC.IL12 
treatment) in all functional analyses performed (Figures 4C, 5A and B, and Appendix Figure 
3). 
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Figure 5. CD8
+
 TIL from DC.IL12-treated mice are enriched in effector cells reactive against 
tumor pericytes and/or VEC, as well as TASA peptides.  
B16 tumor-bearing mice were treated as described in Figure 4. On day 17 post-tumor 
inoculation, CD8
+
 TIL were isolated from all cohorts of mice, and pericytes and VEC were 
isolated from the tumors and kidneys of untreated mice as described in the Materials and 
Methods section. Freshly sorted CD8
+
 TIL were then co-cultured with pericytes, VEC, or T2 
cells ± TASA peptides and analyzed for intracellular expression of (A) IFN-γ or cell-surface 
expression of (B) CD107a/b by flow cytometry. Inset numbers reflect the percentage of CD8
+
 T 
cells expressing intracellular interferon (IFN)-γ or cell surface CD107a/b. Data are from one 
representative experiment of two performed. 
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2.4.4 CD8+ T cells from HLA-A2+ normal donors or HLA-A2+ melanoma patients 
recognize TASA-derived peptides in vitro 
To assess whether the TASA-derived peptides identified in our HHD tumor model were 
also capable of being recognized by human CD8
+
 T cells, we performed IVS using T cells 
isolated from the peripheral blood of HLA-A2
+
 normal donors or HLA-A2
+
 patients with 
melanoma.  DC were pulsed with peptides derived from a given TASA and used as stimulator 
cells for autologous CD8
+
 T cells.  In cases where more than one peptide existed for a given 
protein, we pulsed DC with an equimolar (10 µmol/l) mixture of each peptide.  Based on our past 
experience using IVS protocols to elicit specific T cell responses against TAA (where the 
precursor frequency was far lower in normal donors versus cancer patients (57)), we applied two 
rounds of IVS using TASA for normal donors and a single-round of IVS using TASA for 
melanoma patients.  Using this approach, we observed that HLA-A2
+
 normal donors and 
melanoma patients (Figure 6; Tables 1 and 3) were each capable of recognizing many of the 
TASA-derived peptides. 
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Figure 6. In vitro immunogenicity of TASA-derived peptides in HLA-A2
+
 normal donors and 
patients with melanoma.  
The indicated peptides were pulsed onto autologous DC and used to prime and boost CD8
+
 T 
cells isolated from the peripheral blood of eight normal HLA-A2
+
 donors or ten HLA-
A2
+
 patients with melanoma as described in the Materials and Methods section. Seven days after 
the primary IVS (melanoma patients) or a secondary IVS boost (normal donors), T cells were 
analyzed for their reactivity against HLA-A2
+
 T2 cells pulsed with the relevant peptide versus 
the negative control HIV-nef190–198 peptide and analyzed for levels of secreted IFN-γ by ELISA. 
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Data are reported in Bar and Whisker plots, with P values provided for paired pre- versus post-
IVS data from normal donors and patients. In addition, we noted P < 0.05 for MEL-post versus 
ND-post for the following peptides: DLK1 (309), NG2 (770), NG2 (2238), PDGFRβ (891), and 
RGS5 (5). 
 
 
Table 3. Normal donor and melanoma patient demographics and responsiveness to TASA.  
Abbreviations: AD, active disease; C, chemotherapy; CTLA-4, cytototoxic T-lymphocyte 
antigen-4; DC, dendritic cell; F, female; GM2, ganglioside M2; IFN, interferon-α; IRB, 
institutional review board; IL-2, interleukin-2; KLH, keyhole limpet hemocyanin; M, male; 
MAA, melanoma-associated antigen; NED, no evidence of disease; R, radiotherapy; S, surgery; 
VAC, vaccine.  Peripheral blood was obtained from HLA-A2
+
 normal donors and patients with 
melanoma with consent under IRB-approved protocols. Human responses were designated as + 
if T cell reactivity against T2 cells presenting the indicated peptide (IFN-γ ELISA) was >30 
pg/ml and more than twofold higher than reactivity versus T2 cells pulsed with the negative 
control HIV-nef190–198 peptide (with P < 0.05 versus T2 + HIV-nef190–198). ADeceased at the 
time of this report. 
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2.5 DISCUSSION 
The major finding of this chapter is that protective CD8
+
 T cells induced as a 
consequence of effective i.t. DC.IL12 therapy recognize both tumor-associated stromal cells (i.e., 
flow-sorted pericytes and VEC) and naturally processed and HLA-A2-presented peptides derived 
from TASA.  CD8
+
 T cell recognition of pericytes and VEC was tumor specific, since therapy-
induced CD8
+
 T cells did not recognize these same cell populations sorted from tumor-
uninvolved “normal” kidneys.  Based on our PCR analyses, such differential Tc1 recognition of 
tumor stromal cells may be directly related to the higher levels of TASA transcripts (and 
possibly protein) expressed by pericytes/VEC isolated from the TME versus the kidney. As 
expected, in our HHD recipient mouse model system, protective HLA-A2-restricted Tc1 cells 
failed to recognize HLA-A2
neg
 B16 tumor cells, even though CD8
+
 T cells appeared to be 
crossprimed against HLA-A2-presented B16 melanoma-associated antigens MART-1 and gp100 
(Figure 7), presumably via cross-presentation mediated by HLA-A2
+
 APC emigrating from the 
TME (163).
  
Overall, protective immunity in our model was associated with polyspecific Tc1 
responses against at least one peptide epitope derived from 11 of 12 TASA evaluated (with NG2 
being the lone exclusion).   
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Figure 7. Splenic CD8
+
 T cells from HHD mice effectively treated with DC.IL12 gene therapy 
develop HLA-A2-restricted responses against melanoma-associated antigens.  
HHD mice bearing day 7 HLA-A2
neg
 (MART-1
+
, gp100
+
) B16 melanomas were left untreated or 
they were treated with i.t. injection of control DC.ψ5 or DC.IL12 as described in Figure 4. On 
day 19 post-tumor inoculation, CD8
+
 spleen cells were isolated and analyzed for reactivity 
against the hMART-126–35 and h/mgp100209–217 peptide epitopes presented by the HLA-
A2
+
 T2 cell line. After 48 hours coculture of T cells and Ag-loaded T2 cells, cell-free 
supernatants were harvested and analyzed for IFN-γ content by ELISA. *P < 0.05 versus T2 only 
control. 
 
Since the peptides analyzed in the current study are non-mutated and were chosen to be 
evolutionarily conserved sequences in humans and mice, i.t. DC.IL12 gene therapy must be 
capable of breaking operational tolerance in the T cell repertoire reactive against these “self” 
antigens/epitopes.  Indeed, we observed that HHD mice and HLA-A2
+
 normal human donors, as 
well as, HLA-A2
+
 patients with melanoma exhibited detectable CD8
+
 T cell responses against 
the vast majority of TASA evaluated. Although previous reports have characterized human 
CD8
+
 T cell responses against HLA-A2-presented peptides derived from the TASA EphA2, 
NG2, PSMA, RGS5, VEGFR1, and VEGFR2 (57, 170-172, 176, 177), the current HHD model 
studies support the natural (tumor stromal cell) presentation of novel HLA-A2-presented 
epitopes derived from the DLK1, HBB, NRP1, PDGFRβ, and TEM1 gene products in situ. 
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Although our study of HLA-A2
+
 normal donor and melanoma patient responses is small 
in size, these data suggest that melanoma patients and normal donors are capable of mounting 
type-1 CD8
+
 T cell responses against many “self” TASA when appropriately stimulated (as a 
proof-of-principle for the development of future vaccines targeting such antigens).  Although 
somewhat an unfair comparison given the application of two IVS cycles for normal donors and 
one IVS cycle for disease patients, post-stimulation CD8
+
 T cell responses between these cohorts 
were statistically different for only a minor subset of TASA peptides (Figure 6 legend).  Such 
differences could reflect the differential presence of specific CD8
+
 memory T cells in the 
peripheral blood of melanoma patients.  Furthermore, given the diversity of prior therapies 
received by the evaluated melanoma patients and variance in their current disease status (i.e., no 
evidence of disease versus active disease; Table 3), it is impossible to correlate T cell 
responsiveness to TASA with clinical outcome at the current time.  Such information can only be 
determined with longitudinal immunomonitoring in prospective therapeutic trials.  In this regard, 
our data argue for the translational utility of TASA peptides in the context of active vaccination 
protocols and/or clinical trials implementing immunotherapeutic/antiangiogenic approaches 
(including IL-12p70 gene therapy, TKI) for the treatment of solid cancers.  While one could 
readily envision the development of phase I/II TASA peptide-based vaccines, it may ultimately 
be most attractive to consider recombinant TASA protein- or gene-based formulations. These 
latter agents would presumably have the capacity to promote polyspecific, polyfunctional T cell-
mediated immunity in HLA-heterogeneous cancer patients, thereby obviating the need to restrict 
accrual to a given HLA allotype.  Such approaches would also allow one to concomitantly elicit 
TASA-specific type-1 CD4
+
 T cell-mediated immunity that may prove directly reactive against 
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MHC class II
+
 pericytes or VEC in the proinflammatory TME and/or support optimal Tc1 
functionality/durability in cancer patients (180).   
Treatment-associated vascular “normalization,” which has been reported to be a preferred 
clinical outcome in successful cancer therapies (68, 181-183), could also be the direct result of 
the CD8
+
 T cell-mediated death/regulation of VEC or pericytes that are required to sustain VEC 
within the TME in vivo.  In such a scenario, tumor-associated pericytes/VEC could be induced to 
undergo either apoptosis or granzyme/perforin-mediated lysis by effector Tc1 cells (115, 184, 
185).  Alternatively or additionally, the intimate communication between pericytes and VEC 
(i.e., via PDGF, VEGF, TGF-β, etc.) could be disrupted by IFN-γ, TNF-α, and/or additional 
factors secreted by Tc1 in response to cognate Ag presented by tumor pericytes or VEC, or 
crosspresented by tumor-associated APC (186, 187).  Such a pathway could be reinforced in an 
autocrine manner based on the expected upregulation of pericyte/VEC MHC class I expression 
by IFN-γ (188), allowing for improved CD8+ T cell recognition of these target cells. 
Furthermore, it remains possible that IL-12 gene therapy-induced inhibition of vasculogenesis in 
the TME may be related to systemic T cell-mediated targeting and eradication of circulating 
TASA
+
 pericyte and/or VEC progenitors that could otherwise have been recruited into, and co-
opted to become components of the tumor vascular bed (189).   
Beyond the predicted direct suppression of tumor growth by treatment-induced, TASA-
specific CD8
+
 T cells, these strategies would be presumed to reduce tumor interstitial pressure, 
thereby enhancing the “deliverability” of systemic therapeutic agents (such as chemotherapeutic 
drugs or even therapeutic T cells themselves) into the TME.  Additionally, such treatments 
would be expected to promote loco-regional tumor cell death (necrosis and/or apoptosis), 
providing an enriched source of tumor antigen in vivo that may allow for secondary waves of 
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crosspriming and the “epitope spreading” of the antitumor T cell repertoire (168, 190-192).  This 
diversification in the specificity of protective T cells would theoretically allow for enhanced 
therapeutic efficacy and more durable T cell-mediated protection against tumor recurrence or the 
progression of micro-metastatic disease. 
Ultimately, the clinical success of therapies that evoke anti-TASA Tc1 responses will 
depend on whether such T effector cells are preferentially recruited into, and sustained within, 
the TME versus normal vascularized tissues.  In this regard, recent reports studying peptide- or 
DNA-based vaccines targeting the TASA EphA2, NG2, or VEGFR2 have all exhibited some 
degree of antitumor effectiveness with little or no off-target disruption of the normal vasculature 
(121), the cutaneous wound-healing process (170-172) or normal fertility, gestational period, or 
litter size in treated mice.  Thus far, we have not observed any acute behavioral or physical 
manifestations of toxicity in HHD mice cured of B16 tumors as a result of DC.IL12 therapy.  
Furthermore, our in vitro analyses suggest that therapeutic anti-TASA Tc1 cells do not recognize 
normal tissue-derived pericytes or VEC.  Nevertheless, given our belief that “epitope spreading” 
[classically associated with the development of chronic autoimmune diseases (193)], underlies 
effective IL-12 gene therapy, we will continue to assess the health/performance status of treated 
animals for any signs of evolving autoimmune pathology. 
In conclusion, our data suggest that therapies that promote CD8
+
 T cell targeting of 
tumor-associated TASA, such as DLK1, EphA2, HBB, NRP1, RGS5, and TEM1, may be 
meritorious for translation into the clinic for the treatment of patients with solid, vascularized 
tumors.  In particular, vaccines based on such TASA are of compelling interest and may prove 
effective in the treatment of a broad range of cancers regardless of the immunophenotype (MHC 
and tumor antigen) status of the patient's tumor cells in vivo. 
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3.1 ABSTRACT 
We have shown that effective cytokine gene therapy of solid tumors in HLA-A2 Tg 
(HHD) mice lacking murine MHC class I molecule expression results in the generation of HLA-
A2-restricted CD8
+ T effector cells selectively recognizing tumor stroma-associated pericytes 
and/or VEC.  Using an HHD model in which HLA-A2
neg tumor (MC38 colon carcinoma or B16 
melanoma) cells are not recognized by the CD8+ T cell repertoire, we now show that vaccines 
based on TASA elicit protective Tc1-dependent immunity capable of mediating tumor regression 
or extending overall survival.  Vaccine efficacy was not observed if (HLA-A2
neg
) wild-type 
C57BL/6 mice were used as recipient animals.  In the HHD model, effective vaccination resulted 
in profound infiltration of tumor lesions by CD8
+ (but not CD4+) T cells, in a coordinate 
reduction of CD31
+ blood vessels in the TME and in the “epitope spreading” of CD8+ T cell 
responses to alternate TASA that were not intrinsic to the vaccine.  Protective Tc1-mediated 
immunity was durable and directly recognized pericytes and/or VEC flow-sorted from tumor 
tissue, but not from tumor-uninvolved normal kidneys harvested from these same animals. 
Strikingly, depletion of CD8
+
, but not CD4
+
, T cells at late time points after effective therapy 
frequently resulted in the recurrence of disease at the site of the regressed primary lesion.  This 
suggests that the vaccine-induced anti-TASA T cell repertoire can mediate the clinically-
preferred outcomes of either effectively eradicating tumors or policing a state of (occult) tumor 
dormancy. 
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3.2 INTRODUCTION 
Cancer vaccines based on tumor-associated Ags (TAA) have been extensively evaluated 
in both translational models and in the clinic.  Although by most accounts TAA-based vaccines 
have been found to be immunogenic in promoting increased frequencies of antigen-specific T 
cell responses in a large proportion of treated patients, they have only rarely proven curative 
(118, 158, 194).  This limitation in efficacy may relate, at least in part, to the heterogeneity of 
cancer cells found within a given tumor lesion, particularly with regard to subpopulation 
“immunophenotypes” (195-197). Indeed, many times patients that have exhibited objective 
clinical responses to immunomodulatory therapies ultimately progress with tumors characterized 
by defects in their antigen-processing/presentation machinery and altered immunophenotypes 
(155, 160). 
A theoretical means by which to promote antitumor immunity, while coordinately 
circumventing the (immuno)phenotypic “instability” of cancer cells themselves, involves the 
development of vaccines eliciting T cells capable of selectively targeting tumor-associated 
stromal cells, such as (myo)fibroblasts, vascular pericytes, and VEC (115-117, 119, 162, 198-
204).  Interestingly, prophylactic peptide-based and/or recombinant vaccines, based on TASA 
such as endoglin (CD105), NG2, PDGFRβ, VEGFR1, or VEGFR2, have been previously 
reported to provide partial protection against challenge with tumor cell lines that do not express 
these antigens, presumably on the basis of T cell-mediated antiangiogenic activity in the TME 
(170-173, 198-200, 205, 206).  However, when applied therapeutically, such vaccines have only 
slowed the progressive growth of established tumors and modestly extended the overall survival 
period of treated mice (171, 172, 200). 
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In the previous chapter, I reported that IL-12 cytokine gene therapy of established HLA-
A2
neg
 B16 melanomas growing in HLA-A2 trangenic (Tg) mice results in CD8
+
 T cell-mediated 
protective immunity directed against host HLA-A2
+
 stromal cells within the TME.  In this 
chapter, I show that therapeutic vaccination of HLA-A2 transgenic mice (HHD) mice with 
TASA-derived peptides defined in this previous study results in CD8
+
 T cell-dependent 
regression of colon carcinoma and melanoma and long-term protection against disease relapse. 
3.3 MATERIALS AND METHODS 
3.3.1 Mice 
HHD mice are D
b
 × β2-microglobulin null Tg for the modified HLA-A*0201 human β2-
microglobulin single chain (HHD gene; (207)) and exhibit CD8
+
 T cell responses that 
recapitulate those observed in HLA-A2
+
 human donors (165, 207, 208). C57BL/6 wild-type 
mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Female 6- to 8-wk-old 
mice were used in all experiments and were handled in accordance with an Institutional Animal 
Care and Use Committee-approved protocol. 
3.3.2 Cell lines 
MC38, a methylcholanthrene-induced (HLA-A2
neg
) murine colon carcinoma cell line, 
and B16, an HLA-A2
neg
 melanoma cell line (syngenic to the H-2
b
 background of HHD mice), 
have been described previously (166, 209). The T2 cell line is a TAP-deficient T cell/B cell 
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hybridoma that constitutively expresses HLA-A2 (210). All cell lines were free of mycoplasma 
contamination. 
3.3.3 Peptides 
All peptides were synthesized using 9-fluorenylmethoxycarbonyl (Fmoc) chemistry by 
the University of Pittsburgh Cancer Institute’s Peptide Synthesis Facility (a Shared Resource). 
Peptides were >96% pure based on HPLC profile and mass spectrometric analysis performed by 
the University of Pittsburgh Cancer Institute’s Protein Sequencing Facility (a Shared Resource). 
3.3.4 Production of murine bone marrow-derived DC and DC.IL12 
DC were generated from bone marrow precursors, as described previously in Chapter 2 
(208). The Ad.mIL-12p70 recombinant adenoviral vector was produced and provided by the 
University of Pittsburgh Cancer Institute’s Vector Core Facility (a Shared Resource), as reported 
previously in Chapter 2 (121).  
3.3.5 Vaccine experiments 
For prophylactic experiments, HHD mice were immunized s.c. on the right flank with 
100 μl PBS or PBS containing 106 syngenic DC.IL12 cells that had been untreated or prepulsed 
for 4 h at 37°C with 10 μM synthetic peptide(s).  Immunizations occurred on days −14 and −7, 
with mice subsequently receiving injections of MC38 (2 × 10
6
) tumor cells in the left flank on 
day 0.  In all cases, treatment groups contained five mice per cohort.  For analysis of tumor 
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cellular composition in repeat experiments, MC38 tumors were isolated by surgical resection 10 
d after tumor inoculation and prepared for fluorescence imaging, as described below. For 
therapeutic experiments, MC38 (2 × 10
6
) or B16 melanoma cells (1 × 10
5
) were injected s.c. in 
the right flank and allowed to establish/progress for 7 d, at which time, the mice were 
randomized into cohorts of five mice each, with each group exhibiting an approximate mean 
tumor size of 50–75 mm2.  Mice were then untreated or treated with control, syngeneic DC.IL12 
or DC.IL12 (10
6
 cells injected s.c in the left flank on days 7 and 14) pulsed with synthetic TASA 
peptides. In some experiments, as indicated, in vivo Ab depletions (on days 6, 13, and 20 after 
tumor inoculation to assess early involvement or on days 60 and 67 or 180 and 187 to assess late 
involvement) of protective CD4
+
 T cells or CD8
+
 T cells were performed and monitored as 
described previously in Chapter 2 (208).  In all cases, tumor size (area) was monitored every 3–4 
d and is reported as mean ± SD in square millimeters. 
3.3.6 Evaluation of specific CD8+ T cell responses in HHD mice 
MACS (Miltenyi Biotec) sorted CD8
+
 splenocytes were harvested (from three mice per 
group) 7 d after the second round of DC-based vaccination (i.e., day 21 after tumor inoculation) 
and analyzed for reactivity against unpulsed T2 cells, TASA peptide-pulsed T2 cells, or day 19 
(flow-sorted) B16-derived PDGFRβ+CD31negH-2Kb(neg) pericytes or PDGFRβnegCD31+H-
2K
b(neg)
 VEC isolated as described previously in Chapter 2 (208). Where indicated, 10 μg anti–
HLA-A2 mAb BB7.2 or control anti-class II mAb L243 (both from American Type Culture 
Collection, Manassas, VA) were added to replicate coculture wells. After 48 h, supernatants 
were analyzed for murine IFN-γ content by specific ELISA (lower detection limit = 31.3 pg/ml; 
BD Biosciences). Data are reported as the mean ± SD of triplicate determinations. 
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3.3.7 Reverse transcriptase-PCR 
Reverse transcriptase (RT)-PCR was performed using primer pairs as described 
previously in Chapter 2 (208). 
3.3.8 Fluorescence imaging of tumor sections 
Tumor tissue samples were prepared and 6-μm sections prepared as reported previously 
in Chapter 2 (121).  
3.3.9 Cutaneous wound healing assays 
Wound-healing analyses were performed in HHD mice as described by Maciag et al. 
(170). 
3.3.10 Statistical analysis 
Two-tailed Student t test or two-way ANOVA were used to test overall differences 
between groups (StatMate III; ATMS, Tokyo, Japan) with p < 0.05 considered significant. 
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3.4 RESULTS 
3.4.1 Vaccines incorporating peptide epitopes derived from TASA are immunogenic and 
protect HHD mice against HLA-A2
neg
 MC38 tumor challenge 
To assess the immunogenicity of TASA-derived peptides, female HLA-A2 Tg mice were 
vaccinated twice on a weekly schedule with 10
6
 peptide-pulsed (HHD) DC.IL12.  One week 
after the booster immunization, CD8
+
 splenocytes were isolated and analyzed for their ability to 
secrete IFN-γ in response to peptide-pulsed HLA-A2+ T2 cells in vitro.  As shown in Figure 8A, 
the majority (17 of 20; p < 0.05 versus T cells stimulated with DC only) of TASA-derived 
peptides analyzed primed Tc1 responses in vivo that could be detected in vitro.   We noted that 
the DLK1, EphA2, HBB, NG2, NRP1, NRP2, PDGFRβ, PSMA, RGS5, TEM1, VEGFR1, and 
VEGFR2 antigens were expressed in situ by blood vessel cells in the MC38 colon carcinoma 
TME (Appendix Figure 4).  These findings were similar to our previous observations in the B16 
TME, shown in Chapter 2 (208). This led us to next analyze whether immunization with TASA-
derived peptides on days −14 and −7 would protect HHD mice against a subsequent challenge 
with HLA-A2
neg
 MC38 tumor cells injected s.c. on day 0.  As depicted in Figure 8B, vaccines 
incorporating peptides from the TASA DLK1, EphA2, HBB, NRP1, PDGFRβ, RGS5, or TEM1 
were effective in preventing HLA-A2
neg
 MC38 tumor establishment or they resulted in the 
regression of tumors (after a transient period of establishment) in HHD mice.  In contrast, 
vaccines based on the TASA NG2, NRP2, PSMA, VEGFR1 or VEGFR2 yielded minimal 
protection (Figure 8B).  On the basis of the data provided in Figure 8, vaccine immunogenicity 
and efficacy were not always correlated with one another in the MC38 prophylaxis model 
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(Appendix Figure 5), a finding in accordance with reports for peptide-based vaccines in human 
clinical trials (118, 158, 194). 
 
Figure 8. Induction of specific/protective CD8
+
T cells reactive against TASA as a consequence 
of DC/peptide-based vaccination.  
(A) HHD mice (five animals per cohort) were vaccinated twice (day 14 or 7) s.c. with PBS or 
with isologous DC.IL12 pulsed with PBS or synthetic peptides (Appendix Table 2) derived 
from the indicated TASA. In cases where more than one peptide was identified for a given target 
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Ag, an equimolar pool of the indicated peptides (each 10 μM) was pulsed onto DC.IL12 and 
used for vaccination in the relevant cohort. One week after the second immunization, splenic 
CD8
+
 T cells were isolated and stimulated in vitro using the HLA-A2
+
 T2 cell line pulsed with 
relevant TASA versus irrelevant HIV-nef190-198 (171) peptides and analyzed for IFN-γ production 
by ELISA. Data are reported as mean ± SD for triplicate ELISA determinations, and are 
representative of three independent experiments performed. *p < 0.05 versus HIV-nef control 
peptide responses. (B) HHD mice were vaccinated twice (days −14 and −7; right flank) s.c. with 
PBS or with isologous DC.IL12 pulsed with or without TASA peptides as indicated in A. One 
week after the booster vaccine animals were challenged s.c. on their left flank with 2 × 
10
6
 MC38 colon carcinoma cells. Tumor growth was then monitored every 3–4 d through day 
24. All data represent mean tumor area (in mm
2
) ± SD determined from five mice/cohort, and are 
representative of three independent experiments performed. *p < 0.05 versus DC only on the 
indicated days. 
 
3.4.2 Protective vaccines incorporating TASA peptides promote enhanced infiltration of 
the TME by CD8
+
 T cells in association with an inhibition of tumor vascularity 
Because a cohort of the protective vaccines allowed for a transient period of tumor 
growth prior to ultimate tumor regression, we isolated MC38 tumor lesions from all cohorts of 
animals with evidence of disease on day 14 (after tumor inoculation) and performed 
immunofluorescence microscopy on tumor sections. We observed that although control 
(untreated or vaccinated with DC.IL12/no peptide) mice contained few CD8
+
 T cells in the TME, 
the majority of the peptide-vaccinated cohorts exhibited a variable but significantly elevated 
number of CD8
+
 TIL (Figure 9A and B).  In marked contrast, CD4
+
 T cell infiltration in the 
TME was sparse, and the data were indistinguishable when comparing control versus vaccinated 
mice (data not shown).  An analysis of vascular structures in these tumors revealed that mice pre-
vaccinated with peptides derived from the TASA EphA2, RGS5, or TEM1 had the greatest 
degree of suppression in CD31
+
 vessel counts in the MC38 TME, with somewhat less 
pronounced effects also noted for groups vaccinated against HBB or VEGFR2 (p < 0.05 versus 
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untreated mice or mice vaccinated with DC.IL12/no peptide; Figure 9C and D).  Correlative 
analyses indicated an association between the antitumor efficacy of vaccines and their ability to 
promote CD8
+
 T cell infiltration and reduced vascularity in the TME (Appendix Figure 5). 
 
Figure 9. MC38 tumors in mice prevaccinated with TASA-derived peptides exhibit differential 
infiltration by CD8
+
 T cells and alterations in vascular density.  
On day 14 MC38 tumors were harvested from HHD mice that had been vaccinated as outlined in 
Fig. 8B with the indicated peptides (or control PBS or DC.IL12 alone). (A) 6m tissue sections 
were costained with anti-CD8 (green) and anti-NG2 (red) Abs and imaged by fluorescence 
microscopy. Blue signal = nuclear counterstain using DAPI. Original magnification ×40. B 
provides a summary of the mean ± SD number of CD8
+
 cells per high-power field (HPF) in 
MC38 tumors isolated from control or vaccinated mice as depicted in A. (C) Tissue sections 
were co-stained with anti-CD31 (green) and anti-NG2 (red) Abs and imaged by fluorescence 
 67 
microscopy. Blue signal = nuclear counterstain using DAPI. Original magnification ×40. (D) The 
mean ± SD number of CD31
+
 vessels per HPF of MC38 tumors in control or vaccinated mice are 
summarized. Representative data are depicted from one of three independent experiments 
performed. *p < 0.05 versus DC only or untreated control mice. 
3.4.3 Therapeutic vaccines incorporating TASA-derived peptide epitopes are effective 
against established HLA-A2
neg
 MC38 colon carcinomas and HLA-A2
neg
 B16 melanomas in 
HHD mice 
Given the robust antitumor activity noted for vaccines based on a subset of TASA in the 
prophylactic model, we next studied how well these vaccines would perform as immunotherapies 
in mice bearing established day 7 s.c. MC38 or B16 tumors. In the MC38 model, we treated 
HHD mice with DC.IL12 cells pulsed with (an equimolar mixture of) peptides derived from an 
TASA shown most capable of regulating tumor growth under prophylactic conditions (Figure 
8B) and exhibiting the highest degree of immunogenicity, based on data provided in (Figure 8A) 
(i.e., DLK1326–334, EphA2883–891, HBB31–39, NRP1869–877, PDGFRβ890–898, RGS55–13, and 
TEM1691–700).  As shown in Figure 10A, the combination peptide vaccine effectively promoted 
the regression of established MC38 tumors. Furthermore, on the basis of the antibody depletion 
analyses, therapeutic benefit was largely due to the action of CD8
+
, but not CD4
+
, T cells 
(Figure 10A).  Therapeutic vaccines applied to mice bearing B16 melanomas were also effective 
in suppressing tumor growth if: 1) the vaccine incorporated peptides derived from the stromal 
antigens DLK1, EphA2, HBB, NRP1, RGS5 (and to a lesser extent TEM1); and 2) recipient 
mice were competent to respond to these peptides in an HLA-A2–restricted manner (Figure 
10B).  Hence, none of the vaccines evaluated perturbed B16 tumor growth in syngeneic B6 mice, 
which do not express the relevant HLA-A2 class I restriction element required for CD8
+
 T cell 
recognition of the immunizing peptides. We did not evaluate therapeutic vaccines using the 
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NRP2 or PSMA peptides in the B16 model on the basis of their poor performance in the 
preliminary MC38 protection model (Figure 8B). 
 
Figure 10. DC.IL12 vaccines containing TASA-derived peptides are therapeutic against MC38 
colon carcinomas and B16 melanomas in HHD mice: requirement for CD8
+
 T cells and HLA-
A2
+
 host (stromal) cells.  
(A) HHD mice bearing established day 7 s.c. MC38 tumors (right flank) were left untreated, or 
they were vaccinated in the left flank with control DC.IL12 or DC.IL12 pulsed with an 
equimolar pool of the following TASA-derived peptides: DLK1326–334, EphA2883–891, HBB31–39, 
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NRP1869–877, PDGFRβ890–898, RGS55–13, and TEM1691–700. Identical booster vaccines were 
provided on day 14 after tumor inoculation. As indicated, two vaccine cohorts were treated with 
depleting anti-CD4 or anti-CD8 mAbs as outlined in Materials and Methods. (B) Female HHD 
or C57BL/6 (B6) mice with established B16 tumors received vaccines consisting of control or 
peptide-pulsed DC.IL12 10 and 17 (after tumor inoculation). Tumor size (mean ± SD) was 
monitored every 3–4 d through day 34. Data are representative of those obtained in two 
independent experiments in each case. *p < 0.05 versus DC only on the indicated days. (C) HHD 
mice bearing s.c. B16 melanomas were treated as described in B and followed through day 60 
after tumor inoculation. Data are reported in Kaplan–Meier plots depicting overall percentage of 
surviving animals over time. *p < 0.02 versus DC only; **p < 0.002 versus DC only (with 
refined p values for differences between treatment cohorts reported in Appendix Table 2). Data 
are cumulative for three independent experiments performed. 
3.4.4 HHD mice cured of B16 tumors by TASA peptide-based therapeutic vaccines 
exhibit extended survival and durable Tc1 responses against tumor-associated pericytes 
and/or VEC and spreading in anti-TASA CD8
+
 T cell repertoire 
We followed mice treated in Figure 10B through 60 d after tumor inoculation and 
observed significant survival benefits if the animals had been treated with vaccines containing 
peptides derived from the TASA DLK-1, EphA2, HBB, NRP1, RGS5, or TEM1 (Figure 10C, 
Appendix Table 2).  To analyze the status and specificity of Tc1 cells, HHD mice rendered free 
of B16 melanoma after therapeutic vaccination with DLK or RGS5 peptide-based vaccines were 
sacrificed 60 d after tumor inoculation.  Freshly isolated spleen CD8
+
 T cells were then analyzed 
for reactivity against HLA-A2
+PDGFRβ+CD31negpericytes, HLA-A2+PDGFRβnegCD31+ VEC, 
or HLA-A2
neg
 tumor cells flow-sorted from day 19 B16 tumors growing progressively in 
untreated HHD mice.  As shown in Figure 11, splenic Tc1 cells isolated from mice cured after 
vaccination with DLK1 peptides recognized tumor-associated pericytes and VEC in an MHC 
class I-restricted manner but did not recognize pericytes or VEC isolated from the tumor-
uninvolved kidneys of these same donor animals.  These type 1 CD8
+
 T cells strongly recognized 
the DLK1 peptides used in the protective vaccine formulation, but also (to a variable degree), a 
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number of additional TASA-derived peptides that were not included in the therapeutic vaccine. 
Similarly, B16-bearing HHD mice cured using a vaccine on the basis of the RGS55–13 peptide, 
demonstrated clear Tc1 recognition of tumor (but not tumor-uninvolved kidney) pericytes, as 
well as statistically significant response against HLA-A2
+
 T2 cells pulsed with peptides derived 
from the TASA DLK1, EphA2, NG2, NRP1, PSMA, RGS5, or TEM1 (Figure 11). 
 
Figure 11. HHD mice cured of B16 melanoma by treatment with DC.IL12/peptide vaccination 
exhibit polyspecific anti-TASA Tc1 responses.  
HHD mice bearing established day 7 B16 melanomas were therapeutically vaccinated with 
peptides derived from the TASA DLK1 or RGS5 as described in Figure 10B. Tumors regressed 
completely over the next 2 wk. Sixty days after tumor inoculation, splenic CD8
+
 T cells were 
isolated and evaluated for IFN-γ production (by ELISA) in response to pericytes and VEC as 
well as HLA-A2
+
 T2 cells (control or pulsed with the indicated peptides) as described in 
Materials and Methods. *p < 0.05 versus anti-class I mAb blockade (when evaluating responses 
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against pericytes, VEC, or B16 tumor cells) or T2 cells only (when evaluating anti-peptide 
responses). Data are representative of responses observed in three independent experiments. 
3.4.5 HHD mice cured of B16 tumors by TASA peptide-based therapeutic vaccines either 
exhibit true “molecular cures” or a state of CD8+ T cell-mediated tumor dormancy 
Despite the high frequency of complete tumor regressors as a consequence of treating 
B16-bearing HHD mice with TASA peptide-based vaccines, it was conceivable that TASA-
targeting T cells limit tumor expansion yielding occult disease rather than the complete 
eradication of cancer cells (i.e., “molecular” cure).  To assess this possibility, effectively treated 
HHD mice with no evidence of (macroscopic) disease were depleted of CD8
+
 or CD4
+
 T cells on 
days 60 and 67 or 180 and 187 by injection of specific Abs in vivo.  As shown in Figure 12, 
depletion of CD8
+
 T cells, but not CD4
+
 T cells, resulted in the re-establishment of melanoma 
growth at sites of the primary tumor placement in seven of nine (i.e., 78% for depletions on day 
60 or 67) and three of eight (i.e., 38% for depletions on day 180 or 187) cases, respectively. 
Interestingly, two of nine (22%) mice in the day 60 or 67 CD8
+
 T cell-depleted group exhibited 
transient tumor expansion and then spontaneous regression over a period of weeks to months 
(Figure 12), presumably as TASA/tumor-specific CD8
+
 T effector cells were recovered in these 
animals.  We also noted that at the time of primary disease recurrence in CD8
+
 T cell-depleted 
animals, melanomas did not present in distal cutaneous sites and that metastases were not 
detected in the lung, liver, or brain based on a histopathology examination of resected tissues 
(data not shown). 
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Figure 12. In vivo depletion of CD8
+
, but not CD4+, T cells from a cohort of HHD mice 
effectively treated with TASA peptide-based vaccines results in recurrence of disease at the site 
of primary tumor inoculation.  
HHD mice harboring established s.c. B16 melanomas received vaccines consisting of syngeneic 
DC.IL12 pulsed with a mixture of TASA peptides on days 7 and 14 (after tumor inoculation) as 
outlined in Figure 10A, resulting in tumor regression in 100% of treated animals. On days 60 
and 67 or days 180 and 187 (after tumor inoculation), mice were depleted of CD4
+
 or CD8
+
 T 
cells as described in Materials and Methods. Control animals received isotype control Ab. 
Animals were then monitored for the reappearance and size of melanomas every 4–7 d. The 
number of animals evaluated per cohort is indicated within a given panel, with each line 
representing longitudinal data from a given animal. Data are cumulative from three experiments 
performed. 
3.5 DISCUSSION 
One major finding of the current chapter is that vaccines based on a subset of TASA-
derived peptides elicit protective/therapeutic immunity against HLA-A2
neg
 (MC38 or B16) 
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transplantable tumors in HHD mice because of the apparent CD8
+
 T cell targeting of HLA-
A2
+
 pericytes or VEC in the TME.  Once protective anti-TASA immunity was established as a 
consequence of specific immunization, vaccinated animals exhibited durable protection against 
challenge with tumors of divergent histology (Appendix Figure 6).  Similar peptide-based 
vaccines applied to CD8-depleted HHD mice or HLA-A2
neg
recipient (C57BL/6) mice failed to 
yield treatment benefit, arguing for the critical involvement of CD8
+
 T cells and the need for 
these effector cells to target HLA-A2
+
stromal cells in vivo (Figure 11 and Appendix Figure 6).  
A second major finding is that many apparent complete responders in our therapeutic vaccine 
models retain occult disease, because CD8
+
, but not CD4
+, T cell depletion of “cured” animals 
resulted in the rapid recurrence of tumors selectively at the site of the original primary lesion in 
many cases.  Although in most instances, recurrent tumors grew quickly and proved lethal, in 
some cases (i.e., 2 of 10), tumors grew slowly and subsequently underwent spontaneous 
regression presumably after the Ab-depleted CD8
+
 T cell repertoire had recovered. These data 
suggest that TASA peptide-based vaccines promote complete eradication of tumors or the 
establishment of a state of (occult) tumor dormancy over extended periods of time, which is 
regulated by vaccine-instigated CD8
+
 T cells. 
The exact nature of residual occult disease in treated animals that recur upon CD8
+
 T cell 
depletion remains unknown.  In our HHD model system, we failed to detect direct tumor cell 
recognition by therapeutic T cells, hence HLA-A2
neg
 cancer cells would be afforded the 
possibility of maintaining microscopic nests that were limited in their expansion potential based 
on the anti-angiogenic activity of protective Tc1 effector cells as suggested in alternate models of 
immune-mediated tumor dormancy (211). Alternatively, or additionally, slowly 
replicating/quiescent tumor cells or tumor-initiating cell populations may persist in low numbers 
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in close proximity to blood vessels within the primary lesion site, undergoing a proliferative 
switch upon removal of existing anti-TASA CD8
+
 T cells (212, 213).  In such circumstances, 
combinational vaccines simultaneously targeting multiple TASA as well as Ag expressed by 
tumor cells and/or tumor-initiating cells might be expected to yield higher rates of complete 
cures (201, 214, 215). 
Our data suggest that the strongest “clinical” correlates for vaccine efficacy may be the 
degree of therapeutic type 1 CD8
+
 T cell infiltration into the TME and the degree to which Tc1 
cells regulate the tumor blood supply.  This is in keeping with current paradigms for successful 
immunotherapy outcome, where levels of specific TIL rather than circulating peripheral blood T 
cells may be predictive of better clinical prognosis (216).  As we have previously suggested (68), 
treatment-associated vascular “normalization” in the TME may directly result from CD8+ T cell-
mediated death or functional disruption of VEC or pericytes in vivo.  Such anti-vascular effects 
may provide a rich source of dead or dying tumor/stromal cells capable of supporting the 
corollary cross-priming of an evolving protective Tc1 repertoire (190).  Indeed, we observed that 
TASA-based therapeutic vaccines that were capable of inducing tumor clearance resulted in the 
broadening of the protective memory Tc1 repertoire to include specificity against TASA 
unrelated to the original vaccine formulation.  Our findings are consistent with the general 
paradigm of “epitope spreading” of the antitumor T cell repertoire as a mechanism underlying 
superior immunotherapeutic outcome (168, 191, 192). 
Despite theoretical concerns that the anti-TASA CD8
+
 T cell response could negatively 
impact normal tissue blood vessels or the normal process of neoangiogenesis/neovascularization, 
we failed to detect vaccine induced: 1) T cell responses against normal tissue pericytes or VEC; 
or 2) delay in the kinetics of skin closure after full thickness wounding (data not shown).  Such 
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differential recognition of tumor over non-tumor blood vessel cells by Tc1 effector cells may 
well relate to higher levels of TASA expression (and by extension their derivative MHC-
presented peptides) by tumor- versus normal tissue-associated pericytes and VEC (Appendix 
Figure 4B) (208), but this could also reflect tissue site-specific variation in blood vessel cell 
expression of 1) MHC class I APM components, 2) costimulatory/adhesion or coinhibitory 
molecules, or 3) “repulsion” molecules that inhibit CD8+ T cell–target cell interactions (195-197, 
217-219). 
In conclusion, our data support the translational use of TASA-based vaccines and the 
integration of TASA targets in immune monitoring strategies applied to patients with solid forms 
of cancer.  In particular, the ability to immunologically target tumor-associated pericytes and 
VEC via specific vaccination may pave the way for combinational therapy designs integrating 
anti-angiogenic agents (i.e., TKI, VEGF/VEGFR antagonists) that have thus far yielded 
promising, but frequently transient, objective clinical responses in cancer patients (218-220).  In 
these individuals, tumor blood vessels that become refractive to therapy are characterized by a 
high numbers of pericytes (220), potentially making these structures ideal targets for TASA 
vaccine-induced, anti-pericyte Tc1 cells. 
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4.1 ABSTRACT 
Tumor blood vessels are frequently inefficient in their design and function, leading to 
high interstitial fluid pressure, hypoxia, and acidosis in the TME, rendering tumors refractory to 
the delivery of chemotherapeutic agents and immune effector cells.  Here we identified the 
Notch antagonist delta-like 1 homolog (DLK1) as a vascular pericyte-associated antigen 
expressed in RCC, but not in normal kidney tissues in mice and humans.  Vaccination of mice 
bearing established RCC against DLK1 led to immune-mediated elimination of DLK1
+
 pericytes 
and to blood vessel normalization (i.e., decreased vascular permeability and intra-tumoral 
hypoxia) in the TME, in association with tumor growth suppression. After therapeutic 
vaccination, tumors displayed increased prevalence of activated VCAM1
+
CD31
+
 vascular 
endothelial cells and CXCL10, a Type-1 T cell recruiting chemokine, in concert with increased 
levels of Type-1 CD8
+
 TIL. Vaccination against DLK1 also yielded; i.) dramatic reductions in 
Jarid1B
+
, CD133
+
 and CD44
+
 (hypoxia-responsive) stromal cell populations, ii.) enhanced tumor 
cell apoptosis and iii.) increased Notch signaling in the TME. Co-administration of a -secretase 
inhibitor that interferes with canonical Notch signaling resulted in the partial loss of therapeutic 
benefits associated with DLK1-based vaccination. 
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4.2 INTRODUCTION 
The vasculature of solid tumors is structurally and functionally “abnormal”, being 
composed of an irregular network of blood vessels characterized by aberrant coverage of 
endothelial tubes and a loosely-attached, largely immature population of mural cells (i.e. smooth 
muscle cells, pericytes) (73, 82).  In contrast to mature pericyte-VEC interactions found in 
normal tissues that orchestrates blood vessel integrity/stability (221), in tumors, this relationship 
is deranged leading to a high-degree of vascular permeability, high interstitial fluid pressure, 
hypoxia and acidosis  (79). 
RCC is highly-vascularized and generally considered to represent an immunogenic form 
of cancer (222-224).  Current treatment options mediate only transient efficacy in a minority of 
RCC patients, with frequent development of progressive disease that is refractory to 
conventional chemo-/radio-therapy (100, 102, 220, 225).  Vaccines targeting tumor-associated 
antigens have also thus far demonstrated only modest curative value (118).  The limited 
perfusion of tumor blood vessels likely contributes to the muted benefits of these treatment 
approaches by preventing the efficient delivery of chemotherapeutic agents and anti-tumor T 
cells into the TME (119, 120).  As a consequence, the development of novel therapies that can 
“normalize” the tumor vasculature (by coordinately improving blood vessel perfusion, reducing 
tumor hypoxia, and allowing for improved and sustained delivery of anti-cancer agents into the 
TME) remains a high-priority (68, 95, 98, 120, 121).  
To achieve the goal of tumor vascular normalization via immunization, we and others 
have recently advocated the use of vaccine formulations capable of promoting specific Type-1 
CD8
+
 T cell (aka Tc1) recognition of tumor-associated vascular cell antigens (119-121), 
including DLK1 (Chapters 2 and 3).  DLK1 is a member of the EGF-like family of proteins, 
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which includes Notch receptors and their ligands (127, 131, 132) and serves as a functional 
inhibitor of Notch signaling.  DLK1 has been reported to inhibit a broad range of Notch-
dependent cell differentiation pathways (127). In the cancer setting, the functional impact of 
DLK1 modulation cannot be intuitively assumed, since Notch activation has been reported to 
either promote or suppress tumor development/progression based on the contextual influences of 
DLK1 on the myriad cell populations located within the evolving TME (127, 131, 132).
 
 
In this chapter, we investigated the therapeutic impact of active vaccination against 
DLK1 in a murine model of RCC (i.e., RENCA tumor cells transplanted s.c. into syngenic 
BALB/c mice), where the DLK1 antigen is preferentially expressed by blood vessel-associated 
pericytes in the progressively-growing TME.  We show that DLK1 peptide- or gene-based 
vaccines are both immunogenic and therapeutic against established RCC, with treatment benefits 
linked to CD8
+
 T cell-mediated “normalization” of tumor-associated blood vessels (i.e., 
reduction in blood vessel numbers and extent of arborization, loss of hypoxia and reduced 
vascular permeability) (98, 182).  Responder tumors were highly-infiltrated by CD8
+
 TIL that 
localized within the perivascular (pericyte-enriched) space.  Residual pericytes lacked expression 
of DLK1 and were tightly-approximated to CD31
+
 VEC.  Consistent with the vaccine-induced, 
immune-mediated eradication of tumor-associated DLK1 protein expression, increased Notch 
signaling was evidenced within the therapeutic TME.  These results are consistent with the 
ability of DLK1-based vaccines to promote therapeutic CD8
+
 T cell-dependent vascular 
normalization in the RCC microenvironment, supporting the clinical translation of such 
approaches in the setting of RCC and other forms of solid cancer. 
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4.3 MATERIALS AND METHODS 
4.3.1 Mice 
Female 6-8 week old BALB/c mice (The Jackson Laboratory, Bar Harbor, ME) were 
maintained in a pathogen-free animal facility, with all animal work performed in accordance 
with an IACUC-approved protocol. 
4.3.2 Tumor cells 
The mouse RCC line RENCA derived from a spontaneous renal cortical adenocarcinoma 
in BALB/cCr mice (CRL-2947; American Type Culture Collection, Manassas, VA) (226) was 
cultured as previously reported (121). 
4.3.3 Stromal cell isolation 
Human RCC tumor and adjacent (patient-matched) normal kidney specimens were 
obtained with written-consent under an IRB-approved protocol.  Murine RCC tumors and tumor-
uninvolved kidneys were harvested 21 days after s.c. injection of 10
6
 RENCA cells into syngenic 
BALB/c recipient animals.  VEC and pericytes were isolated as previously mentioned in 
Chapters 2 and 3 with minor modifications (78).  Briefly, tissues were enzymaticaly digested into 
a single cell suspensions and, for human specimens, labeled with anti- human CD146 FITC 
(Serotec), anti-human CD34 PE (DAKO), anti-human CD56 PE-Cy7 (Serotec), anti-human 
CD45 APC (BD-Biosciences) and for murine specimens, labeled with anti-mouse CD34-FITC 
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(eBioscience, San Diego, CA), anti-mouse CD146-PE (BD-Biosciences, San Diego, CA), and 
anti-mouse CD45-APC (BD-Biosciences) prior to flow sorting into pericyte 
(CD146+CD34
neg
CD56
neg
CD45
neg
) and VEC (CD146+CD34
+
CD56
ne
CD45
neg
) populations. 
4.3.4 Real-time PCR 
Messenger RNA was isolated from pericytes and VEC using the RNeasy® Plus Micro kit 
(Qiagen, Valencia, CA) according to manufacturer’s instructions. cDNA was then generated 
using High Capacity RNA-to-cDNA kit (Applied Biosystems, Carlsbad, CA) and real-time PCR 
performed using Fast SYBR® Green Master Mix (Applied Biosystems) with primer pairs for 
human or mouse HPRT1 (Qiagen), human DLK1 (Applied Biosystems) or mouse DLK1 
(forward primer: TGTGACCCCCAGTATGGATT, reverse primer: 
CCAGGGGCAGTTACACACTT). Reactions were performed in duplicate in a 96-well reaction 
plate on a StepOnePlus real-time PCR thermocycler (Applied Biosystems) using cycling 
conditions of 95°C for 20 min., then 35 cycles of 95°C for 3 min. and 60°C for 30 min. 
4.3.5 In vitro generation of bone marrow-derived dendritic cells (DC) and DC.IL12 
DC.IL12 were generated as previously described in Chapter 2 (208).  
4.3.6 Synthetic peptides 
The H-2
d
 class I-presented DLK1158-166 (CPPGFSGNF; presented by H-2L
d
), DLK1161-169 
(GFSGNFCEI; presented by H-2K
d
), DLK1259-270 (TILGVLTSLVVL; containing overlapping 
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DLK1259-267 and DLK1262-270 sequences presented by H-2K
d
) peptide were synthesized as 
previously described (120). 
4.3.7 Recombinant lentiviral vector production 
Genes encoding mDLK1 and the reverse sequence of mRGS5 (as a negative control) 
were cloned into the pLenti6/V5 D-TOPO vector downstream of the CMV promoter using the 
Lentiviral Directional TOPO® Expression Kit (Invitrogen, Grand Island, NY). To determine 
insert presence in the plasmid, expression of the V5 tag was detected by immunofluorescence 
using an anti-V5 FITC antibody (Invitrogen) and by western blot using an anti-V5 HRP antibody 
(Invitrogen). In the initial production of the lentiviruses, 293FT cells (Invitrogen) were 
transfected with plasmid DNA pLenti-DLK1 (or pLenti-NEG) using ViraPower™ Packaging 
Mix (Invitrogen) combined with Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s instructions. After 48 hours, lentivirus was collected and concentrated using a 
Fast-Trap Virus Purification and Concentration kit (Millipore). Lentiviral (lvDLK1 and lvNEG) 
titers, reported in transduction units (TU), were determined by quantitating blasticidin 
(Invitrogen)-resistance in HT-1080 cells (kindly provided by Dr. Chuanyue Wu, University of 
Pittsburgh) according to the manufacturer’s instructions. Expanded lentiviral production was 
performed by the University of Pittsburgh Cancer Institute Lentiviral Vector Core Facility. 
Lentivirus quality was assessed by infecting HT-1080 cells for 24h and monitoring cells for 
coordinate V5 protein expression (western blot) and cell-surface expression of DLK1 (flow 
cytometry using an anti-DLK1-PE conjugated antibody; Adipogen, San Diego, CA). 
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4.3.8 Animal therapy experiments 
BALB/c mice received s.c. injection of 10
6
 RENCA tumor cells (right flank) on day 0. 
Six days later, the animals were randomized into cohorts of 5 mice with comparable mean tumor 
sizes. On days 7 and 14 after tumor implantation, mice were treated with 100 l s.c. injections 
(left flank) of PBS, 10
6
 DC.IL12 or 10
6
 DC.IL12 that had been pre-pulsed for 2h at 37°C with an 
equimolar (10 M) mixture of the DLK1158-166, DLK1161-169 and DLK1259-270 peptides. For 
lentivirus vaccination experiments, randomized BALB/c mice bearing established (day 10; right 
flank) s.c. RENCA tumors received a single left flank intradermal injection of lvDLK1 or 
negative control lvNEG at a dose of 4 x 10
4
 or 2 x 10
5
 TU in a total volume of 50 l PBS. For all 
animal experiments, tumor size was assessed every 3 to 4 days and recorded in mm
2
, as 
determined by the product of orthogonal measurements taken using vernier calipers. Data are 
reported as mean tumor area ± SD. To determine the impact of canonical NOTCH signaling on 
vaccine efficacy, tumor-bearing animals vaccinated with lvDLK1 or lvNEG were injected i.p. 
with the -secretase inhibitor DAPT (10 mg/kg/day in 50 l DMSO (Sigma-Aldrich) on a 3 
consecutive days (followed by 4 days without injections) per week schedule, for 2 weeks 
beginning on day 12 post-tumor inoculation) or vehicle control (DMSO).    
4.3.9 Evaluation of specific CD8+ T cell responses in vitro 
Spleens were harvested from 3 mice per group 7 days after the second DC injection. 
Splenocytes were then stimulated in vitro for 5 days with syngeneic DC pulsed with an 
equimolar (10 M mix of the 3 DLK1 peptides applied in the vaccine.  Responder CD8+ T cells 
were then isolated using magnetic bead cell sorting (Miltenyi Biotec) and co-cultured with 
 84 
syngeneic DC pulsed with individual DLK1 peptides for 72h, 37
o
C and 5% CO2, at which time 
cell-free supernatants were analyzed for mIFN- content using a cytokine-specific ELISA (BD-
Biosciences). 
4.3.10 Fluorescent imaging of tumors 
Tumor tissue samples were prepared and sectioned as previously reported in Chapter 2 
(120). Six-micron tissue sections were analyzed for expression of CD31 (BD-Biosciences), 
VCAM1 (R & D Systems, Minneapolis, MN), CXCL10 (R & D Systems), NG2 (Millipore, 
Billerica, MA), DLK1 (Santa Cruz), RGS5, Jarid1b (all from Abcam; Cambridge, MA), CD133 
(BD-Biosciences), CD44 (Abcam) and Hes1 (Millipore) by immunofluorescence microscopy, 
with wide field images collected with fixed illumination conditions using a cooled CCD camera 
(Olympus Magnafire, Center Valley PA). Using Metamorph software (Molecular Devices, 
Downingtown PA), images were thresholded to delineate signal above background and 
individual structures measured as the integration of pixel number (total number of positive pixels 
in the structure above background) multiplied by the brightness of each pixel in grey scales. This 
product provides the integrated pixel intensity of positive structures and is reported as the mean 
integrated fluorescence intensity +/- SD. For the analysis of activated VEC in the TME, cellular 
identity was first defined using co-localization of specific markers (cells staining for both CD31 
and VCAM-1) using image overlay and manual counting. We found this method was essential to 
ensure accuracy in cell identification in tissue with complex morphologies. To perform the 
quantification images were overlaid with Metamorph software and co-localized structures that 
could be defined as cells were counted. For analysis of cellular apoptosis, tissue sections were 
labeled using TUNEL kit (Roche; Indianapolis, IN) as per manufacturer’s instructions, followed 
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by incubation with secondary anti-streptavidin Cy3 antibody (Jackson Immunoresearch, West 
Grove, PA). Some sections were analyzed by confocal microscopy to generate 30 m 3-
dimensional reconstructions of images. For the vascular permeability imaging, animals received 
retro-orbital intravenous injections of FITC-labeled tomato lectin (Sigma) and red 20 nm 
FluoSpheres® (Invitrogen), followed by cardiac perfusion of PBS and 4% paraformaldehyde. 
Tumors were then immediately resected and imaged by confocal microscopy to generate 17 m 
3-dimensional (3-D) reconstructions. White ruler insets: 50 microns (low magnification upper 
sub-panels); 10 microns (high magnification lower sub-panels). 
4.3.11 Hemoglobin quantitation 
The amount of hemoglobin contained in tissues was quantitated using the Drabkin 
method (227) and reported as g Hb per mg wet weight of tissue. 
4.3.12 Measurement of tumor hypoxia using pimonidazole 
BALB/c mice bearing established (treated or untreated) day 21 s.c. RENCA tumors were 
injected intraperitoneally (i.p.) with 60 mg/kg pimonidazole hydrochloride (Hypoxyprobe
TM
; 
HPI Inc., Burlington, MA) 30 min prior to euthanasia and tumor harvest and 6 m tissue sections 
prepared and analyzed by immunohistochemistry as previously reported (121).  
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4.3.13 RNA purification and Real-Time PCR array 
Total RNA was isolated from bulk single-cell suspensions of day 21 tumors harvested 
from lvNEG- or lvDLK1-treated mice using Trizol reagents (Invitrogen). Total RNA was further 
purified using the RNeasy Plus Mini Kit (Qiagen) including the gDNA Eliminator spin column. 
The purity and quantity of the total RNA was assessed using Nanodrop ND-1000 (CelBio SpA, 
Milan, Italy). Total RNA (1 g) was reversed transcribed into cDNA using the RT2 First Strand 
Kit (Qiagen) and the cDNA added to RT2 SYBR Green ROX™ qPCR Mastermix (Qiagen) and 
used for quantitative PCR using the RT2 Profiler PCR Array (96-well) for Mouse Notch 
Signaling Pathway (Qiagen) all according to the manufacturer’s instructions. Reactions were 
performed on a StepOnePlusTM Real-Time PCR thermocycler (Applied Biosystems) using the 
recommended cycling conditions. All mRNA expression levels were normalized to the 
expression of GAPDH. 
4.3.14 Statistical analysis 
Comparisons between groups were performed using a two-tailed Student's t test or one-
way Analysis of Variance (ANOVA) with Tukey post-hoc analysis, as indicated. All data were 
analyzed using SigmaStat software, version 3.5 (Systat Software, Chicago, IL). Differences 
between groups with a p-value < 0.05 were considered significant.   
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4.4 RESULTS 
4.4.1 RCC-associated pericytes differentially express the DLK1 antigen 
In Chapters 2 and 3, we identified several melanoma-associated vascular antigens, 
including DLK1, which may represent promising therapeutic vaccine targets. Before assessing 
the therapeutic potential of DLK1 peptide- and gene-based vaccines in the setting of RCC, we 
first investigated the pattern of DLK1 expression in the TME and tumor-uninvolved kidneys of 
BALB/c mice harboring established syngeneic RENCA tumors.  After enzymatic digestion of 
tissues, tumor- and kidney-derived pericytes and VEC were isolated via flow sorting from single-
cell suspensions (Figure 13A) and their extracted mRNA (along with mRNA from the cultured 
RENCA cell line) was analyzed by real-time PCR for DLK1 (and housekeeping control HPRT1) 
transcript content (Figure 13B).  We observed that pericytes sorted from RCC tumors were 
uniquely enriched for DLK1 transcripts (Figure 13B) when compared to normal kidney vascular 
cells or RENCA tumor cells, suggesting that DLK1 may represent a general tumor pericyte-
associated antigen.  Immunofluorescence microscopy performed on day 21 RENCA tumor 
sections confirmed that DLK1 protein was co-expressed by NG2
+
 pericytes that were closely 
approximated to CD31
+
 VEC in situ (Figure 13C), NG2 being a general pericyte marker in both 
normal and tumor tissues (228).   
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Figure 13. DLK1 is differentially expressed by RENCA tumor-associated pericytes. 
RENCA (10
6
 tumor cells) was injected s.c. into female BALB/c mice and allowed to progress for 
21 days after which animals were euthanized and tumors and normal kidneys harvested. In A, 
tissues were processed into single-cell suspensions and sorted by flow cytometry based on 
forward versus side-scatter profiles, DAPI exclusion (to reject dead cells), a CD45
neg
 phenotype 
(i.e. non-leukocytic), and then selectively into CD146
+
CD34
neg
 pericytes and CD146
+
CD34
+
 
VEC populations based on published assignments of these cell lineage-restricted phenotypes
 
(78, 
229). In B, mRNA was then isolated from flow-sorted pericytes and VEC, and analyzed for 
DLK1 transcript expression by real-time PCR. Relative mRNA expression was normalized to 
housekeeping HPRT1 mRNA expression. In C, day 21 RENCA tumor tissue sections were 
analyzed for expression of CD31 (blue), NG2 (green), and DLK1 (red) by immunofluorescence 
microscopy. Metamorph quantitation (Materials and Methods) was performed on 10 high power 
field (HPF) of the fluorescent images, with 28.1 + 4.4% of tumor-associated NG2
+
 pericytes co-
expressing the DLK1 marker. The analysis also revealed that the majority (i.e. 58.9 + 7.6%) of 
DLK1
+
 cells co-expressed the NG2 marker within the TME. All data are representative of 3 
independent experiments performed. 
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4.4.2 Treatment of RENCA tumor-bearing mice with a DLK1 peptide-based vaccine is 
therapeutic and associated with specific Type-1 CD8
+
 T cell (Tc1) activation and 
recruitment into the TME 
As shown in Chapters 2 and 3, we demonstrated that vaccine formulations composed of 
DC.IL12 pulsed with MHC class I-presented peptides promote robust CD4
+
 T helper cell-
independent priming of antigen-specific CD8
+
 T cells in vivo.  Using this approach, we analyzed 
the impact of treating BALB/c mice bearing established s.c. RENCA tumors with a DLK1 
peptide (a pooled equimolar mixture of the DLK1158-166, DLK1161-169 and DLK1259-270 peptides)-
based vaccine.  As depicted in Figure 14A, mice treated with the DLK1 peptide-based vaccine, 
but not a control vaccine (i.e., DC.IL12, no peptide) or PBS, exhibited a significant reduction in 
the growth of RENCA tumors (Figure 14A; p < 0.05 (ANOVA) on days >13).  On day 21 (i.e. 7 
days after the booster immunization), CD8
+
 splenocytes were isolated and analyzed for secretion 
of IFN- in response to stimulation with specific DLK1 peptides presented by syngeneic DC in 
vitro.  We noted elevated levels of IFN- secretion from CD8+ T cells isolated from mice treated 
with the DC.IL12 + DLK1 peptide vaccine (versus mice treated with DC.IL12 only or PBS) after 
stimulation with individual DLK1 peptides, indicating that the vaccine induced poly-specific, 
anti-DLK1 CD8
+
 T cell responses in vivo (Figure 14B).  
Since therapeutic Type-1 CD8
+
 T cells preferentially express a VLA-4
+
CXCR3
+
 
phenotype (111, 230), we next determined whether specific vaccination resulted in the altered 
expression of VLA-4 and CXCR3 ligands, VCAM-1 and CXCL10, respectively in the TME. A 
coordinate immunofluorescence microscopy analysis of the TME after DLK1 peptide-based 
vaccination versus control treatment revealed fewer CD31
+
 tumor blood vessels (Figure 14C), 
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and these vessels contained VEC enriched in the activated VCAM1
+
 phenotype (Figure 14D). 
We also observed that these same tumors contained elevated levels of CXCL10/IP-10 chemokine 
protein expression versus control tumors (Figure 14C), suggesting that the DLK1-based 
vaccination induces a pro-inflammatory TME that is competent to recruit Type-1 T effector cells. 
 
Figure 14. DC/DLK1 peptide-based vaccines are both immunogenic and therapeutic in the 
murine RENCA model of RCC.  
BALB/c mice were inoculated with RENCA tumor cells s.c. on the right flank on day 0. (A) 
Mice were injected s.c. on their left flank on days 7 and 14 (post-tumor inoculation) PBS, 10
6
 
DC.IL12 or 10
6
 DC.IL12 pre-pulsed DLK1 peptides. Tumor growth (mean ± SD) was then 
monitored over time. (B) On day 20 post-tumor inoculation, splenic CD8
+
 T cells were isolated 
from each cohort and co-cultured with syngenic DC pre-pulsed with individual DLK1 peptides 
for 24h, at which time, IFN- ELISA were performed on the harvested cell-free supernatants. In 
C and D, day 20 tumors were fixed, sectioned and analyzed by immunofluorescence microscopy; 
CD31 (green in panels C, D), CXCL10 (red in C), VCAM1 (red in panel D). The percentage of 
VCAM1 co-localization with CD31 is depicted as a yellow signal in panel D and was quantitated 
using Metamorph software as described in Materials and Methods. Histograms to the right of 
images reflect mean fluorescence intensity quantitation of the indicated markers (+/- SD) from 3 
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independent fields per slide as described in Materials and Methods. Data are representative of 3 
independent experiments performed. *p < 0.05 versus control treatments (ANOVA).  
 
4.4.3 Vaccination with a recombinant lentivirus encoding murine DLK1 cDNA is 
therapeutic in the RENCA model of RCC 
Clinical trials implementing synthetic tumor peptide-based vaccines have needed to 
restrict patient accrual to those individuals expressing relevant HLA class I (peptide-presenting) 
allotypes.  To develop a more universal immunization platform, we next engineered a genetic 
vaccine that would theoretically allow for virally-transduced host antigen-presenting cells to 
cross-prime a more comprehensive anti-DLK1 T effector cell repertoire.  Given the reported 
superiority of lentiviral-based vaccines to promote prolonged antigen-specific CD8
+
 T cell 
responses after a single administration in vivo (125), we first constructed a recombinant 
lentivirus encoding full-length murine DLK1 (lvDLK1) and a negative control virus (lvNEG; 
Appendix Figure 7).  
To assess the therapeutic efficacy of specific genetic vaccination against the full-length 
DLK1 antigen, BALB/c mice bearing established day 7 RENCA tumors received a single 
intradermal (i.d.) injection of lvDLK1 or control lvNEG at a site distal to tumor (i.e., 
contralateral).  Animals treated with lvDLK1 exhibited significant reductions in tumor growth 
compared to animals treated with lvNEG (Figure 15A).  As was the case for DLK1 peptide-
based vaccines, immunofluorescence microscopy analysis of tumor sections supported decreased 
vascularity and loss of (DLK1
+
) vascular pericytes (Figure 15B), and increased presence of the 
CXCR3 ligand chemokine, CXCL10 and VCAM1
+
CD31
+
 VEC, in the TME of mice treated with 
lvDLK1 versus lvNEG (Figure 15C and D).  Enhanced expression of CXCL10 and VCAM1 in 
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the TME was associated with greater numbers of CD8
+
 TIL in mice receiving lvDLK1-based 
vaccines (Figure 15E).  These findings suggest that immune targeting of DLK1 via a single 
administration of lvDLK1 can effectively limit tumor growth and induce a pro-inflammatory 
TME promoting the improved recruitment of TIL. 
 
Figure 15. Recombinant lvDLK1-based vaccines are therapeutic and promote a Type-1-
polarized TME.   
BALB/c mice were inoculated s.c. with RENCA tumor cells in the right flank on day 0. (A) On 
day 10 mice were treated i.d. in the left flank with 40 or 200 transduction units (TU) of lvDLK1 
or control virus, lvNEG. Tumor size was then monitored longitudinally. In panels B-E, on day 
27, tumors were analyzed by immunofluorescence microscopy for  expression of (B-D) CD31 
(green) and (B) DLK1 (red) with white arrows indicating DLK1
+
 cells, (C) CXCL10, (D) co-
localization of VCAM1 with CD31, and (E) CD8
+
 TIL (green) and NG2 (red). Histograms to the 
right of images reflect mean fluorescence intensity quantitation of the indicated markers (+/- SD) 
from 3 independent fields per slide as described in Materials and Methods. Data are 
representative of 3 independent experiments performed. *p < 0.05 versus control treatments 
(ANOVA). 
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4.4.4 Vaccination with lvDLK1 normalizes the RENCA vasculature 
It has been suggested that the tumor-associated vasculature of mice deficient in immature 
pericytes appears “normal” with minimal arborization and reduced vascular permeability (68), 
supporting therapeutic strategies to selectively reduce or eradicate immature vascular pericytes 
within tumor sites.  Given the ability of our lvDLK1-based genetic vaccine to reduce the content 
of DLK1
+
 (immature) pericytes in the tumor stroma, we sought further evidence supporting 
therapeutic vascular remodeling as a consequence of treatment with this modality.  We noted that 
RENCA tumors harvested from mice treated with lvDLK1 appeared “anemic” when compared to 
control tumors (Figure 16A), a subjective index that was subsequently confirmed based on an 
analysis of hemoglobin content in tumor lysates (Figure 16B).  When we analyzed tumors for 
expression of NG2 using immunofluorescence microscopy, we observed that animals vaccinated 
with lvDLK1 exhibited tumors with significant reductions in numbers of NG2
+
 pericytes in their 
TME versus tumors from animals vaccinated with lvNEG (Figure 16C and D).  Residual tumor 
pericytes in lvDLK1-treated animals were tightly-approximated to CD31
+
 VEC, unlike the 
randomly-distributed pattern of pericytes detected in the stroma of tumors isolated from control 
mice.  
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Figure 16. Recombinant lvDLK1-based vaccines promote normalization of the tumor 
vasculature.  
Mice bearing day 10 RENCA tumors were treated with 200 TU of lvDLK1 or lvNEG as outlined 
in Figure 15. On day 27 post-tumor inoculation, tumors were evaluated macroscopically (A) and 
for hemoglobin content (B). In C and D, tumor sections were analyzed by immunofluorescence 
microscopy for expression of CD31 (green) and NG2 (red). In C, 6 m sections were imaged by 
wide-field microscopy, while in D, 30 m sections were imaged by confocal microscopy to 
generate 3-D reconstructions. For C, mean data ± SD of three independent fields per slide is 
reported for each group from 1 representative experiment of 3 performed. 
 
 
To investigate changes in tumor vascular permeability, vaccinated animals received intravenous 
injections of two fluorescently-labeled probes, tomato lectin-FITC to bind/mark the vascular 
endothelium and small 20 nm (red) FluoSpheres® to determine vessel leakiness into tissue. 
When compared to controls, the tumor blood vessels in mice vaccinated with lvDLK1 displayed 
a simple tubular architecture devoid of extensive branching (Figure 17A). Furthermore, while 
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the perivascular stroma of tumors in control animals was littered with the red FluoSpheres®, 
these probes were virtually undetected in tumors harvested from lvDLK1 vaccinated mice, 
consistent with diminished vascular permeability in the TME of these latter animals (Figure 
17A).  
Given the apparent trimming of vascular branches in the RENCA TME, and reduction in 
vascular permeability after vaccination with lvDLK1 (but not lvNEG), we hypothesized that 
plasma nutrients required for sustaining tumor cell viability would be limited to regions adjacent 
to the remaining normalized blood vessel network.  TUNEL analyses revealed that indeed, the 
level of cellular apoptosis in the TME of lvDLK1-treated mice was substantially increased when 
compared with tumors isolated from control treated animals (Figure 17B).  Furthermore, 
virtually all apoptotic events (i.e., “dead zones”) in RENCA tumors isolated from lvDLK1-
vaccinated mice were located in tissue regions approximately 60 microns away from residual 
CD31
+
 blood vessels in planar tissue imaging analyses (Figure 17B).  These data suggest that 
immunization against DLK1 allows for the immunotherapeutic “normalization” of tumor blood 
vessels in vivo.   
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Figure 17. Recombinant lvDLK1-based vaccination reduces tumor vascular permeability 
resulting in the development of apoptotic “dead zones” in the TME distal to residual blood 
vessels.  
In repeated experiments as outlined in Figure 15, (A) treated mice received intravenous 
injections of tomato lectin-FITC to label vascular endothelium (green) and 20 nm FluorSpheres® 
to assess vascular permeability (red) on day 24 post-tumor inoculation. Whole tumor tissue was 
then imaged immediately by confocal microscopy at a depth of 17 m. *p < 0.05 for lvDLK1 
versus lvNEG (t-test).  (B) On the same day, tumors resected from unlabeled mice were analyzed 
for expression of CD31 (green) and apoptotic nuclear staining with TUNEL reagent (red). 
Histograms to the right of images reflect mean fluorescence intensity quantitation of the 
indicated markers (+/- SD) from 3 independent fields per slide as described in Materials and 
Methods. Data are representative of 3 independent experiments performed. *p < 0.05 for 
lvDLK1 versus lvNEG (t-test). 
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4.4.5 Therapeutic vaccination with lvDLK1 results in reduced hypoxia and a lower 
incidence of cell populations expressing hypoxia-responsive markers in the TME 
Hypoxia frequently occurs in solid cancers as a consequence of inefficient perfusion of 
oxygen into tumors by “aberrant” blood vessels (231, 232), resulting in reduced recruitment and 
function of TIL, increased prevalence of immunosuppressive cells/modulators, dysregulated 
angiogenesis, and the accumulation of “stem-like” cell populations (i.e. cancer stem cells/tumor 
initiating cells, cells undergoing epithelial-to-mesenchymal transition) in the TME (233, 234).  
To investigate changes in hypoxia within tumors after vaccination with lvDLK1 versus lvNEG, 
we injected mice i.p. with pimonidazole (a hypoxia marker that undergoes reductive activation 
and then conjugates to thiol-containing proteins specifically in hypoxic cells, allowing for 
immunohistochemical detection of tissue regions exhibiting low [< 1.3%] O2 tension) (235). 
Using this imaging technology, we found that tumors isolated from mice receiving lvDLK1 
vaccines had a very low hypoxic index when compared to tumors culled from control animals 
(Figure 18A).  Given this large reduction in TME hypoxia post-vaccination with lvDLK1, we 
next investigated treatment impact on expression of hypoxia-responsive gene products associated 
with immature vascular stromal cells (i.e., RGS5) and/or stem-like cell populations (i.e., Jarid1B 
aka histone demethylase lysine demethylase 5b; CD133, CD44) (236-238).  Immunofluorescence 
microscopy analysis of day 27 tumor sections revealed that the expression of these markers was 
coordinately reduced in RENCA tumors after host vaccination with lvDLK1 (Figure 18B-F). 
When taken together, these data indicate that vaccination with lvDLK1 results in the recovery of 
normoxia in the TME in association with the conditional alteration in the phenotype (and 
presumably function) of a range of stromal cell subpopulations in vivo. 
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Figure 18. Recombinant lvDLK1-based vaccines promote normoxia in the TME in association 
with the loss of cells bearing stem cell-like phenotypes.  
Mice bearing day 10 RENCA tumors were treated with 200 TU of lvDLK1 or lvNEG as outlined 
in Figure 15. (A) On day 21, mice were injected i.p. with the hypoxia probe pimonidazole, after 
which tumors were analyzed by HRP- immunohistochemistry. In B-E, day 21 tumors from that 
did not receive pimonidazole hydrochloride were analyzed by immunofluorescence microscopy 
for expression of CD31 and RGS5 (B), Jarid1b (C), CD133 (D) and CD44 (E). In F, histograms 
to the right of panel B-E images reflect mean fluorescence intensity quantitation of the indicated 
markers (+/- SD) from 3 independent fields per slide as described in Materials and Methods. 
Data are representative of 3 independent experiments performed. *p < 0.05 for lvDLK1 versus 
lvNEG (t-test). 
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4.4.6 Loss of DLK1 expression in the TME after therapeutic vaccination with lvDLK1 
leads to increased locoregional activation of Notch. 
Since lvDLK1-based vaccination leads to loss of DLK1 expression in the TME (Figure 
15) and DLK1 represents a functional inhibitor of Notch signaling (127), we hypothesized that 
this therapeutic vaccine would promote enhanced canonical Notch signaling in therapeutic 
RENCA TME. As shown in Figure 19A and B, RENCA tumors isolated from lvDLK1-treated 
(but not control) mice contained cells strongly expressing cytoplasmic/nuclear Hes1 protein, a 
Notch transcriptional target required for the tumor-suppressor action of activated Notch (132, 
134). Hes1
+
 cells included both CD31
+
 VEC and non-VEC stromal cell populations in the TME 
(Figure 19A). Corollary gene array analyses also supported the enhanced transcription of 
numerous Notch target genes (including the canonical Notch ligands (DLL1, DDL3, DLL4, 
Jag1/2) and the Notch1-4 receptors, among others), but not control β2-microglobulin, in 
lvDLK1- versus lvNEG-treated tumors (Figure 19C).   To determine the importance of 
canonical Notch signaling on the anti-tumor efficacy of genetic vaccination against DLK1, we 
immunized BALB/c mice bearing established s.c. RENCA tumors with lvNEG or lvDLK1 as 
described in Figure 15A, with cohorts of lvDLK1-vaccinated animals injected i.p. with the γ-
secretase inhibitor DAPT, which inhibits the generation of the Notch intracellular domain 
(NICD) required for downstream Notch signaling events (239), or vehicle control DMSO. As 
shown in Figure 19D, administration of DAPT partially suppressed the anti-tumor action of 
lvDLK1-based therapeutic vaccination. 
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Figure 19. Treatment with lvDLK1 vaccines results in Notch activation in the TME which is 
partially responsible for the anti-tumor effectiveness of this treatment strategy.  
(A) Tumor sections were isolated as described in Figure 15 and evaluated by fluorescence 
microscopy using specific antibodies against CD31 (green) and Hes1 (red; from Millipore). 
DAPI counterstaining was used to image cell nuclei (blue). White arrows in image insets indicate 
Hes1
+
CD31
+
 VEC. (B) Mean fluorescence intensity quantitation of Hes1 protein expression (+/- 
SD) from 3 independent fields per slide is reported as described in Materials and Methods. Data 
are representative those obtained in 3 independent experiments performed. *p < 0.05 (t-Test).  
(C) mRNA transcripts of Notch target genes were analyzed using an Real time PCR gene array. 
The ratio of transcript levels for a given gene product among total tumor mRNA isolated from 
lvDLK1- versus lvNEG-treated mice is reported.  Negative control transcript = 2-microglobulin 
(beta 2-m). (D) Established day 8 s.c. RENCA tumors were treated with 200 TU of lvNEG or 
lvDLK1 (i.e., VAC) as described in the Figure 15A legend and Materials and Methods. DAPT 
(depicted as small gray ovals labeled “D” on the x-axis) or vehicle control DMSO was then 
provided as indicated. Tumor size was then monitored longitudinally. *p < 0.05 for lvDLK1 + 
DAPT treatment versus lvDLK1 treatment; also p < 0.05 for the lvDLK1 + DAPT and lvDLK1 
treatments versus lvNEG control treatment on days > 15 post-tumor inoculation (ANOVA). 
 
 101 
4.5 DISCUSSION 
The major finding in this report is that DLK1 is a tumor pericyte-associated antigen that 
can be immunologically targeted via specific peptide- or gene-based vaccination in vivo, leading 
to the effective “normalization” of the vasculature in the TME and a drastic reduction in solid 
tumor growth in vivo.  Effective therapeutic vaccination resulted in the activation of Type-1 
(IFN- producing) DLK1-specific CD8+ T cells in the periphery and the improved recruitment of 
CD8
+
 T cells into/around residual blood vessels in the TME.  Therapeutically-normalized blood 
vessels in tumors exhibit a simplified conduit design with tightly-approximated (abluminal) 
NG2
+
DLK1
neg
RGS5
neg
 mature pericyte populations that appear improved in their structural 
integrity based on a reduction in vascular permeability.  Tumors in DLK1-vaccinated mice 
became normoxic and displayed a dramatic increase in the rate of apoptotic death in regions of 
the tumor that were further away from residual blood vessels. These findings support a model 
paradigm in which specific immune effector T cells may serve as regulators of the “angiogenic 
switch” (68, 95, 120, 121, 231) by monitoring and controlling the status of DLK1+ pericytes 
within the TME. 
Vaccination against DLK1 also induced a pro-inflammatory TME based on the 
acquisition of activated VCAM1
+
 VEC and concomitant production of the CXCR3 ligand 
chemokine CXCL10, responsible for recruiting Type 1 TIL.  We hypothesize that an initial wave 
of DLK1-reactive Type-1 TIL results in perivascular secretion of IFN- and TNF- in the TME, 
leading to locoregional upregulation of IFN-/TNF--responsive gene products such as VCAM-
1 and CXCL10 (240, 241).  Such alterations in the TME would then be expected to foster 
improved uptake of tumor debris (i.e., apoptotic bodies) by recruited/activated antigen-
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presenting cells and the corollary reiterative cross-priming of an expanded, protective T cell 
repertoire reactive against both tumor- and tumor vascular-associated antigens (120) that may be 
directed into the pro-inflammatory TME.  
Interestingly, a recent report by Reis et al. (242) suggests that the conditional activation 
of the Wnt/-catenin/Notch signaling pathway can lead to vascular normalization, as indicated 
by reduced vascular density and improved mural cell attachment, in intracranial murine glioma 
models.  Our data support such a paradigm, with specific vaccination resulting in removal of 
DLK1 expression (and Notch antagonism (127, 243)) in the TME.  Such immune pressure 
improved Notch signaling based on a dramatic increase in the intratumoral expression of Hes1 
protein and the transcriptional activation of multiple Notch target genes.  The transcriptional 
profiling also supports differentially increased expression of Frzd2, Frzd4, Frzd7 and-catenin 
(Ctnnb1) in RENCA tumors harvested from lvDLK1-vaccinated mice supporting the co-
activation of canonical Wnt/-catenin signaling (244) in the therapeutic TME, consistent with 
the model proposed by Reis et al. (242).  As such, our data suggest that vaccination against 
DLK1 (as an integral transmembrane protein or via its shed extracellular domain (245)) may 
derepress canonical Notch/Wnt/-catenin signaling in endothelial cells (and other stromal cell 
populations) within the TME, thereby promoting vascular quiescence/normalization (127, 242, 
246).  Vaccination against DLK1 may also improve Type-1 functionality of tumor-associated 
macrophages and DC (i.e., enhanced IL-12p70 and CXCL10 production) and T cells (247). 
Indeed, we observed that the functional antagonism of Notch signaling in vivo (based on 
administration of the -secretase inhibitor DAPT) partially ablated the anti-tumor benefits 
associated with lvDLK1-based therapeutic vaccination, suggesting a supporting role for 
canonical Notch signaling in treatment outcome.  Future studies will investigate the potential role 
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of Wnt/-catenin signaling in therapeutic benefit associated with DLK1-based vaccines by 
applying specific inhibitors of these pathways in our therapeutic model. 
The TME of progressively-growing, control tumors was enriched in cells expressing 
markers known to contain HRE in their promoter regions, such as CD44, CD133 and Jarid1B 
(236-238), that have been previously linked to cell populations with “stem-like” characteristics 
(233, 234).  Notably, the “normalized” TME after therapeutic vaccination with lvDLK1 was 
normoxic and largely devoid of cells expressing these hypoxia-responsive antigens. Although the 
most simplistic reason for this change reflects the transcriptional silencing of these gene products 
in the TME of lvDK1-vaccinated animals, it is also conceivable that the therapeutic TME is poor 
in recruiting cells bearing these phenotypic markers, and/or that the vaccine evoked corollary 
cross-priming of cytotoxic CD8
+
 T cell responses capable of eradicating CD44
+
, CD133
+
 and 
Jarid1B
+
 target cells in effectively-treated tumors. With regard to the latter scenario, we currently 
plan to longitudinally evaluate the reactivity of the evolving therapeutic CD8
+
 T cell repertoire 
against peptide epitopes derived from the CD44, CD133 and Jarid1B (as well as alternate “stem 
cell”-associated/hypoxia-responsive markers such as ALDH1, Oct4 and Nanog) (237) antigens in 
RENCA-bearing mice treated with DLK1 peptide/gene-based vaccines. 
The anti-angiogenic action mediated by the DLK1 vaccine-induced CD8
+
 T cell 
repertoire would be anticipated to differ, and likely complement, that of alternative 
pharmacological anti-angiogenic treatment modalities such as anti-VEGF antibodies (i.e., 
bevacizumab) and small molecule TKI (i.e., sunitinib) (99, 220, 248).  In most cases, tumors 
treated with these agents rapidly become drug-refractory due to their adoption of compensatory 
growth/progression pathways.  As such, DLK1-based vaccines could represent a logical second-
line approach in the many cases of developed resistance to bevacizumab, sunitinib or similar 
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anti-angiogenic drugs. DLK1-based vaccines may also represent effective co-first line 
therapeutic agents, since the specific activation, recruitment and function of anti-DLK1 T 
effector cells in the TME would be anticipated to be improved by the co-administration of anti-
angiogenic TKI that reduce suppressor cell populations (most notably in RCC patients) and 
activate a pro-inflammatory TME in vivo (109-111). Based on these expectations, we plan to 
evaluate the comparative therapeutic efficacy of combined sunitinib + lvDLK1 vaccination 
treatment in our existing subcutaneous RENCA model, as well as, in an orthotopic RCC model 
using RENCA.luc (RENCA cells transduced with luciferase cDNA) to allow for vital 
bioluminescence monitoring of tumor growth and metastasis.  Although we have not observed 
signs of off-target autoimmune pathology as a consequence of DLK1-targeted vaccination (i.e., 
inhibition of cutaneous wound healing (120), tissue vasculitis; data not shown) to date, these new 
models will provide us with additional opportunities to investigate potential combination 
treatment-associated toxicities in future.             
Consistent with our findings in the RENCA model, pericytes from freshly-isolated human 
RCC (but not patient-matched normal adjacent kidney tissue) also differentially (over)express 
the DLK1 antigen in situ (Appendix Figure 8). When coupled with the knowledge that anti-
DLK1 CD8
+
 T cell responses can be developed from human cancer patients after in vitro 
sensitization, as shown in Chapter 2 (208), we believe that DLK1-based vaccines (as single 
agents or in combination approaches) represent attractive candidates for clinical translation in the 
setting of RCC and alternate well-vascularized forms of solid cancer. 
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5.0  GENERAL DISCUSSION 
Given the muted clinical efficacy that has been observed thus far for conventional 
therapeutics applied against solid tumor targets, including RCC, there has been increasing 
interest in developing and applying agents that mitigate the pro-cancer supportive influence of 
stromal cell populations in the TME [including VEC, pericytes and (myo)fibroblasts (119, 249)]. 
In the second chapter, I reported that therapeutic intratumoral treatment with DC engineered to 
express IL-12 induces the crosspriming of protective CD8
+
 T cells reactive against tumor-
associated pericytes and VEC, as well as, antigens that are differentially expressed by these cell 
populations in the B16 melanoma TME (i.e., DLK1, HBB, PDGFRβ, RGS5, EphA2, and TEM1) 
but expressed at very low levels, if at all, on pericytes and VEC isolated from normal tissues. 
Additionally, I found via real-time PCR that DLK1, RGS5, PDGFRβ, and TEM1 expression was 
enriched in the tumor pericytes isolated from the RENCA RCC TME, but these genes were 
minimally expressed in pericytes from normal kidney and VEC from tumor and normal kidney 
(Appendix Figure 9), thereby limiting concerns for any off-target effects in treated individuals.  
Indeed, vascular antigen vaccine-induced CD8
+
 T cells failed to react against VEC and pericytes 
isolated from the tumor-uninvolved kidneys of treated mice and no apparent inflammation or 
vasculitis in normal tissue.  We also did not observe any delay in the kinetics of the cutaneous 
wound-healing processes, changes in blood chemistry, or alterations in gross tissue pathology in 
healthy mice pre-vaccinated against TASA.   
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There exists a number of therapeutic means by which to target the tumor-associated 
blood vasculature that can lead to at least transient tumor regression (68, 96, 111, 119, 122).  In 
the third chapter of my thesis, I described an anti-vasculature vaccine implementing DC.IL12 
loaded with MHC class I-restricted TASA peptides, and found that not only did this vaccine 
elicit anti-tumor immunity, it promoted reduced vascularity and increased CD8
+
 TIL in the TME, 
implying that the treatment had invoked vascular remodeling or “normalization” in vivo. The 
“normalization” of the tumor vasculature in response to treatment has shown correlative clinical 
benefit in successful cancer therapies (68, 181-183) and may be the direct result of the CD8
+
 T 
cell-mediated death of pericytes and/or VEC within the TME.  Indeed, we have shown through 
various studies that this vaccine formuation induces MHC class I/CD8
+
 T cell-dependent 
recognition of tumor vascular cells and TASA peptides.  As a result, tumor-associated stromal 
cells become targets of activated effector Tc1 cells resulting in a downstream vascular 
remodeling event.  These vascular changes may then lead to accumulation of dead/dying tumor 
cells, as well as other stromal cell populations within the TME, providing non-pericyte/VEC 
antigens for cross-priming of an evolving protective and highly-diversified Tc1 repertoire (168, 
190-192) capable of destroying the myriad targets within the heterogeneous TME.  
Based on these findings, I examined the efficacy of a targeted vaccine against tumor 
pericytes.  As shown in Chapters 2 and 3, and in Appendix Figure 9, RGS5 is overexpressed in 
tumor pericytes and was an immunologically relevant target in both the B16 melanoma and 
MC38 colon carcinoma models.  It has been reported that RGS5 is transiently expressed 
throughout development, with one of the earliest studies showing RGS5 expression restricted to 
pericytes in mouse embryos (84).  RGS5 was also found to be highly upregulated in PDGFRβ+ 
pericytes isolated from murine tumors (83).  Indeed, I showed RGS5 to be expressed in pericytes 
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isolated from both human and mouse RCC tumors, but not in normal kidney pericytes or VEC 
(Appendix Figure 10).   
It has been shown that genetic deletion of RGS5 led to a normalized vasculature in 
insulinomas, similar to what is observed in disease free pancreas (68).  Given the observed 
therapeutic benefit seen in HHD mice when given DC.IL12 with HLA-A2-restricted RGS5 
peptides in both the B16 melanoma and MC38 colon carcinoma models, I investigated the 
effects of a similar vaccine in the mouse RENCA tumor model with BALB/c mice.  In chapters 2 
and 3, synthetic RGS5 peptides were selected for the study based on a high algorithm predicted 
binding score to the HLA-A2.1 class I molecule.  In the RENCA model RGS5 epitopes were 
selected based on a predicted high binding affinity to the BALB/c MHC class I molecule, H-2
d
: 
RGS5161-176 (LPRFVRSEF), RGS511-20 (SCLERAKEI), and RGS5150-159 (SFDLAQKRI).  
Animals with established RENCA tumors were injected twice with DC.IL12 loaded with pooled 
equimolar amounts of the RGS5 peptides.  However, treated animals showed no changes in 
tumor growth compared to control groups receiving PBS or DC.IL12 without peptide (Appendix 
Figure 11).  This lack of response was confounding, given the profound effect observed in the 
HHD model using HLA-A2 presented RGS5 peptides.  We postulated that the predicted H-2
d
-
presented epitopes chosen may not have been immunogenic or recognizable to the endogenous T 
cell repertoire of the BALB/c model.  It has been shown that cutaneous vaccination with 
lentivirus results in specific transduction of skin DC, leading to activation of antigen-specific T 
cells (125), therefore we tested the therapeutic efficacy of a genetic vaccine using a lentivirus 
encoding full-length human RGS5 (lvRGS5) that was currently available.  Human RGS5 shares 
88% homology with mouse RGS5 with shared epitopes, as shown in Chapters 2 and 3, therefore 
we assumed the human homolog could be processed and presented similarly in the mouse.  I first 
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confirmed that the lentivirus was functional by transducing bone marrow derived dendritic cells 
and looked for RGS5 mRNA expression by reverse transcriptase PCR (Appendix Figure 12A).  
I treated RENCA tumor-bearing mice with a single intradermal injection of lvRGS5 or PBS and 
found that animals treated with the lentivirus had significantly delayed tumor growth compared 
to PBS-treated animals (Appendix Figure 12B).  When I looked at expression of Type-1 pro-
inflammatory genes in bulk tumor lysate by reverse transcriptase PCR, I found and overall 
increase of proinflammatory chemokine/cytokine transcript levels (CXCL9, CXCL10, CXCL11, 
IL-12p40, and IFN-γ) in lentivirus-treated animals compared to PBS controls (Appendix Figure 
12C).  Interestingly, splenic T cells isolated from animals treated with varying concentrations of 
lentivirus (lv-LO, lv-MED, lv-HI), which despite exhibiting a seemingly dose-dependent anti-
tumor response (Appendix Figure 13A) showed no RGS5-specific response (as measured by 
CFSE dilution and IFN-γ production of CD4+ and CD8+ T cells) compared to PBS-treated 
animals (Appendix Figure 13B-E).  This raises the question of whether the anti-tumor effect 
and increase in pro-inflammatory gene expression observed was due to immune targeting of 
RGS5 of simply a general response against the lentivirus itself.  At the time these experiments 
were performed, no blank lentivirus (i.e., lentivirus that did not encode a gene) was available as a 
negative control.  However, these experiments were repeated using a lentivirus that encoded full-
length ovalbumin (lvOVA) as a negative control.  To determine whether the lvOVA was 
functional, I transduced bone marrow DC with the lentivirus (DC.ova) and co-cultured them with 
OT-I T cells.  OT-I T cells proliferated, as indicated by CFSE dilution, and produced high 
amounts of IFN-γ when co-cultured with DC.ova compared to DC that were not transduced 
(DC.null) or when cultured alone (Appendix Figure 14A and B), confirming that lvOVA was a 
functional lentivirus that could transduce DC to express the antigen.  When I tested lvRGS5, 
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using lvOVA as a negative control, I found that lvRGS5 did not confer any therapeutic benefit 
compared to lvOVA (Appendix Figure 14C).  While it is possible that RGS5 is not as 
immunogenic of a target in the BALB/c model as it is in the HHD model, explaining why neither 
peptide nor gene vaccine was effective in inhibition of RENCA tumor growth, there may still be 
alternative RGS5 epitopes that would be more immunologically relevant that were not produced 
with the lentivirus encoding the human homolog of RGS5.  A lentivirus encoding mouse RGS5 
is currently under development to further investigate whether RGS5 could be a therapeutic target 
for vaccination in the RENCA model. 
In my subsequent studies reported in the fourth chapter, the focus of anti-vascular therapy 
was narrowed down to another antigen that was enriched in tumor pericytes: DLK1.  As shown 
in Chapters 2 and 3, DLK1 was an immunologically relevant target for TASA-based vaccines.  
We found that, as was the case in the B16 melanoma and MC38 colon carcinoma models with 
HHD mice, DLK1 was also overexpressed in the tumor-associated pericytes RENCA RCC 
tumors grown in BALB/c mice but not from same animal-matched (tumor-uninvolved) kidney 
tissue.  To recapitulate the studies performed in Chapters 2 and 3, I effectively treated 
established RENCA tumor-bearing animals with a cellular vaccine consisting of DC.IL12 loaded 
with MHC class I (H-2
d
)-restricted DLK1 peptides.  Since clinical trials implementing synthetic 
tumor peptide-based vaccines are restricted to those patients expressing relevant MHC class I 
allotypes, I also developed a lentivirus-based genetic vaccine that could theoretically allow for 
virally-transduced host antigen-presenting cells to cross-prime a more comprehensive anti-DLK1 
T cell repertoire in any treated individual. I showed that therapeutic vaccination (cellular or 
genetic) results in the activation of Type-1 (IFN- producing) DLK1-specific CD8+ T cells in the 
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periphery (spleen) and the improved recruitment of these CD8
+
 T cell populations into/around 
residual blood vessels in the TME.  
In the third chapter, I reported that a reduction in vascularity was observed in 
therapeutically vaccinated animals, implying that immunological targeting of the tumor stroma 
led to vascular “normalization.”  I investigated this phenomenon further in studies reported in the 
fourth chapter and discovered that upon treatment with lvDLK1, blood vessels in RENCA 
tumors exhibited a simple conduit design with tightly-approximated mature pericytes with 
improved structural integrity based on a reduction in vascular leakiness/permeability and 
hypoxia. I also found that vaccination against DLK1 induced a pro-inflammatory TME with 
increased VCAM1
+
 VEC and concomitant production of CXCL10 chemokine.  These 
“normalizing” conditions render the TME to be more permissive to Type 1 T cell recruitment 
and function. 
It has been shown that cutaneous injection with lentivirus leads to transduction and 
activation of skin-derived dendritic cells (bearing a DEC205
+
, CD8
-/lo
 phenotype) (125). These 
skin DC become activated in mice injected i.d. with lentivirus encoding ovalbumin leading to 
DC transport of the OVA antigen to draining lymph nodes leading to stimulation of specific 
CD8
+
 T cells capable of regulating the growth of OVA-expressing melanoma. While my studies 
have focused on increased CD8
+
 TIL upon lentivirus treatment, it is also possible that apoptosis 
of lentivirally-transduced cells (both APC and non-APC, i.e., fibroblasts, etc.) could lead to 
extracellular antigen uptake by DC, and the subsequent induction of Ag-specific CD4
+
 T cells.  
If such activated CD4
+
 T cells were Type-1 in functionality, they would be expected to release 
IFN- into their surroundings, promoting the proinflammatory skewing of the TME as well as 
provide “help” in the development and recruitment of effector CD8+ TIL. 
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While these findings address the immune-mediating effects of an anti-DLK1 vaccine, as 
mentioned in the introduction of Chapter 4, DLK1 also plays an important role as a regulator of 
Notch signaling.  It has been shown that activation of the Wnt/-catenin/Notch signaling 
pathway can lead to vascular normalization (242).  Indeed, our data support such a paradigm, 
with immune-mediated removal of DLK1 expression resulting in the activation of Notch, and 
possibly Wnt signaling (as indicated by increased expression of Frzd2, Frzd4 and Frzd7 
transcription in RENCA tumors harvested from lvDLK1-vaccinated mice), (127) (244) in the 
TME.  As such, inhibition of DLK1 expression may actually reinforce Notch/Wnt signaling it its 
negative regulation of angiogenesis (127, 250).  A more comprehensive prospective investigation 
of the impact of anti-DLK1 vaccine on the Wnt/-catenin/Notch signaling pathway in the 
RENCA TME is clearly warranted.  This question may be at least partially addressed based on 
Notch signaling interference by administration of inhibitors of -secretase (aka ADAM10), an 
enzyme that releases the Notch intracellular domain from its membrane anchor, allowing for the 
activation of Notch-dependent gene transcriptional programs (251).  While global knockouts of 
Notch1 alone or Notch1/4 together are embryonic lethal with evidence of severe vascular defects 
(252), mice with Floxed alleles flanking Notch signaling molecules may be crossed with Cre 
recombinase mice to generate conditional knockouts (253).  Specifically, mice with flox alleles 
of Adam10 bred with Tie2-Cre mice produce mice deficient in Notch signaling in endothelial 
cells that would allow one to observe whether the anti-tumor impact of DLK1-based vaccines 
depends on Notch signaling in the vasculature compartment of the TME. 
 The Notch pathway has also been shown to regulate and shape the immune response.   
Dendritic cells express both Notch and Notch ligands (254), but depending on which ligands 
bind to their Notch receptors, DC may become either proinflammatory or immunosuppressive. 
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Jagged and Delta-like ligands activate the canonical Notch signaling pathway in DC; however, 
DC matured via Jagged1 and LPS secrete high levels of IL-2 and IL-10, resulting in the 
expansion of regulatory T cells.  Notch activation is also involved in a differential secretion of 
cytokines and chemokines by DC subsets (247).  Notch signaling has also been implicated in 
macrophage differentiation and polarization.  Xu et al. showed Notch regulated expression of 
IRF8 and downstream activation of M1 macrophage-promoting genes in response to LPS (66).  
Interestingly, the binding of Notch ligand, Delta-1, inhibits the differentiation of monocytes into 
macrophages, but permits their differentiation into dendritic cells (255), thus supporting the 
functional importance of the context in which the Notch pathway is activated.  In our tumor 
model, we assume a sterile environment, in which TLR4 ligands are absent, and therefore any 
activation of Notch signaling by DC would be expected to be largely proinflammatory in nature.  
Additionally, it has recently been shown that Notch signaling plays an important role in CD8
+
 T 
cell activation (256).  Here the authors showed that antagonism of Notch led to reduced 
expansion and function of tumor antigen-specific CD8
+
 T cells.  Given the inhibitory role of 
DLK1 in Notch signaling, it is possible that vaccine-induced immune-mediated removal of 
DLK1 would also lead to the proinflammatory activation of DC as well as, the increased 
activation and proliferation of endogenous tumor-specific CD8
+
 T cells, resulting in reduced 
tumor growth in vivo.  In addition to removal of Notch antagonism via vaccination, treatment 
with recombinant agonists may further augment T cell activation and function to inhibit tumor 
growth.  In a recent publication by Huang et al., the authors showed that tumor immune escape 
was caused, at least in part, by VEGF-mediated reduction in Notch signaling of T cell precursors 
(65).  Selective stimulation of DLL1-Notch signaling with DLL1-Fc fusion protein rescues T cell 
function and reduces tumor progression.  It would be of interest to observe any additive effects 
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of such a treatment along with an anti-DLK1 vaccine towards promoting a more robust anti-
tumor T cell response. 
In my studies, it was also interesting to observe that the therapeutically “normalized” 
TME post-vaccination with lvDLK1 exhibited a decrease in cell populations expressing stem 
cell-associated markers.  This treatment-associated difference could reflect the ability of vaccine-
induced T cells to: i.) alter the supportive TME in a manner that limits the recruitment, 
accumulation or expansion of such stem cell-like populations in the TME; ii.) decrease hypoxia 
in the TME, leading to transcriptional silencing of hypoxia-responsive stem cell-associated gene 
products (236-238); iii.) promote the corollary cross-priming (120, 208) of specific immune 
responses against alternate tumor-associated stromal antigens, including stem cell antigens, 
leading to the inhibition/eradication of cells expressing these markers in vivo.  It has been 
reported that pericytes exhibit mesenchymal stem cell characteristics in their ability to 
differentiate into mature cells of various tissues (78).  Presumably, by immunologically targeting 
and removal of DLK1
+
 tumor pericytes, we may in fact be eliminating these MSC-like cells from 
the TME.  Additionally, given the role of DLK1 in various stem cell differentiation pathways via 
its repression of Notch signaling, it is also possible that by eliminating DLK1, and thus 
activating Notch signaling in vaccinated animals, stem-like cell populations are permitted to 
undergo terminal differentiation (leading to a loss of stem-cell phenotype).  Lastly, it is 
conceivable that cells bearing stem cell-associated markers may be directly targeted by anti-
DLK1 Tc1, since cells expressing DLK1 may co-express stem cell-associated markers such as 
CD133, c-kit, and SOX2 (257, 258).  These mechanisms of action are clearly not mutually-
exclusive and a combination of these processes may be involved in the biologic outcomes that I 
have reported in my publications and the current thesis document.  
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Although there is a significant delay in tumor progression of animals treated with 
lvDLK1, ultimately tumors progress in these mice.  I have shown that DLK1 antigen cannot be 
detected in tumor-bearing mice treated with a single lvDLK1 injection; however, in progressor 
tumors, it is possible that DLK1 expression could be resumed based on a re-establishment of 
hypoxia or to the suppression of anti-DLK1 T effector cells.  In such a scenario, a prime-boost 
vaccination strategy could be implemented to fortify and sustain T cell memory against the 
DLK1 antigen.  In a preliminary study, I showed no therapeutic benefit of treating animals twice 
with lvDLK1 versus a single injection (data not shown).  To eliminate the possibility of 
neutralizing antibodies against the lentivirus, I also conducted a study in which animals were 
primed with the DC.IL12 loaded with DLK1 peptides, followed by the lvDLK1 boost.  However, 
this study also failed to show a therapeutic advantage over the single lvDLK1 treatment (data not 
shown).  While this may be due to a sub-optimal treatment schedule, it may also be due to 
compensatory transcriptional mechanisms occurring after DLK1 removal from the TME. It has 
been shown that DLK2, an alternate (non-canonical) Notch ligand, that is highly-homologous to 
DLK1, also acts as a Notch signaling antagonist (130) and is upregulated in cells upon 
suppression of DLK1 expression. It is possible that upon vaccine-mediated removal of DLK1, 
expression of DLK2 in the TME may be augmented as a compensatory mechanism to counter-
regulate Notch signaling in support of renewed tumor progression.  Indeed, preliminary studies 
in our group support increased DLK2 expression in RENCA tumors only after successful 
vaccination against DLK1. This would clearly support future development of vaccines capable of 
promoting the coordinate CD8
+
 T cell targeting of both tumor-associated DLK1
+
 and DLK2
+
 
cells, leading to sustained, reinforced Notch signaling in the therapeutic TME 
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Targeting the Notch signaling pathway in the cancer setting is not a novel concept, as 
NOTCH was first identified as an oncogene in T-ALL (259).  Notch has been suggested to 
contribute to carcinogenesis in a variety of ways, including inhibiting cell differentiation, 
inhibiting apoptosis, promoting tumor proliferation (239), promoting the process of EMT (260-
262) and sustaining cancer stem/initiating cell populations (239, 263).  In addition to its role in 
tumor cell maintenance, there is also strong evidence for Notch signaling involvement in tumor-
stroma interactions and in promoting angiogenesis (264).  Indeed, given that Notch signaling has 
been found to be constitutively active in many cancers (239) multiple clinical trials are currently 
testing the safety and efficacy of inhibitors, such as -secretase inhibitors (GSI), in the setting of 
solid tumors (265-268).  Conversely, an emerging body of evidence suggests that Notch 
signaling is critically involved in tumor suppression.  Hence, the deletion or inactivation of 
Notch may lead to increased incidence of squamous cell carcinomas (269).  An inverse 
correlation has also been observed between Notch and HER2 signaling, in which breast cancer 
cell lines with increased HER2 expression exhibit reduced levels of Notch transcriptional activity 
(270).  This functional duality in Notch signaling appears to depend on the activation/repression 
of specific genes along the signaling pathway as well as the cell type in which these signals are 
being modulated (239, 269).  Thus, the context-dependent nature of Notch signaling in cancer 
will likely further complicate attempts to treat patients with therapies that generically target and 
inhibit/inactivate the Notch signaling pathway.   
In conclusion, I have shown that immune targeting of the solid tumor stroma, specifically 
tumor pericytes, as an effective means to inhibit tumor progression.  Activation of the host 
immune response against specific tumor stromal antigens can be achieved via multiple routes, 
including cellular vaccination with engineered dendritic cells or genetic vaccination with 
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lentivirus.  Immune targeting of DLK1, a tumor pericyte antigen involved in the repression of 
Notch signaling and stem cell differentiation, is a promising therapeutic strategy in the setting of 
RCC, as it leads to a vascular normalization event that promotes and/or syngergizes with anti-
tumor effects.  While much remains to be explored in regards to anti-tumor immunotherapy, I 
believe that the results and conclusions presented in this thesis document will greatly enhance the 
foundation for developing more effective treatments for many vascularized forms of solid 
cancer, including RCC. 
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6.0  APPENDIX 
 
Appendix Table 1. RT-PCR primers used in this study. 
Target RT-PCR primers Product (bp) 
CD31 Forward 5’-3’: AGCCCACCAGAGACATGGAA 
Reverse 5’-3’: CTGGCTCTGTTGGAGGCTGT  
337 
DLK1 Forward 5’-3’: CTGCACACCTGGGTTCTCTG 
Reverse 5’-3’: GCATGGGTTAGGGGTACAGC 
202 
EphA2 Forward 5’-3’: GGGGATGCCAACAGCTATAA 
Reverse 5’-3’: CTCCTGCCAGTACCAGAAGC 
232 
gp100 Forward 5’-3’: CATCAATGGGAGCCAGGTGT 
Reverse 5’-3’: TGAAGGTTGAACTGGCGTGA 
296 
HBB Forward 5’-3’: TCAGAAACAGACATCATGGTGC 
Reverse 5’-3’: TAGACAATAGCAGAAAAGGGGC 
480 
NG2 Forward 5’-3’: ACAGACGCCTTTGTTCTGCT 
Reverse 5’-3’: TCGGAAGAAATGTCCAGGAG 
399 
NRP1 Forward 5’-3’: TCCAAGTGGACCTGGGAGAT 
Reverse 5’-3’: TTCACAGCCCAGTAGCTCCA 
299 
NRP2 Forward 5’-3’: CCGGAAGAGACCTGTGGTTG 
Reverse 5’-3’: CCGATCGTCCCTTCCCTATC 
394 
PDGFR Forward 5’-3’: TGCTCCTGGAGAGGCTTCTG 
Reverse 5’-3’: GGAGGAAGTGTTGACTTCATTC 
301 
PSMA Forward 5’-3’: CCTGCGGTGAAGTCCTATCC 
Reverse 5’-3’: GTTTCCAGCAAAGCCAGGTC 
300 
RGS5 Forward 5’-3’: AAGTTGGGAATTCTCCTCCAG 
Reverse 5’-3’: TTCCTCACTGAATTCAGACTTC 
203 
TEM1 Forward 5’-3’: TTCACCAACTGGGCCCAGC 
Reverse 5’-3’: GTTGACACACATCTGCTGGC 
645 
VEGFR1 Forward 5’-3’: CCAACTACCTCAAGAGCAAAC 
Reverse 5’-3’: CCAGGTCCCGATGAATGCAC 
318 
VEGFR2 Forward 5’-3’: ACAGACAGTGGGATGGTCC 
Reverse 5’-3’: AAACAGGAGGTGAGCGCAG 
271 
-actin Forward 5’-3’: GGCATCGTGATGGACTCCG 
Reverse 5’-3’: GCTGGAAGGTGGACAGCGA 
615 
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Appendix Figure 1. Synthetic peptides are competent to bind and stabilize HLA-A2 complexes 
by T2 cells. 
TASA-derived peptides bind to HLA-A2 to a variable degree based on the T2 class I 
stabilization assay. Peptide stabilization of HLA-A2 complexes on the T2 cell line by synthetic 
peptides was assessed as previously described [50]. FluM158-66 (GILGFVFTL) was used as a 
positive HLA-A2 binding control peptide [27]. Overlays of fluorescence histograms are provided 
for each peptide over a 1-10000 nM dose range, as indicated. Evidence for productive 
stabilization of HLA-A2 complexes is supported by a shift in staining intensity to the right vs. 
the no peptide control. Negative control (HLA-A3/A11-binding) HIV-nef73-82 peptide [27] 
failed to promote enhanced HLA-A2 stabilization on T2 cells (data not shown). Data are from 1 
representative experiment of 3 independent assays performed. 
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Appendix Figure 2. Splenic CD8
+
 T cells isolated from the untreated and DC.ψ5-treated 
animals failed to recognize HLA-A2
+
 pericytes and VEC flow sorted from single-cell digests of 
B16 tumors (versus DC.IL12 treatment).  
CD8
+
 T cells isolated from B16-bearing HHD mice left untreated or treated with DC. ψ5 fail to 
recognize tumor-associated pericytes/VEC. CD8+ T cells were MACS-isolated from the spleens 
of tumor-bearing animals that were left untreated (Control) or that were treated with i.t. delivered 
DC.5, as outlined in Figure 4B. These T cells were then cultured with flow-sorted tumor- or 
kidney-derived pericytes or VEC +/- blocking anti-HLA-A2 (BB7.2) or class II (L243) mAbs as 
described in Materials and Methods. Cell-free supernatant was harvested after 24h incubation at 
37°C and analyzed using a specific IFN-γ ELISA. Representative data is presented from 1 of 2 
independent experiments performed. 
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Appendix Figure 3. CD8
+
 TIL isolated from untreated or DC.ψ5-treated melanoma had 
decreased recognition of tumor-associated pericytes (versus DC.IL12 treatment). 
CD8
+
 TIL isolated from B16-bearing HHD mice treated with DC.IL12 recognize tumor-
associated pericytes in an HLA-A2-restricted manner, and fail to recognize HLA-A2neg B16 
tumor cells. TIL were isolated from the day 17 melanomas of mice (treated as indicated) and 
analyzed for reactivity against flow-sorted tumor pericytes as described in Figure 5 for 
intracellular IFN-γ or cell surface expression of translocated CD107 using flow cytometry. To 
assess MHC-restriction in T cell recognition of tumor pericytes, 10 μg of anti-HLA-A2 mAb 
BB7.2 or anti-pan class II mAb L243 were added to cultures during the 4-5h co-incubation 
period prior to flow cytometry-based analysis. Inset numbers reflect the percentage of CD8
+
 T 
cells exhibiting positive response to tumor pericytes or B16 melanoma cells. Data derive from 1 
representative experiment of 2 independent experiments performed. 
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Appendix Table 2. In vivo immunogenicity and anti-tumor efficacy of TASA-based vaccines in 
HHD models. 
Data are summarized from Figures 3 and 5. a+, p < 0.05 versus DC only. bVaccines consisted 
of DC.IL12 pulsed with a pool of 1 or more peptides derived from the indicated TASA. +/-, p < 
0.05 versus DC only for 2 consecutive time points; +, p < 0.05 versus DC only for > 2 
consecutive time points; - not significant at any time point analyzed. cp-value versus mice 
treated with DC only vaccine (from Figure 5C). NS, not significant; NT, not tested. 
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Appendix Figure 4. Expression of TASA in the established MC38 TME.  
(A) MC38 colon carcinoma cells were injected s.c. in the right flank of female HHD mice and 
allowed to establish/progress for 14 days.  Animals were then euthanized, with tumors resected, 
fixed, sectioned and analyzed for expression of the indicated antigens using specific Abs and 
fluorescence microscopy as outlined in Materials and Methods. Specific pAb against NG2 
(green), the indicated antigen of interest (red), and CD3 1 (blue) were used to distinguish 
preferential antigen expression in tumor blood vessel-associated pericytes, VEC, alternate 
stromal cells and/or tumor cells. Images are reflective of those obtained in 3 independent 
experiments performed. (B) MC38 colon carcinoma cell lines, as well as, flow-sorted pericytes 
and VEC (isolated from HHD mice bearing untreated day 14 MC38 tumors) isolated from 
tumors and tumor-uninvolved kidneys were analyzed for expression of the indicated mRNAs 
using RT-PCR as described in Materials and Methods. 
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Appendix Figure 5. Correlation of biologic parameters assessed in the MC38 tumor model 
system.  
Data gathered from Figures 3 and 4 were analyzed for the correlation of indicated markers in a 
pair-wise manner.  Individual data included: i.) CD8
+
 TIL (day 7 post tumor-inoculation (in 
mean numbers per HPF), ii.) CD31
+
 vessels in these same lesions (reported a mean number/10 
HPF), iii.) Tumor size (in mm
2
) on day 24 post-tumor inoculation, and iv.) specific production of 
IFN- from splenic CD8+ T cells harvested from control and vaccinated mice on day 14 post-
tumor inoculation. Each dot represents a control (DC only) or vaccine cohort evaluated (n = 10). 
For panels including in vitro T cell response data, each symbol reflects cumulative response 
against a given TASA (i.e. for DLK1, this represents the summation of responses against each of 
3 peptides, while for RGS5, this reflects response against the single peptide evaluated in these 
studies) . Note that in all instances, except for the IFN- x Tumor Size comparison (n = 13), the 
cohorts vaccinated using DLK1-, NRP1- or PDGFR - derived peptides are not included in the 
indicated analysis, as these mice failed to develop lesions capable of being resected for analyses. 
Linear regression lines are inserted in each panel , with the associated r
2
 values reported in each 
in stance. Lines indicating 95% confidence intervals are also provided in each panel. 
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Appendix Figure 6. Mice protected against initial MC38 tumor challenge as a consequence of 
TASA-based prophylactic vaccination display durable immunity against a subsequent 
challenge with both MC38 sarcoma and B16 melanoma cells.  
(A) HHD mice received prophylactic vaccination as described in Figure 3B with DC.IL12 pulsed 
with an equimolar pool of TASA peptides (per Figure 5A). All animals rejected this initial MC38 
tumor challenge. Fifty days after the initial challenge, animals were challenged with 2 x 10
6
 
MC38 sarcoma (s.c., right flank) and 10
5
 BI6 melanoma (s.c., left flank) cells. (B) The size of 
each tumor was monitored every 3-4 days thereafter in these day 50 immune animals or in naïve, 
control mice. (C) CD8
+
 T cells isolated from day 50 immune animals were analyzed for 
reactivity against flow-sorted PDGFR+CD31neg pericytes or PDGFRnegCD31+ vascular 
endothelial cells (VEC) flow-sorted from the tumor or tumor-uninvolved kidneys of MC38-
bearing HHD mice. Cultured HLA-A2
neg
 MC38 tumor cells were also analyzed as target cells. T 
cells and target cells were co-cultured for 24h prior to analysis of the cell-free supernatant using 
IFN- ELISA as outlined in Materials and Methods. The MHC-restricted nature of specific T cell 
recognition was assessed by inclusion of no mAb, or 10 g/well of anti-HLA-A2 (BB7.2; 
ATCC, Manassas, VA) or anti-H2-IA
b
 mAb (AF6-120.1; Biolegend, San Diego, CA). K = 
Kidney; Tu = Tumor; *p < 0.05 for tumor versus kidney, and for anti-HLA-A2 versus No block 
or anti-H2-IA
b
. 
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Appendix Figure 7. Production of recombinant lvDLK1 and control lvNEG lentiviruses.  
(A) A schematic diagram is provided for lvDLK1. pRSV/5′LTR, RSV LTR and HIV LTR 
chimeric promoter; RRE, Rev response element sequences; CMVp, CMV promoter used to drive 
transgene expression; whole mouse DLK1 gene with V5 reporter tag; SV40p-Blasticidin, SV40 
virus promoter used to drive selection marker blasticidin gene expression; ΔU3/HIV 3′LTR, 
promoter deleted in U3 region so that the lvv become self-inactivated; TOPO cloning sites also 
indicated. 293T cells were transfected with plasmid DNA pLenti-DLK1 (or pLenti-NEG) and 
analyzed for V5 protein expression by immunofluorescence and western blot as shown in B and 
C. HT-1080 cells were infected with lentivirus and analyzed for V5 protein expression by 
western blot and DLK1 protein expression by flow cytometry as shown in C and D, respectively. 
(E) Production of a live functional virus (lvNEG) is confirmed by the formation of blasticidin-
resistant colonies of lentivirus-infected HT-1080 cells stained with crystal violet. 
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Appendix Figure 8. DLK1 is differentially expressed by human RCC-associated pericytes.  
(A) Freshly-harvested RCC tumor and patient-matched normal adjacent kidney tissues (NAT) 
were mechanically and enzymatically digested into single-cell suspension and sorted by flow 
cytometry based on forward scatter and side scatter, DAPI exclusion (to exclude dead cells), a 
CD56negCD45neg phenotype, and then selectively into CD146
+
CD34
neg
 pericytes and 
CD146
+
CD34
+
 VEC populations. (B) mRNA was isolated from sorted pericytes and VEC from 
NAT and RCC tumor and analyzed for DLK1 expression by real-time PCR. Relative mRNA 
expression was normalized to housekeeping HPRT1 transcript expression. (C) RCC tumor and 
NAT sections were analyzed for expression of DLK1 (red) by immunofluorescence microscopy. 
Mean fluorescence intensity +/- SD was quantitated from 3 independent fields per slide as 
described in Materials and Methods. Data are representative those obtained in 3 independent 
experiments performed. *p < 0.05 (t-Test). 
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Appendix Figure 9. Expression of subset of TASA in RENCA tumor pericytes. 
RENCA tumor cells were injected s.c. in the right flank of female BALB/c mice and allowed to 
establish/progress for 21 days.  Freshly-harvested tumor and normal kidneys were mechanically 
and enzymatically digested into single-cell suspension and sorted by flow cytometry.  mRNA 
was isolated from sorted pericytes and VEC analyzed for DLK1, RGS5, PDGFRβ, and TEM1 
expression by real-time PCR. Relative mRNA expression was normalized to housekeeping 
HPRT1 transcript expression. 
 
 
 
Appendix Figure 10. RGS5 expression in RENCA tumor pericytes. 
(A) Pericytes and VEC from human RCC tumors and NAT were sorted by flow cytometry as 
mentioned in Appendix Figure 8.  mRNA was isolated from sorted pericytes and VEC and 
analyzed for RGS5 expression by reverse transcriptase PCR as mentioned in Materials and 
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Methods in Chapter 2.  (B) Relative RGS5 transcript levels were quantified based on 
densitometry values normalized to -actin control.  (C) Pericytes and VEC were sorted from 
mouse RENCA tumors and tumor-uninvolved kidneys as shown in Figure 13.  mRNA was then 
isolated from flow-sorted pericytes and VEC, and analyzed for RGS5 transcript expression by 
real-time PCR. Relative mRNA expression was normalized to housekeeping HPRT1 mRNA 
expression. 
 
 
 
Appendix Figure 11. DC/RGS5 peptide-based vaccine does not impact tumor growth in the 
murine RENCA model of RCC. 
BALB/c mice were inoculated with RENCA tumor cells s.c. on the right flank on day 0. After 
randomizing for similar mean tumor size per treatment cohort (n = 5), mice were injected s.c. on 
their left flank on days 7 and 14 (post-tumor inoculation) PBS, 10
6
 DC.IL12 or 10
6
 DC.IL12 pre-
pulsed with equimolar mix (10 M each) of the 3 synthetic RGS5 peptides. Tumor growth (mean 
± SD) was then monitored over time. 
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Appendix Figure 12. Live lentivirus encoding human RGS5 delayed tumor growth in murine 
RENCA tumor model with increased expression of Type 1 proinflammatory genes in the TME.   
(A) Bone marrow dendritic cells from female BALB/c mice were transduced with lvRGS5 at 
9.6x10
6
 and 8.6x10
8
 pg/ml as previously reported (29) and analyzed for human RGS5 mRNA 
expression by reverse transcriptase PCR with GAPDH as control.  In (B) BALB/c mice were 
inoculated s.c. with RENCA tumor cells in the right flank on day 0. After cohort (n = 4) 
randomization for similar mean tumor size on day 7 post-tumor inoculation, mice were treated 
s.c. in the left flank with 2.4x10
6
 pg/mouse lvRGS5 or PBS control. Tumor size was then 
monitored longitudinally.  * p < 0.05 versus PBS control (student t-test). (C) Day 24 tumors 
were isolated from lvRGS5-treated and PBS-treated control mice as outlined in B, with total 
mRNA extracted for reverse transcriptase PCR using specific primer pairs for mouse CXCL9, 
CXCL10, CXCL11, IL-12p40, IFN-γ, and β-actin.  For these analyses, relative gene expression 
values based on densitometry were normalized to β-actin. 
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Appendix Figure 13. Vaccination of RENCA tumor-bearing mice with lvRGS5 does not 
induce RGS5-specific T cell responses. 
BALB/c mice were inoculated s.c. with RENCA tumor cells in the right flank on day 0. (A) 
After cohort (n = 5) randomization for similar mean tumor size on day 10 post-tumor 
inoculation, mice were treated s.c. in the left flank with 1.44x10
6
, 1.44x10
7
, and 
1.44x10
8
pg/mouse (lv-LO, lv-MED, and lv-HI, respectively) of lvRGS5.  Tumor growth was 
monitored longitudinally. *p < 0.05 versus lower dilutions of lvRGS5 (ANOVA). (B - E) On day 
21 post-tumor inoculation, splenic CD4
+
 and CD8
+
 T cells were isolated from each cohort, 
labeled with CFSE, and co-cultured with syngenic DC transduced with lvRGS5.  In B and C, 
percent proliferation of the CD4
+
 and CD8
+
 T cells, respectively, was measured by CFSE 
dilution using flow cytometry.  In D and E, IFN- ELISA was performed on cell-free 
supernatants collected from the CD4
+
 and CD8
+
 co-cultures, respectively. 
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Appendix Figure 14. Vaccination of RENCA tumor-bearing mice with lvRGS5 does not confer 
additional therapeutic benefit compared to vaccination with lentivirus encoding irrelevant 
antigen ovalbumin.   
In A and B, bone marrow DC from female C57/B6 mice were transduced with lentivirus 
encoding full-length ovalbumin (lvOVA) as previously reported (29) at 1x10
9
 pg/ml and co-
cultured with freshly isolated OT-I T cells.  T cell responses were measured by (A) CFSE 
dilution via flow cytometry and (B) IFN-γ levels from harvested cell-free supernatants via 
ELISA.  In C, BALB/c mice were inoculated s.c. with RENCA tumor cells in the right flank on 
day 0. After cohort (n = 4) randomization for similar mean tumor size on day 14 post-tumor 
inoculation, mice were treated s.c. in the left flank with 2.4x10
6
 pg/mouse lvRGS5 or lvOVA.  
Tumor growth was monitored longitudinally. 
 132 
7.0  BIBLIOGRAPHY 
 
1. Finn, O. J. 2012. Immuno-oncology: understanding the function and dysfunction of the 
immune system in cancer. Annals of oncology : official journal of the European Society 
for Medical Oncology / ESMO 23 Suppl 8: viii6-9. 
2. van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den 
Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by 
cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647. 
3. Novellino, L., C. Castelli, and G. Parmiani. 2005. A listing of human tumor antigens 
recognized by T cells: March 2004 update. Cancer Immunol Immunother 54: 187-207. 
4. Ritchie, A. W., and J. B. deKernion. 1987. The natural history and clinical features of 
renal carcinoma. Semin Nephrol 7: 131-139. 
5. Rohrmann, K., M. Staehler, N. Haseke, A. Bachmann, C. G. Stief, and M. Siebels. 2005. 
Immunotherapy in metastatic renal cell carcinoma. World J Urol 23: 196-201. 
6. Radhakrishnan, S., K. R. Wiehagen, V. Pulko, V. Van Keulen, W. A. Faubion, K. L. 
Knutson, and L. R. Pease. 2007. Induction of a Th1 response from Th2-polarized T cells 
by activated dendritic cells: dependence on TCR:peptide-MHC interaction, ICAM-1, IL-
12, and IFN-gamma. J Immunol 178: 3583-3592. 
7. Krawczyk, C. M., H. Shen, and E. J. Pearce. 2007. Functional plasticity in memory T 
helper cell responses. J Immunol 178: 4080-4088. 
8. Giermasz, A. S., J. A. Urban, Y. Nakamura, P. Watchmaker, R. L. Cumberland, W. 
Gooding, and P. Kalinski. 2009. Type-1 polarized dendritic cells primed for high IL-12 
production show enhanced activity as cancer vaccines. Cancer Immunol Immunother 58: 
1329-1336. 
9. Arroyo, J. C., F. Gabilondo, L. Llorente, M. A. Meraz-Rios, and C. Sanchez-Torres. 
2004. Immune response induced in vitro by CD16- and CD16+ monocyte-derived 
dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell 
vaccines. J Clin Immunol 24: 86-96. 
10. Wesa, A., P. Kalinski, J. M. Kirkwood, T. Tatsumi, and W. J. Storkus. 2007. Polarized 
type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue 
patient TH1-type antimelanoma CD4+ T cell responses in vitro. J Immunother 30: 75-82. 
11. Lipscomb, M. W., L. Chen, J. L. Taylor, C. Goldbach, S. C. Watkins, P. Kalinski, L. H. 
Butterfield, A. K. Wesa, and W. J. Storkus. 2009. Ectopic T-bet expression licenses 
dendritic cells for IL-12-independent priming of type 1 T cells in vitro. J Immunol 183: 
7250-7258. 
12. Uemura, H., K. Fujimoto, M. Tanaka, M. Yoshikawa, Y. Hirao, S. Uejima, K. 
Yoshikawa, and K. Itoh. 2006. A phase I trial of vaccination of CA9-derived peptides for 
 133 
HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin 
Cancer Res 12: 1768-1775. 
13. Iiyama, T., K. Udaka, S. Takeda, T. Takeuchi, Y. C. Adachi, Y. Ohtsuki, A. Tsuboi, S. 
Nakatsuka, O. A. Elisseeva, Y. Oji, M. Kawakami, H. Nakajima, S. Nishida, T. 
Shirakata, Y. Oka, T. Shuin, and H. Sugiyama. 2007. WT1 (Wilms' tumor 1) peptide 
immunotherapy for renal cell carcinoma. Microbiol Immunol 51: 519-530. 
14. Rahma, O. E., E. Ashtar, R. Ibrahim, A. Toubaji, B. Gause, V. E. Herrin, W. M. Linehan, 
S. M. Steinberg, F. Grollman, G. Grimes, S. A. Bernstein, J. A. Berzofsky, and S. N. 
Khleif. A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune 
therapy in metastatic renal cell carcinoma. J Transl Med 8: 8. 
15. Miller, G. A., J. E. Pontes, R. P. Huben, and M. H. Goldrosen. 1985. Humoral immune 
response of patients receiving specific active immunotherapy for renal cell carcinoma. 
Cancer Res 45: 4478-4482. 
16. Tani, K., Y. Nakazaki, H. Hase, K. Takahashi, M. Azuma, J. Ohata, R. Kitamura, F. 
Komine, M. Oiwa, A. Masunaga, T. Maekawa, N. Satoh, D. Adachi, Y. Soda, U. 
Machida, M. Endo, T. Yamazaki, K. Watari, A. Tojo, N. Yamashita, S. Tomikawa, M. 
Eriguchi, H. Hamada, Y. Wakumoto, K. Hanazawa, and K. Okumura. 2000. Progress 
reports on immune gene therapy for stage IV renal cell cancer using lethally irradiated 
granulocyte-macrophage colony-stimulating factor-transduced autologous renal cancer 
cells. Cancer chemotherapy and pharmacology 46 Suppl: S73-76. 
17. Maini, A., N. Nishisaka, Y. Kinoshita, R. F. Jones, C. Y. Wang, and G. P. Haas. 2003. 
Combination of radiation and vaccination with autologous tumor cells expressing IL-2, 
IFN-gamma and GM-CSF for treatment of murine renal carcinoma. In vivo 17: 119-123. 
18. Avigan, D. E., B. Vasir, D. J. George, W. K. Oh, M. B. Atkins, D. F. McDermott, P. W. 
Kantoff, R. A. Figlin, M. J. Vasconcelles, Y. Xu, D. Kufe, and R. M. Bukowski. 2007. 
Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous 
tumor-derived cells in patients with stage IV renal cell carcinoma. Journal of 
immunotherapy 30: 749-761. 
19. Heiser, A., M. A. Maurice, D. R. Yancey, D. M. Coleman, P. Dahm, and J. Vieweg. 
2001. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-
cell responses against antigens expressed by primary and metastatic tumors. Cancer Res 
61: 3388-3393. 
20. Geiger, C., S. Regn, A. Weinzierl, E. Noessner, and D. J. Schendel. 2005. A generic 
RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma. Journal of 
translational medicine 3: 29. 
21. Su, Z., J. Dannull, A. Heiser, D. Yancey, S. Pruitt, J. Madden, D. Coleman, D. 
Niedzwiecki, E. Gilboa, and J. Vieweg. 2003. Immunological and clinical responses in 
metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. 
Cancer Res 63: 2127-2133. 
22. Bleumer, I., D. M. Tiemessen, J. C. Oosterwijk-Wakka, M. C. Voller, K. De Weijer, P. F. 
Mulders, and E. Oosterwijk. 2007. Preliminary analysis of patients with progressive renal 
cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. Journal of 
immunotherapy 30: 116-122. 
23. Wierecky, J., M. Mueller, and P. Brossart. 2006. Dendritic cell-based cancer 
immunotherapy targeting MUC-1. Cancer Immunol Immunother 55: 63-67. 
 134 
24. Walter, S., T. Weinschenk, A. Stenzl, R. Zdrojowy, A. Pluzanska, C. Szczylik, M. 
Staehler, W. Brugger, P. Y. Dietrich, R. Mendrzyk, N. Hilf, O. Schoor, J. Fritsche, A. 
Mahr, D. Maurer, V. Vass, C. Trautwein, P. Lewandrowski, C. Flohr, H. Pohla, J. J. 
Stanczak, V. Bronte, S. Mandruzzato, T. Biedermann, G. Pawelec, E. Derhovanessian, H. 
Yamagishi, T. Miki, F. Hongo, N. Takaha, K. Hirakawa, H. Tanaka, S. Stevanovic, J. 
Frisch, A. Mayer-Mokler, A. Kirner, H. G. Rammensee, C. Reinhardt, and H. Singh-
Jasuja. 2012. Multipeptide immune response to cancer vaccine IMA901 after single-dose 
cyclophosphamide associates with longer patient survival. Nature medicine 18. 
25. Bonini, C., S. P. Lee, S. R. Riddell, and P. D. Greenberg. 2001. Targeting antigen in 
mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells. J 
Immunol 166: 5250-5257. 
26. Hodge, J. W., M. Chakraborty, C. Kudo-Saito, C. T. Garnett, and J. Schlom. 2005. 
Multiple costimulatory modalities enhance CTL avidity. J Immunol 174: 5994-6004. 
27. Kass, E., J. Schlom, J. Thompson, F. Guadagni, P. Graziano, and J. W. Greiner. 1999. 
Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen 
in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer 
Res 59: 676-683. 
28. Yang, S., K. Y. Tsang, and J. Schlom. 2005. Induction of higher-avidity human CTLs by 
vector-mediated enhanced costimulation of antigen-presenting cells. Clin Cancer Res 11: 
5603-5615. 
29. He, Y., J. Zhang, Z. Mi, P. Robbins, and L. D. Falo, Jr. 2005. Immunization with 
lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell 
responses and therapeutic immunity. J Immunol 174: 3808-3817. 
30. Auman, J. T. 2010. Gene therapy: Have the risks associated with viral vectors been 
solved? Current opinion in molecular therapeutics 12: 637-638. 
31. Amato, R. J., W. Shingler, S. Naylor, J. Jac, J. Willis, S. Saxena, J. Hernandez-McClain, 
and R. Harrop. 2008. Vaccination of renal cell cancer patients with modified vaccinia 
ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II 
trial. Clin Cancer Res 14: 7504-7510. 
32. Amato, R. J., W. Shingler, M. Goonewardena, J. de Belin, S. Naylor, J. Jac, J. Willis, S. 
Saxena, J. Hernandez-McClain, and R. Harrop. 2009. Vaccination of renal cell cancer 
patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone 
or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial. Journal 
of immunotherapy 32: 765-772. 
33. Amato, R. J., R. E. Hawkins, H. L. Kaufman, J. A. Thompson, P. Tomczak, C. Szczylik, 
M. McDonald, S. Eastty, W. H. Shingler, J. de Belin, M. Goonewardena, S. Naylor, and 
R. Harrop. 2010. Vaccination of metastatic renal cancer patients with MVA-5T4: a 
randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res 16: 5539-
5547. 
34. Oudard, S., O. Rixe, B. Beuselinck, C. Linassier, E. Banu, J. P. Machiels, M. Baudard, F. 
Ringeisen, T. Velu, M. A. Lefrere-Belda, J. M. Limacher, W. H. Fridman, M. Azizi, B. 
Acres, and E. Tartour. 2011. A phase II study of the cancer vaccine TG4010 alone and in 
combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical 
and immunological findings. Cancer Immunol Immunother 60: 261-271. 
35. Rittig, S. M., M. Haentschel, K. J. Weimer, A. Heine, M. R. Muller, W. Brugger, M. S. 
Horger, O. Maksimovic, A. Stenzl, I. Hoerr, H. G. Rammensee, T. A. Holderried, L. 
 135 
Kanz, S. Pascolo, and P. Brossart. 2011. Intradermal vaccinations with RNA coding for 
TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in 
vaccinated patients. Mol Ther 19: 990-999. 
36. Saenger, Y. M., and J. D. Wolchok. 2008. The heterogeneity of the kinetics of response 
to ipilimumab in metastatic melanoma: patient cases. Cancer Immun 8: 1. 
37. Schlom, J., P. M. Arlen, and J. L. Gulley. 2007. Cancer vaccines: moving beyond current 
paradigms. Clin Cancer Res 13: 3776-3782. 
38. Zhou, J., D. Weng, F. Zhou, K. Pan, H. Song, Q. Wang, H. Wang, Y. Li, L. Huang, H. 
Zhang, W. Huang, and J. Xia. 2009. Patient-derived renal cell carcinoma cells fused with 
allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses. 
Cancer Immunol Immunother 58: 1587-1597. 
39. Jocham, D., A. Richter, L. Hoffmann, K. Iwig, D. Fahlenkamp, G. Zakrzewski, E. 
Schmitt, T. Dannenberg, W. Lehmacher, J. von Wietersheim, and C. Doehn. 2004. 
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients 
with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled 
trial. Lancet 363: 594-599. 
40. Berntsen, A., R. Trepiakas, L. Wenandy, P. F. Geertsen, P. thor Straten, M. H. Andersen, 
A. E. Pedersen, M. H. Claesson, T. Lorentzen, J. S. Johansen, and I. M. Svane. 2008. 
Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a 
clinical phase 1/2 trial. J Immunother 31: 771-780. 
41. Schwaab, T., A. Schwarzer, B. Wolf, T. S. Crocenzi, J. D. Seigne, N. A. Crosby, B. F. 
Cole, J. L. Fisher, J. C. Uhlenhake, D. Mellinger, C. Foster, Z. M. Szczepiorkowski, S. 
M. Webber, A. R. Schned, R. D. Harris, R. J. Barth, Jr., J. A. Heaney, R. J. Noelle, and 
M. S. Ernstoff. 2009. Clinical and immunologic effects of intranodal autologous tumor 
lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy 
in metastatic renal cell carcinoma patients. Clin Cancer Res 15: 4986-4992. 
42. Keilholz, U., J. Weber, J. H. Finke, D. I. Gabrilovich, W. M. Kast, M. L. Disis, J. M. 
Kirkwood, C. Scheibenbogen, J. Schlom, V. C. Maino, H. K. Lyerly, P. P. Lee, W. 
Storkus, F. Marincola, A. Worobec, and M. B. Atkins. 2002. Immunologic monitoring of 
cancer vaccine therapy: results of a workshop sponsored by the Society for Biological 
Therapy. J Immunother 25: 97-138. 
43. Lyerly, H. K. 2003. Quantitating cellular immune responses to cancer vaccines. Semin 
Oncol 30: 9-16. 
44. Nagorsen, D., C. Scheibenbogen, E. Thiel, and U. Keilholz. 2004. Immunological 
monitoring of cancer vaccine therapy. Expert Opin Biol Ther 4: 1677-1684. 
45. Joyce, J. A., and J. W. Pollard. 2009. Microenvironmental regulation of metastasis. Nat 
Rev Cancer 9: 239-252. 
46. Robson, N. C., S. Hoves, E. Maraskovsky, and M. Schnurr. 2010. Presentation of tumour 
antigens by dendritic cells and challenges faced. Current opinion in immunology 22: 137-
144. 
47. Savina, A., and S. Amigorena. 2007. Phagocytosis and antigen presentation in dendritic 
cells. Immunological reviews 219: 143-156. 
48. Turcotte, S., and S. A. Rosenberg. 2011. Immunotherapy for metastatic solid cancers. 
Advances in surgery 45: 341-360. 
 136 
49. Kolbeck, P. C., F. F. Kaveggia, S. L. Johansson, M. T. Grune, and R. J. Taylor. 1992. 
The relationships among tumor-infiltrating lymphocytes, histopathologic findings, and 
long-term clinical follow-up in renal cell carcinoma. Mod Pathol 5: 420-425. 
50. Hernberg, M. 1999. Lymphocyte subsets as prognostic markers for cancer patients 
receiving immunomodulative therapy. Med Oncol 16: 145-153. 
51. Nakano, O., M. Sato, Y. Naito, K. Suzuki, S. Orikasa, M. Aizawa, Y. Suzuki, I. Shintaku, 
H. Nagura, and H. Ohtani. 2001. Proliferative activity of intratumoral CD8(+) T-
lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic 
demonstration of antitumor immunity. Cancer Res 61: 5132-5136. 
52. Kondo, T., H. Nakazawa, F. Ito, Y. Hashimoto, Y. Osaka, K. Futatsuyama, H. Toma, and 
K. Tanabe. 2006. Favorable prognosis of renal cell carcinoma with increased expression 
of chemokines associated with a Th1-type immune response. Cancer Sci 97: 780-786. 
53. Troy, A. J., K. L. Summers, P. J. Davidson, C. H. Atkinson, and D. N. Hart. 1998. 
Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin 
Cancer Res 4: 585-593. 
54. Uzzo, R. G., P. Rayman, V. Kolenko, P. E. Clark, T. Bloom, A. M. Ward, L. Molto, C. 
Tannenbaum, L. J. Worford, R. Bukowski, R. Tubbs, E. D. Hsi, N. H. Bander, A. C. 
Novick, and J. H. Finke. 1999. Mechanisms of apoptosis in T cells from patients with 
renal cell carcinoma. Clin Cancer Res 5: 1219-1229. 
55. Kiertscher, S. M., J. Luo, S. M. Dubinett, and M. D. Roth. 2000. Tumors promote altered 
maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 164: 
1269-1276. 
56. Rayman, P., A. K. Wesa, A. L. Richmond, T. Das, K. Biswas, G. Raval, W. J. Storkus, C. 
Tannenbaum, A. Novick, R. Bukowski, and J. Finke. 2004. Effect of renal cell 
carcinomas on the development of type 1 T-cell responses. Clin Cancer Res 10: 6360S-
6366S. 
57. Tatsumi, T., C. J. Herrem, W. C. Olson, J. H. Finke, R. M. Bukowski, M. S. Kinch, E. 
Ranieri, and W. J. Storkus. 2003. Disease stage variation in CD4+ and CD8+ T-cell 
reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. 
Cancer Res 63: 4481-4489. 
58. Tatsumi, T., L. S. Kierstead, E. Ranieri, L. Gesualdo, F. P. Schena, J. H. Finke, R. M. 
Bukowski, J. Mueller-Berghaus, J. M. Kirkwood, W. W. Kwok, and W. J. Storkus. 2002. 
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against 
MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp 
Med 196: 619-628. 
59. Onishi, T., Y. Ohishi, K. Imagawa, Y. Ohmoto, and K. Murata. 1999. An assessment of 
the immunological environment based on intratumoral cytokine production in renal cell 
carcinoma. BJU Int 83: 488-492. 
60. Griffiths, R. W., E. Elkord, D. E. Gilham, V. Ramani, N. Clarke, P. L. Stern, and R. E. 
Hawkins. 2007. Frequency of regulatory T cells in renal cell carcinoma patients and 
investigation of correlation with survival. Cancer Immunol Immunother 56: 1743-1753. 
61. Saff, R. R., E. S. Spanjaard, A. M. Hohlbaum, and A. Marshak-Rothstein. 2004. 
Activation-induced cell death limits effector function of CD4 tumor-specific T cells. J 
Immunol 172: 6598-6606. 
62. Lu, B., and O. J. Finn. 2008. T-cell death and cancer immune tolerance. Cell Death Differ 
15: 70-79. 
 137 
63. Welford, S. M., and A. J. Giaccia. 2011. Hypoxia and senescence: the impact of 
oxygenation on tumor suppression. Molecular cancer research : MCR 9: 538-544. 
64. Yu, H., M. Kortylewski, and D. Pardoll. 2007. Crosstalk between cancer and immune 
cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7: 41-51. 
65. Huang, Y., L. Lin, A. Shanker, A. Malhotra, L. Yang, M. M. Dikov, and D. P. Carbone. 
2011. Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch 
signaling in T cells rescues T-cell function and inhibits tumor growth. Cancer Res 71: 
6122-6131. 
66. Xu, H., J. Zhu, S. Smith, J. Foldi, B. Zhao, A. Y. Chung, H. Outtz, J. Kitajewski, C. Shi, 
S. Weber, P. Saftig, Y. Li, K. Ozato, C. P. Blobel, L. B. Ivashkiv, and X. Hu. 2012. 
Notch-RBP-J signaling regulates the transcription factor IRF8 to promote inflammatory 
macrophage polarization. Nature immunology 13: 642-650. 
67. Wang, Y. C., F. He, F. Feng, X. W. Liu, G. Y. Dong, H. Y. Qin, X. B. Hu, M. H. Zheng, 
L. Liang, L. Feng, Y. M. Liang, and H. Han. 2010. Notch signaling determines the M1 
versus M2 polarization of macrophages in antitumor immune responses. Cancer Res 70: 
4840-4849. 
68. Hamzah, J., M. Jugold, F. Kiessling, P. Rigby, M. Manzur, H. H. Marti, T. Rabie, S. 
Kaden, H. J. Grone, G. J. Hammerling, B. Arnold, and R. Ganss. 2008. Vascular 
normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453: 410-
414. 
69. Chung, A. S., J. Lee, and N. Ferrara. 2010. Targeting the tumour vasculature: insights 
from physiological angiogenesis. Nat Rev Cancer 10: 505-514. 
70. Ferrara, N., H. P. Gerber, and J. LeCouter. 2003. The biology of VEGF and its receptors. 
Nature medicine 9: 669-676. 
71. Gerhardt, H., M. Golding, M. Fruttiger, C. Ruhrberg, A. Lundkvist, A. Abramsson, M. 
Jeltsch, C. Mitchell, K. Alitalo, D. Shima, and C. Betsholtz. 2003. VEGF guides 
angiogenic sprouting utilizing endothelial tip cell filopodia. The Journal of cell biology 
161: 1163-1177. 
72. Hellstrom, M., L. K. Phng, J. J. Hofmann, E. Wallgard, L. Coultas, P. Lindblom, J. Alva, 
A. K. Nilsson, L. Karlsson, N. Gaiano, K. Yoon, J. Rossant, M. L. Iruela-Arispe, M. 
Kalen, H. Gerhardt, and C. Betsholtz. 2007. Dll4 signalling through Notch1 regulates 
formation of tip cells during angiogenesis. Nature 445: 776-780. 
73. Gerhardt, H., and H. Semb. 2008. Pericytes: gatekeepers in tumour cell metastasis? J Mol 
Med 86: 135-144. 
74. Betsholtz, C., P. Lindblom, and H. Gerhardt. 2005. Role of pericytes in vascular 
morphogenesis. Exs: 115-125. 
75. Bergers, G., S. Song, N. Meyer-Morse, E. Bergsland, and D. Hanahan. 2003. Benefits of 
targeting both pericytes and endothelial cells in the tumor vasculature with kinase 
inhibitors. J Clin Invest 111: 1287-1295. 
76. Xian, X., J. Hakansson, A. Stahlberg, P. Lindblom, C. Betsholtz, H. Gerhardt, and H. 
Semb. 2006. Pericytes limit tumor cell metastasis. J Clin Invest 116: 642-651. 
77. Farrington-Rock, C., N. J. Crofts, M. J. Doherty, B. A. Ashton, C. Griffin-Jones, and A. 
E. Canfield. 2004. Chondrogenic and adipogenic potential of microvascular pericytes. 
Circulation 110: 2226-2232. 
78. Crisan, M., S. Yap, L. Casteilla, C. W. Chen, M. Corselli, T. S. Park, G. Andriolo, B. 
Sun, B. Zheng, L. Zhang, C. Norotte, P. N. Teng, J. Traas, R. Schugar, B. M. Deasy, S. 
 138 
Badylak, H. J. Buhring, J. P. Giacobino, L. Lazzari, J. Huard, and B. Peault. 2008. A 
perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 
3: 301-313. 
79. Fukumura, D., D. G. Duda, L. L. Munn, and R. K. Jain. 2010. Tumor microvasculature 
and microenvironment: novel insights through intravital imaging in pre-clinical models. 
Microcirculation 17: 206-225. 
80. Lin, P., J. A. Buxton, A. Acheson, C. Radziejewski, P. C. Maisonpierre, G. D. 
Yancopoulos, K. M. Channon, L. P. Hale, M. W. Dewhirst, S. E. George, and K. G. 
Peters. 1998. Antiangiogenic gene therapy targeting the endothelium-specific receptor 
tyrosine kinase Tie2. Proc Natl Acad Sci U S A 95: 8829-8834. 
81. Lu, C., T. Bonome, Y. Li, A. A. Kamat, L. Y. Han, R. Schmandt, R. L. Coleman, D. M. 
Gershenson, R. B. Jaffe, M. J. Birrer, and A. K. Sood. 2007. Gene alterations identified 
by expression profiling in tumor-associated endothelial cells from invasive ovarian 
carcinoma. Cancer Res 67: 1757-1768. 
82. Morikawa, S., P. Baluk, T. Kaidoh, A. Haskell, R. K. Jain, and D. M. McDonald. 2002. 
Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J 
Pathol 160: 985-1000. 
83. Berger, M., G. Bergers, B. Arnold, G. J. Hammerling, and R. Ganss. 2005. Regulator of 
G-protein signaling-5 induction in pericytes coincides with active vessel remodeling 
during neovascularization. Blood 105: 1094-1101. 
84. Bondjers, C., M. Kalen, M. Hellstrom, S. J. Scheidl, A. Abramsson, O. Renner, P. 
Lindahl, H. Cho, J. Kehrl, and C. Betsholtz. 2003. Transcription profiling of platelet-
derived growth factor-B-deficient mouse embryos identifies RGS5 as a novel marker for 
pericytes and vascular smooth muscle cells. Am J Pathol 162: 721-729. 
85. Sen, C. K. 2009. Wound healing essentials: let there be oxygen. Wound repair and 
regeneration : official publication of the Wound Healing Society [and] the European 
Tissue Repair Society 17: 1-18. 
86. Bao, B., A. S. Azmi, S. Ali, A. Ahmad, Y. Li, S. Banerjee, D. Kong, and F. H. Sarkar. 
2012. The biological kinship of hypoxia with CSC and EMT and their relationship with 
deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta 
1826: 272-296. 
87. Denko, N. C. 2008. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev 
Cancer 8: 705-713. 
88. Pugh, C. W., and P. J. Ratcliffe. 2003. Regulation of angiogenesis by hypoxia: role of the 
HIF system. Nature medicine 9: 677-684. 
89. Hermann, P. C., S. Bhaskar, M. Cioffi, and C. Heeschen. 2010. Cancer stem cells in solid 
tumors. Seminars in cancer biology 20: 77-84. 
90. Panchision, D. M. 2009. The role of oxygen in regulating neural stem cells in 
development and disease. Journal of cellular physiology 220: 562-568. 
91. Wang, Z., Y. Li, A. Ahmad, A. S. Azmi, D. Kong, S. Banerjee, and F. H. Sarkar. 2010. 
Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging 
concept in overcoming drug resistance. Drug resistance updates : reviews and 
commentaries in antimicrobial and anticancer chemotherapy 13: 109-118. 
92. Wang, Z., Y. Li, D. Kong, and F. H. Sarkar. 2010. The role of Notch signaling pathway 
in epithelial-mesenchymal transition (EMT) during development and tumor 
aggressiveness. Current drug targets 11: 745-751. 
 139 
93. Folkman, J. 2002. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 
15-18. 
94. Heath, V. L., and R. Bicknell. 2009. Anticancer strategies involving the vasculature. Nat 
Rev Clin Oncol 6: 395-404. 
95. Jain, R. K. 2005. Normalization of tumor vasculature: an emerging concept in 
antiangiogenic therapy. Science 307: 58-62. 
96. Ma, J., and D. J. Waxman. 2008. Combination of antiangiogenesis with chemotherapy for 
more effective cancer treatment. Molecular cancer therapeutics 7: 3670-3684. 
97. Greenberg, J. I., and D. A. Cheresh. 2009. VEGF as an inhibitor of tumor vessel 
maturation: implications for cancer therapy. Expert opinion on biological therapy 9: 
1347-1356. 
98. Huang, Y., J. Yuan, E. Righi, W. S. Kamoun, M. Ancukiewicz, J. Nezivar, M. 
Santosuosso, J. D. Martin, M. R. Martin, F. Vianello, P. Leblanc, L. L. Munn, P. Huang, 
D. G. Duda, D. Fukumura, R. K. Jain, and M. C. Poznansky. 2012. Vascular normalizing 
doses of antiangiogenic treatment reprogram the immunosuppressive tumor 
microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 109: 17561-
17566. 
99. Faivre, S., G. Demetri, W. Sargent, and E. Raymond. 2007. Molecular basis for sunitinib 
efficacy and future clinical development. Nat Rev Drug Discov 6: 734-745. 
100. Motzer, R. J., T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski, S. Oudard, 
S. Negrier, C. Szczylik, R. Pili, G. A. Bjarnason, X. Garcia-del-Muro, J. A. Sosman, E. 
Solska, G. Wilding, J. A. Thompson, S. T. Kim, I. Chen, X. Huang, and R. A. Figlin. 
2009. Overall survival and updated results for sunitinib compared with interferon alfa in 
patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590. 
101. Gore, M. E., C. Szczylik, C. Porta, S. Bracarda, G. A. Bjarnason, S. Oudard, S. 
Hariharan, S. H. Lee, J. Haanen, D. Castellano, E. Vrdoljak, P. Schoffski, P. Mainwaring, 
A. Nieto, J. Yuan, and R. Bukowski. 2009. Safety and efficacy of sunitinib for metastatic 
renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10: 757-763. 
102. Escudier, B., J. Roigas, S. Gillessen, U. Harmenberg, S. Srinivas, S. F. Mulder, G. 
Fountzilas, C. Peschel, P. Flodgren, E. C. Maneval, I. Chen, and N. J. Vogelzang. 2009. 
Phase II study of sunitinib administered in a continuous once-daily dosing regimen in 
patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 27: 4068-
4075. 
103. Huang, D., Y. Ding, Y. Li, W. M. Luo, Z. F. Zhang, J. Snider, K. Vandenbeldt, C. N. 
Qian, and B. T. Teh. 2010. Sunitinib acts primarily on tumor endothelium rather than 
tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 70: 1053-1062. 
104. Czabanka, M., M. Vinci, F. Heppner, A. Ullrich, and P. Vajkoczy. 2009. Effects of 
sunitinib on tumor hemodynamics and delivery of chemotherapy. Int J Cancer 124: 
1293-1300. 
105. Zhou, Q., P. Guo, and J. M. Gallo. 2008. Impact of angiogenesis inhibition by sunitinib 
on tumor distribution of temozolomide. Clin Cancer Res 14: 1540-1549. 
106. Ganss, R., E. Ryschich, E. Klar, B. Arnold, and G. J. Hammerling. 2002. Combination of 
T-cell therapy and trigger of inflammation induces remodeling of the vasculature and 
tumor eradication. Cancer Res 62: 1462-1470. 
107. Feldman, E. D., D. M. Weinreich, N. M. Carroll, M. L. Burness, A. L. Feldman, E. 
Turner, H. Xu, and H. R. Alexander, Jr. 2006. Interferon gamma-inducible protein 10 
 140 
selectively inhibits proliferation and induces apoptosis in endothelial cells. Ann Surg 
Oncol 13: 125-133. 
108. van Cruijsen, H., A. A. van der Veldt, L. Vroling, D. Oosterhoff, H. J. Broxterman, R. J. 
Scheper, G. Giaccone, J. B. Haanen, A. J. van den Eertwegh, E. Boven, K. Hoekman, and 
T. D. de Gruijl. 2008. Sunitinib-induced myeloid lineage redistribution in renal cell 
cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin 
Cancer Res 14: 5884-5892. 
109. Finke, J. H., B. Rini, J. Ireland, P. Rayman, A. Richmond, A. Golshayan, L. Wood, P. 
Elson, J. Garcia, R. Dreicer, and R. Bukowski. 2008. Sunitinib reverses type-1 immune 
suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin 
Cancer Res 14: 6674-6682. 
110. Ozao-Choy, J., G. Ma, J. Kao, G. X. Wang, M. Meseck, M. Sung, M. Schwartz, C. M. 
Divino, P. Y. Pan, and S. H. Chen. 2009. The novel role of tyrosine kinase inhibitor in 
the reversal of immune suppression and modulation of tumor microenvironment for 
immune-based cancer therapies. Cancer Res 69: 2514-2522. 
111. Bose, A., J. L. Taylor, S. Alber, S. C. Watkins, J. A. Garcia, B. I. Rini, J. S. Ko, P. A. 
Cohen, J. H. Finke, and W. J. Storkus. 2011. Sunitinib facilitates the activation and 
recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J 
Cancer 129: 2158-2170. 
112. Khong, H. T., and N. P. Restifo. 2002. Natural selection of tumor variants in the 
generation of "tumor escape" phenotypes. Nature immunology 3: 999-1005. 
113. Ebos, J. M., C. R. Lee, W. Cruz-Munoz, G. A. Bjarnason, J. G. Christensen, and R. S. 
Kerbel. 2009. Accelerated metastasis after short-term treatment with a potent inhibitor of 
tumor angiogenesis. Cancer cell 15: 232-239. 
114. Paez-Ribes, M., E. Allen, J. Hudock, T. Takeda, H. Okuyama, F. Vinals, M. Inoue, G. 
Bergers, D. Hanahan, and O. Casanovas. 2009. Antiangiogenic therapy elicits malignant 
progression of tumors to increased local invasion and distant metastasis. Cancer cell 15: 
220-231. 
115. Okaji, Y., N. H. Tsuno, J. Kitayama, S. Saito, T. Takahashi, K. Kawai, K. Yazawa, M. 
Asakage, N. Hori, T. Watanabe, Y. Shibata, K. Takahashi, and H. Nagawa. 2004. 
Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon 
cancer through autoimmunity. Cancer Sci 95: 85-90. 
116. Yoshiura, K., T. Nishishita, T. Nakaoka, N. Yamashita, and N. Yamashita. 2009. 
Inhibition of B16 melanoma growth and metastasis in C57BL mice by vaccination with a 
syngeneic endothelial cell line. Journal of experimental & clinical cancer research : CR 
28: 13. 
117. Matejuk, A., Q. Leng, S. T. Chou, and A. J. Mixson. 2011. Vaccines targeting the 
neovasculature of tumors. Vascular cell 3: 7. 
118. Vujanovic, L., and L. H. Butterfield. 2007. Melanoma cancer vaccines and anti-tumor T 
cell responses. J Cell Biochem 102: 301-310. 
119. Ahmed, F., J. C. Steele, J. M. Herbert, N. M. Steven, and R. Bicknell. 2008. Tumor 
stroma as a target in cancer. Curr Cancer Drug Targets 8: 447-453. 
120. Zhao, X., A. Bose, H. Komita, J. L. Taylor, N. Chi, D. B. Lowe, H. Okada, Y. Cao, D. 
Mukhopadhyay, P. A. Cohen, and W. J. Storkus. 2012. Vaccines targeting tumor blood 
vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in 
HLA-A2 transgenic mice. J Immunol 188: 1782-1788. 
 141 
121. Komita, H., X. Zhao, J. L. Taylor, L. J. Sparvero, A. A. Amoscato, S. Alber, S. C. 
Watkins, A. D. Pardee, A. K. Wesa, and W. J. Storkus. 2008. CD8+ T-cell responses 
against hemoglobin-beta prevent solid tumor growth. Cancer Res 68: 8076-8084. 
122. Chinnasamy, D., Z. Yu, M. R. Theoret, Y. Zhao, R. K. Shrimali, R. A. Morgan, S. A. 
Feldman, N. P. Restifo, and S. A. Rosenberg. 2010. Gene therapy using genetically 
modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic 
tumors in mice. J Clin Invest 120: 3953-3968. 
123. Rocha, F. G., K. C. Chaves, R. Chammas, J. P. Peron, L. V. Rizzo, N. Schor, and M. H. 
Bellini. 2010. Endostatin gene therapy enhances the efficacy of IL-2 in suppressing 
metastatic renal cell carcinoma in mice. Cancer Immunol Immunother 59: 1357-1365. 
124. Kundig, T. M., C. P. Kalberer, H. Hengartner, and R. M. Zinkernagel. 1993. Vaccination 
with two different vaccinia recombinant viruses: long-term inhibition of secondary 
vaccination. Vaccine 11: 1154-1158. 
125. He, Y., J. Zhang, C. Donahue, and L. D. Falo, Jr. 2006. Skin-derived dendritic cells 
induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic 
immunization. Immunity 24: 643-656. 
126. Wang, Y., K. A. Kim, J. H. Kim, and H. S. Sul. 2006. Pref-1, a preadipocyte secreted 
factor that inhibits adipogenesis. The Journal of nutrition 136: 2953-2956. 
127. Falix, F. A., D. C. Aronson, W. H. Lamers, and I. C. Gaemers. 2012. Possible roles of 
DLK1 in the Notch pathway during development and disease. Biochim Biophys Acta 
1822: 988-995. 
128. Waddell, J. N., P. Zhang, Y. Wen, S. K. Gupta, A. Yevtodiyenko, J. V. Schmidt, C. A. 
Bidwell, A. Kumar, and S. Kuang. 2010. Dlk1 is necessary for proper skeletal muscle 
development and regeneration. PLoS One 5: e15055. 
129. Raghunandan, R., M. Ruiz-Hidalgo, Y. Jia, R. Ettinger, E. Rudikoff, P. Riggins, R. 
Farnsworth, A. Tesfaye, J. Laborda, and S. R. Bauer. 2008. Dlk1 influences 
differentiation and function of B lymphocytes. Stem cells and development 17: 495-507. 
130. Sanchez-Solana, B., M. L. Nueda, M. D. Ruvira, M. J. Ruiz-Hidalgo, E. M. Monsalve, S. 
Rivero, J. J. Garcia-Ramirez, M. J. Diaz-Guerra, V. Baladron, and J. Laborda. 2011. The 
EGF-like proteins DLK1 and DLK2 function as inhibitory non-canonical ligands of 
NOTCH1 receptor that modulate each other's activities. Biochim Biophys Acta 1813: 
1153-1164. 
131. Begum, A., Y. Kim, Q. Lin, and Z. Yun. 2012. DLK1, delta-like 1 homolog (Drosophila), 
regulates tumor cell differentiation in vivo. Cancer letters 318: 26-33. 
132. Ranganathan, P., K. L. Weaver, and A. J. Capobianco. 2011. Notch signalling in solid 
tumours: a little bit of everything but not all the time. Nat Rev Cancer 11: 338-351. 
133. Artavanis-Tsakonas, S., K. Matsuno, and M. E. Fortini. 1995. Notch signaling. Science 
268: 225-232. 
134. Lobry, C., P. Oh, and I. Aifantis. 2011. Oncogenic and tumor suppressor functions of 
Notch in cancer: it's NOTCH what you think. J Exp Med 208: 1931-1935. 
135. Radtke, F., and K. Raj. 2003. The role of Notch in tumorigenesis: oncogene or tumour 
suppressor? Nat Rev Cancer 3: 756-767. 
136. Weng, A. P., A. A. Ferrando, W. Lee, J. P. t. Morris, L. B. Silverman, C. Sanchez-
Irizarry, S. C. Blacklow, A. T. Look, and J. C. Aster. 2004. Activating mutations of 
NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306: 269-271. 
 142 
137. Reedijk, M. 2012. Notch signaling and breast cancer. Advances in experimental medicine 
and biology 727: 241-257. 
138. Van Vlierberghe, P., and A. Ferrando. 2012. The molecular basis of T cell acute 
lymphoblastic leukemia. J Clin Invest 122: 3398-3406. 
139. Zhang, X., T. Chen, J. Zhang, Q. Mao, S. Li, W. Xiong, Y. Qiu, Q. Xie, and J. Ge. 2012. 
Notch1 promotes glioma cell migration and invasion by stimulating beta-catenin and NF-
kappaB signaling via AKT activation. Cancer Sci 103: 181-190. 
140. Grudzien, P., S. Lo, K. S. Albain, P. Robinson, P. Rajan, P. R. Strack, T. E. Golde, L. 
Miele, and K. E. Foreman. 2010. Inhibition of Notch signaling reduces the stem-like 
population of breast cancer cells and prevents mammosphere formation. Anticancer 
research 30: 3853-3867. 
141. Sikandar, S. S., K. T. Pate, S. Anderson, D. Dizon, R. A. Edwards, M. L. Waterman, and 
S. M. Lipkin. 2010. NOTCH signaling is required for formation and self-renewal of 
tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. 
Cancer Res 70: 1469-1478. 
142. Pietras, A., D. Gisselsson, I. Ora, R. Noguera, S. Beckman, S. Navarro, and S. Pahlman. 
2008. High levels of HIF-2alpha highlight an immature neural crest-like neuroblastoma 
cell cohort located in a perivascular niche. The Journal of pathology 214: 482-488. 
143. Nicolas, M., A. Wolfer, K. Raj, J. A. Kummer, P. Mill, M. van Noort, C. C. Hui, H. 
Clevers, G. P. Dotto, and F. Radtke. 2003. Notch1 functions as a tumor suppressor in 
mouse skin. Nature genetics 33: 416-421. 
144. Demehri, S., A. Turkoz, and R. Kopan. 2009. Epidermal Notch1 loss promotes skin 
tumorigenesis by impacting the stromal microenvironment. Cancer cell 16: 55-66. 
145. Viatour, P., U. Ehmer, L. A. Saddic, C. Dorrell, J. B. Andersen, C. Lin, A. F. Zmoos, P. 
K. Mazur, B. E. Schaffer, A. Ostermeier, H. Vogel, K. G. Sylvester, S. S. Thorgeirsson, 
M. Grompe, and J. Sage. 2011. Notch signaling inhibits hepatocellular carcinoma 
following inactivation of the RB pathway. J Exp Med 208: 1963-1976. 
146. Klinakis, A., C. Lobry, O. Abdel-Wahab, P. Oh, H. Haeno, S. Buonamici, I. van De 
Walle, S. Cathelin, T. Trimarchi, E. Araldi, C. Liu, S. Ibrahim, M. Beran, J. Zavadil, A. 
Efstratiadis, T. Taghon, F. Michor, R. L. Levine, and I. Aifantis. 2011. A novel tumour-
suppressor function for the Notch pathway in myeloid leukaemia. Nature 473: 230-233. 
147. Dumont, A. G., Y. Yang, D. Reynoso, D. Katz, J. C. Trent, and D. P. Hughes. 2012. 
Anti-tumor effects of the Notch pathway in gastrointestinal stromal tumors. 
Carcinogenesis 33: 1674-1683. 
148. Jonusiene, V., A. Sasnauskiene, N. Lachej, D. Kanopiene, D. Dabkeviciene, S. 
Sasnauskiene, B. Kazbariene, and J. Didziapetriene. 2013. Down-regulated expression of 
Notch signaling molecules in human endometrial cancer. Med Oncol 30: 438. 
149. Noguera-Troise, I., C. Daly, N. J. Papadopoulos, S. Coetzee, P. Boland, N. W. Gale, H. 
C. Lin, G. D. Yancopoulos, and G. Thurston. 2006. Blockade of Dll4 inhibits tumour 
growth by promoting non-productive angiogenesis. Nature 444: 1032-1037. 
150. Ridgway, J., G. Zhang, Y. Wu, S. Stawicki, W. C. Liang, Y. Chanthery, J. Kowalski, R. 
J. Watts, C. Callahan, I. Kasman, M. Singh, M. Chien, C. Tan, J. A. Hongo, F. de 
Sauvage, G. Plowman, and M. Yan. 2006. Inhibition of Dll4 signalling inhibits tumour 
growth by deregulating angiogenesis. Nature 444: 1083-1087. 
 143 
151. Yan, M., C. A. Callahan, J. C. Beyer, K. P. Allamneni, G. Zhang, J. B. Ridgway, K. 
Niessen, and G. D. Plowman. 2010. Chronic DLL4 blockade induces vascular neoplasms. 
Nature 463: E6-7. 
152. Purow, B. 2012. Notch inhibition as a promising new approach to cancer therapy. 
Advances in experimental medicine and biology 727: 305-319. 
153. Zhou, B. B., M. Peyton, B. He, C. Liu, L. Girard, E. Caudler, Y. Lo, F. Baribaud, I. 
Mikami, N. Reguart, G. Yang, Y. Li, W. Yao, K. Vaddi, A. F. Gazdar, S. M. Friedman, 
D. M. Jablons, R. C. Newton, J. S. Fridman, J. D. Minna, and P. A. Scherle. 2006. 
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-
small cell lung cancer. Cancer cell 10: 39-50. 
154. Ostrand-Rosenberg, S. 2008. Immune surveillance: a balance between protumor and 
antitumor immunity. Current opinion in genetics & development 18: 11-18. 
155. Reiman, J. M., M. Kmieciak, M. H. Manjili, and K. L. Knutson. 2007. Tumor 
immunoediting and immunosculpting pathways to cancer progression. Seminars in 
cancer biology 17: 275-287. 
156. Bui, J. D., and R. D. Schreiber. 2007. Cancer immunosurveillance, immunoediting and 
inflammation: independent or interdependent processes? Current opinion in immunology 
19: 203-208. 
157. Slingluff, C. L., Jr., K. A. Chianese-Bullock, T. N. Bullock, W. W. Grosh, D. W. 
Mullins, L. Nichols, W. Olson, G. Petroni, M. Smolkin, and V. H. Engelhard. 2006. 
Immunity to melanoma antigens: from self-tolerance to immunotherapy. Advances in 
immunology 90: 243-295. 
158. Yu, Z., and N. P. Restifo. 2002. Cancer vaccines: progress reveals new complexities. J 
Clin Invest 110: 289-294. 
159. Singh, R., and Y. Paterson. 2007. Immunoediting sculpts tumor epitopes during 
immunotherapy. Cancer Res 67: 1887-1892. 
160. Gajewski, T. F., F. Fallarino, A. Ashikari, and M. Sherman. 2001. Immunization of HLA-
A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral 
blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res 7: 
895s-901s. 
161. Feltkamp, M. C., H. L. Smits, M. P. Vierboom, R. P. Minnaar, B. M. de Jongh, J. W. 
Drijfhout, J. ter Schegget, C. J. Melief, and W. M. Kast. 1993. Vaccination with cytotoxic 
T lymphocyte epitope-containing peptide protects against a tumor induced by human 
papillomavirus type 16-transformed cells. Eur J Immunol 23: 2242-2249. 
162. Hofmeister, V., D. Schrama, and J. C. Becker. 2008. Anti-cancer therapies targeting the 
tumor stroma. Cancer Immunol Immunother 57: 1-17. 
163. Zhang, B., N. A. Bowerman, J. K. Salama, H. Schmidt, M. T. Spiotto, A. Schietinger, P. 
Yu, Y. X. Fu, R. R. Weichselbaum, D. A. Rowley, D. M. Kranz, and H. Schreiber. 2007. 
Induced sensitization of tumor stroma leads to eradication of established cancer by T 
cells. J Exp Med 204: 49-55. 
164. Loberg, R. D., B. A. Gayed, K. B. Olson, and K. J. Pienta. 2005. A paradigm for the 
treatment of prostate cancer bone metastases based on an understanding of tumor cell-
microenvironment interactions. J Cell Biochem 96: 439-446. 
165. Firat, H., M. Cochet, P. S. Rohrlich, F. Garcia-Pons, S. Darche, O. Danos, F. A. 
Lemonnier, and P. Langlade-Demoyen. 2002. Comparative analysis of the CD8(+) T cell 
 144 
repertoires of H-2 class I wild-type/HLA-A2.1 and H-2 class I knockout/HLA-A2.1 
transgenic mice. International immunology 14: 925-934. 
166. Hatano, M., N. Kuwashima, T. Tatsumi, J. E. Dusak, F. Nishimura, K. M. Reilly, W. J. 
Storkus, and H. Okada. 2004. Vaccination with EphA2-derived T cell-epitopes promotes 
immunity against both EphA2-expressing and EphA2-negative tumors. Journal of 
translational medicine 2: 40. 
167. Burg, M. A., R. Pasqualini, W. Arap, E. Ruoslahti, and W. B. Stallcup. 1999. NG2 
proteoglycan-binding peptides target tumor neovasculature. Cancer Res 59: 2869-2874. 
168. Tatsumi, T., J. Huang, W. E. Gooding, A. Gambotto, P. D. Robbins, N. L. Vujanovic, S. 
M. Alber, S. C. Watkins, H. Okada, and W. J. Storkus. 2003. Intratumoral delivery of 
dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats 
local and distant disease in association with broadly reactive Tc1-type immunity. Cancer 
Res 63: 6378-6386. 
169. Mittendorf, E. A., C. E. Storrer, C. D. Shriver, S. Ponniah, and G. E. Peoples. 2005. 
Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells 
recognizing HER2/neu vaccine peptides. Breast cancer research and treatment 92: 85-
93. 
170. Maciag, P. C., M. M. Seavey, Z. K. Pan, S. Ferrone, and Y. Paterson. 2008. Cancer 
immunotherapy targeting the high molecular weight melanoma-associated antigen protein 
results in a broad antitumor response and reduction of pericytes in the tumor vasculature. 
Cancer Res 68: 8066-8075. 
171. Ishizaki, H., T. Tsunoda, S. Wada, M. Yamauchi, M. Shibuya, and H. Tahara. 2006. 
Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides 
derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res 12: 
5841-5849. 
172. Wada, S., T. Tsunoda, T. Baba, F. J. Primus, H. Kuwano, M. Shibuya, and H. Tahara. 
2005. Rationale for antiangiogenic cancer therapy with vaccination using epitope 
peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res 
65: 4939-4946. 
173. Kaplan, C. D., J. A. Kruger, H. Zhou, Y. Luo, R. Xiang, and R. A. Reisfeld. 2006. A 
novel DNA vaccine encoding PDGFRbeta suppresses growth and dissemination of 
murine colon, lung and breast carcinoma. Vaccine 24: 6994-7002. 
174. Liu, W., A. A. Parikh, O. Stoeltzing, F. Fan, M. F. McCarty, J. Wey, D. J. Hicklin, and L. 
M. Ellis. 2005. Upregulation of neuropilin-1 by basic fibroblast growth factor enhances 
vascular smooth muscle cell migration in response to VEGF. Cytokine 32: 206-212. 
175. Silver, D. A., I. Pellicer, W. R. Fair, W. D. Heston, and C. Cordon-Cardo. 1997. Prostate-
specific membrane antigen expression in normal and malignant human tissues. Clin 
Cancer Res 3: 81-85. 
176. Harada, M., S. Matsueda, A. Yao, R. Ogata, M. Noguchi, and K. Itoh. 2004. Prostate-
related antigen-derived new peptides having the capacity of inducing prostate cancer-
reactive CTLs in HLA-A2+ prostate cancer patients. Oncology reports 12: 601-607. 
177. Boss, C. N., F. Grunebach, K. Brauer, M. Hantschel, V. Mirakaj, T. Weinschenk, S. 
Stevanovic, H. G. Rammensee, and P. Brossart. 2007. Identification and characterization 
of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen. Clin 
Cancer Res 13: 3347-3355. 
 145 
178. Christian, S., R. Winkler, I. Helfrich, A. M. Boos, E. Besemfelder, D. Schadendorf, and 
H. G. Augustin. 2008. Endosialin (Tem1) is a marker of tumor-associated myofibroblasts 
and tumor vessel-associated mural cells. Am J Pathol 172: 486-494. 
179. Kuball, J., F. W. Schmitz, R. H. Voss, E. A. Ferreira, R. Engel, P. Guillaume, S. Strand, 
P. Romero, C. Huber, L. A. Sherman, and M. Theobald. 2005. Cooperation of human 
tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-
affinity p53A2.1-specific TCR. Immunity 22: 117-129. 
180. Woodland, D. L., and R. W. Dutton. 2003. Heterogeneity of CD4(+) and CD8(+) T cells. 
Current opinion in immunology 15: 336-342. 
181. !!! INVALID CITATION !!! 
182. Jain, R. K. 2005. Antiangiogenic therapy for cancer: current and emerging concepts. 
Oncology 19: 7-16. 
183. Manzur, M., J. Hamzah, and R. Ganss. 2008. Modulation of the "blood-tumor" barrier 
improves immunotherapy. Cell cycle 7: 2452-2455. 
184. Krupnick, A. S., D. Kreisel, S. H. Popma, K. R. Balsara, W. Y. Szeto, A. M. Krasinskas, 
M. Riha, A. D. Wells, L. A. Turka, and B. R. Rosengard. 2002. Mechanism of T cell-
mediated endothelial apoptosis. Transplantation 74: 871-876. 
185. Suidan, G. L., J. R. McDole, Y. Chen, I. Pirko, and A. J. Johnson. 2008. Induction of 
blood brain barrier tight junction protein alterations by CD8 T cells. PLoS One 3: e3037. 
186. Suzuki, H., K. Shibano, M. Okane, I. Kono, Y. Matsui, K. Yamane, and H. Kashiwagi. 
1989. Interferon-gamma modulates messenger RNA levels of c-sis (PDGF-B chain), 
PDGF-A chain, and IL-1 beta genes in human vascular endothelial cells. Am J Pathol 
134: 35-43. 
187. Molander, C., A. Kallin, H. Izumi, L. Ronnstrand, and K. Funa. 2000. TNF-alpha 
suppresses the PDGF beta-receptor kinase. Experimental cell research 258: 65-71. 
188. Strehl, B., U. Seifert, E. Kruger, S. Heink, U. Kuckelkorn, and P. M. Kloetzel. 2005. 
Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and 
MHC class I antigen processing. Immunological reviews 207: 19-30. 
189. Sun, Y., S. Stevanovic, M. Song, A. Schwantes, C. J. Kirkpatrick, D. Schadendorf, and 
K. Cichutek. 2006. The kinase insert domain-containing receptor is an angiogenesis-
associated antigen recognized by human cytotoxic T lymphocytes. Blood 107: 1476-
1483. 
190. van der Most, R. G., A. Currie, B. W. Robinson, and R. A. Lake. 2006. Cranking the 
immunologic engine with chemotherapy: using context to drive tumor antigen cross-
presentation towards useful antitumor immunity. Cancer Res 66: 601-604. 
191. Butterfield, L. H., A. Ribas, V. B. Dissette, S. N. Amarnani, H. T. Vu, D. Oseguera, H. J. 
Wang, R. M. Elashoff, W. H. McBride, B. Mukherji, A. J. Cochran, J. A. Glaspy, and J. 
S. Economou. 2003. Determinant spreading associated with clinical response in dendritic 
cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9: 998-1008. 
192. Ranieri, E., L. S. Kierstead, H. Zarour, J. M. Kirkwood, M. T. Lotze, T. Whiteside, and 
W. J. Storkus. 2000. Dendritic cell/peptide cancer vaccines: clinical responsiveness and 
epitope spreading. Immunological investigations 29: 121-125. 
193. Lehmann, P. V., E. E. Sercarz, T. Forsthuber, C. M. Dayan, and G. Gammon. 1993. 
Determinant spreading and the dynamics of the autoimmune T-cell repertoire. 
Immunology today 14: 203-208. 
 146 
194. Jandus, C., D. Speiser, and P. Romero. 2009. Recent advances and hurdles in melanoma 
immunotherapy. Pigment cell & melanoma research 22: 711-723. 
195. Seliger, B., M. J. Maeurer, and S. Ferrone. 2000. Antigen-processing machinery 
breakdown and tumor growth. Immunology today 21: 455-464. 
196. Atkins, D., S. Ferrone, G. E. Schmahl, S. Storkel, and B. Seliger. 2004. Down-regulation 
of HLA class I antigen processing molecules: an immune escape mechanism of renal cell 
carcinoma? The Journal of urology 171: 885-889. 
197. Seliger, B., R. Stoehr, D. Handke, A. Mueller, S. Ferrone, B. Wullich, A. Tannapfel, F. 
Hofstaedter, and A. Hartmann. 2010. Association of HLA class I antigen abnormalities 
with disease progression and early recurrence in prostate cancer. Cancer Immunol 
Immunother 59: 529-540. 
198. Li, Y., M. N. Wang, H. Li, K. D. King, R. Bassi, H. Sun, A. Santiago, A. T. Hooper, P. 
Bohlen, and D. J. Hicklin. 2002. Active immunization against the vascular endothelial 
growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med 195: 
1575-1584. 
199. Niethammer, A. G., R. Xiang, J. C. Becker, H. Wodrich, U. Pertl, G. Karsten, B. P. 
Eliceiri, and R. A. Reisfeld. 2002. A DNA vaccine against VEGF receptor 2 prevents 
effective angiogenesis and inhibits tumor growth. Nature medicine 8: 1369-1375. 
200. Nair, S., D. Boczkowski, B. Moeller, M. Dewhirst, J. Vieweg, and E. Gilboa. 2003. 
Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 102: 964-971. 
201. Yu, P., D. A. Rowley, Y. X. Fu, and H. Schreiber. 2006. The role of stroma in immune 
recognition and destruction of well-established solid tumors. Current opinion in 
immunology 18: 226-231. 
202. Singer, C. F., D. Gschwantler-Kaulich, A. Fink-Retter, C. Haas, G. Hudelist, K. 
Czerwenka, and E. Kubista. 2008. Differential gene expression profile in breast cancer-
derived stromal fibroblasts. Breast cancer research and treatment 110: 273-281. 
203. Ghilardi, C., G. Chiorino, R. Dossi, Z. Nagy, R. Giavazzi, and M. Bani. 2008. 
Identification of novel vascular markers through gene expression profiling of tumor-
derived endothelium. BMC genomics 9: 201. 
204. Hanson, J. A., J. W. Gillespie, A. Grover, M. A. Tangrea, R. F. Chuaqui, M. R. Emmert-
Buck, J. A. Tangrea, S. K. Libutti, W. M. Linehan, and K. G. Woodson. 2006. Gene 
promoter methylation in prostate tumor-associated stromal cells. Journal of the National 
Cancer Institute 98: 255-261. 
205. Luo, Y., D. Markowitz, R. Xiang, H. Zhou, and R. A. Reisfeld. 2007. FLK-1-based 
minigene vaccines induce T cell-mediated suppression of angiogenesis and tumor 
protective immunity in syngeneic BALB/c mice. Vaccine 25: 1409-1415. 
206. Dong, Y., J. Qian, R. Ibrahim, J. A. Berzofsky, and S. N. Khleif. 2006. Identification of 
H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis 
and tumor growth. Journal of immunotherapy 29: 32-40. 
207. Firat, H., F. Garcia-Pons, S. Tourdot, S. Pascolo, A. Scardino, Z. Garcia, M. L. Michel, 
R. W. Jack, G. Jung, K. Kosmatopoulos, L. Mateo, A. Suhrbier, F. A. Lemonnier, and P. 
Langlade-Demoyen. 1999. H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile 
animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur J 
Immunol 29: 3112-3121. 
208. Zhao, X., A. Bose, H. Komita, J. L. Taylor, M. Kawabe, N. Chi, L. Spokas, D. B. Lowe, 
C. Goldbach, S. Alber, S. C. Watkins, L. H. Butterfield, P. Kalinski, J. M. Kirkwood, and 
 147 
W. J. Storkus. 2011. Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 
cells reactive against tumor-associated stromal antigens. Mol Ther 19: 805-814. 
209. Yamaguchi, S., T. Tatsumi, T. Takehara, R. Sakamori, A. Uemura, T. Mizushima, K. 
Ohkawa, W. J. Storkus, and N. Hayashi. 2007. Immunotherapy of murine colon cancer 
using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. 
Cancer 110: 1469-1477. 
210. Stuber, G., G. H. Leder, W. T. Storkus, M. T. Lotze, S. Modrow, L. Szekely, H. Wolf, E. 
Klein, K. Karre, and G. Klein. 1994. Identification of wild-type and mutant p53 peptides 
binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel 
major histocompatibility complex class I peptide binding assay. Eur J Immunol 24: 765-
768. 
211. Teng, M. W., J. B. Swann, C. M. Koebel, R. D. Schreiber, and M. J. Smyth. 2008. 
Immune-mediated dormancy: an equilibrium with cancer. Journal of leukocyte biology 
84: 988-993. 
212. Ossowski, L., and J. A. Aguirre-Ghiso. 2010. Dormancy of metastatic melanoma. 
Pigment cell & melanoma research 23: 41-56. 
213. Brown, C. E., R. Starr, C. Martinez, B. Aguilar, M. D'Apuzzo, I. Todorov, C. C. Shih, B. 
Badie, M. Hudecek, S. R. Riddell, and M. C. Jensen. 2009. Recognition and killing of 
brain tumor stem-like initiating cells by CD8+ cytolytic T cells. Cancer Res 69: 8886-
8893. 
214. Dubinett, S., and S. Sharma. 2009. Towards effective immunotherapy for lung cancer: 
simultaneous targeting of tumor-initiating cells and immune pathways in the tumor 
microenvironment. Immunotherapy 1: 721-725. 
215. Inoda, S., Y. Hirohashi, T. Torigoe, R. Morita, A. Takahashi, H. Asanuma, M. 
Nakatsugawa, S. Nishizawa, Y. Tamura, T. Tsuruma, T. Terui, T. Kondo, K. Ishitani, T. 
Hasegawa, K. Hirata, and N. Sato. 2011. Cytotoxic T lymphocytes efficiently recognize 
human colon cancer stem-like cells. Am J Pathol 178: 1805-1813. 
216. Haanen, J. B., A. Baars, R. Gomez, P. Weder, M. Smits, T. D. de Gruijl, B. M. von 
Blomberg, E. Bloemena, R. J. Scheper, S. M. van Ham, H. M. Pinedo, and A. J. van den 
Eertwegh. 2006. Melanoma-specific tumor-infiltrating lymphocytes but not circulating 
melanoma-specific T cells may predict survival in resected advanced-stage melanoma 
patients. Cancer Immunol Immunother 55: 451-458. 
217. Balabanov, R., T. Beaumont, and P. Dore-Duffy. 1999. Role of central nervous system 
microvascular pericytes in activation of antigen-primed splenic T-lymphocytes. Journal 
of neuroscience research 55: 578-587. 
218. Fabry, Z., M. Sandor, T. F. Gajewski, J. A. Herlein, M. M. Waldschmidt, R. G. Lynch, 
and M. N. Hart. 1993. Differential activation of Th1 and Th2 CD4+ cells by murine brain 
microvessel endothelial cells and smooth muscle/pericytes. J Immunol 151: 38-47. 
219. Buckanovich, R. J., A. Facciabene, S. Kim, F. Benencia, D. Sasaroli, K. Balint, D. 
Katsaros, A. O'Brien-Jenkins, P. A. Gimotty, and G. Coukos. 2008. Endothelin B 
receptor mediates the endothelial barrier to T cell homing to tumors and disables immune 
therapy. Nature medicine 14: 28-36. 
220. Helfrich, I., I. Scheffrahn, S. Bartling, J. Weis, V. von Felbert, M. Middleton, M. Kato, S. 
Ergun, and D. Schadendorf. 2010. Resistance to antiangiogenic therapy is directed by 
vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp 
Med 207: 491-503. 
 148 
221. Gaengel, K., G. Genove, A. Armulik, and C. Betsholtz. 2009. Endothelial-mural cell 
signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol 29: 
630-638. 
222. Finke, J. H., R. Tubbs, B. Connelly, E. Pontes, and J. Montie. 1988. Tumor-infiltrating 
lymphocytes in patients with renal-cell carcinoma. Ann N Y Acad Sci 532: 387-394. 
223. Muul, L. M., P. J. Spiess, E. P. Director, and S. A. Rosenberg. 1987. Identification of 
specific cytolytic immune responses against autologous tumor in humans bearing 
malignant melanoma. J Immunol 138: 989-995. 
224. Lokich, J. 1997. Spontaneous regression of metastatic renal cancer. Case report and 
literature review. Am J Clin Oncol 20: 416-418. 
225. Najjar, Y. G., and B. I. Rini. 2012. Novel agents in renal carcinoma: a reality check. 
Therapeutic advances in medical oncology 4: 183-194. 
226. Murphy, G. P., and W. J. Hrushesky. 1973. A murine renal cell carcinoma. Journal of the 
National Cancer Institute 50: 1013-1025. 
227. Klungsoyr, L., and K. F. Stoa. 1954. Spectrophotometric determination of hemoglobin 
oxygen saturation: the method of Drabkin & Schmidt as modified for its use in clinical 
routine analysis. Scand J Clin Lab Invest 6: 270-276. 
228. Stallcup, W. B. 2002. The NG2 proteoglycan: past insights and future prospects. J 
Neurocytol 31: 423-435. 
229. Trevino-Villarreal, J. H., D. A. Cotanche, R. Sepulveda, M. E. Bortoni, O. Manneberg, T. 
Udagawa, and R. A. Rogers. 2011. Host-derived pericytes and Sca-1+ cells predominate 
in the MART-1- stroma fraction of experimentally induced melanoma. The journal of 
histochemistry and cytochemistry : official journal of the Histochemistry Society 59: 
1060-1075. 
230. Sasaki, K., X. Zhu, C. Vasquez, F. Nishimura, J. E. Dusak, J. Huang, M. Fujita, A. Wesa, 
D. M. Potter, P. R. Walker, W. J. Storkus, and H. Okada. 2007. Preferential expression of 
very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central 
nervous system tumors. Cancer Res 67: 6451-6458. 
231. Huang, Y., S. Goel, D. G. Duda, D. Fukumura, and R. K. Jain. 2013. Vascular 
normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 73: 
2943-2948. 
232. Matsumoto, S., H. Yasui, S. Batra, Y. Kinoshita, M. Bernardo, J. P. Munasinghe, H. 
Utsumi, R. Choudhuri, N. Devasahayam, S. Subramanian, J. B. Mitchell, and M. C. 
Krishna. 2009. Simultaneous imaging of tumor oxygenation and microvascular 
permeability using Overhauser enhanced MRI. Proc Natl Acad Sci U S A 106: 17898-
17903. 
233. Wilson, W. R., and M. P. Hay. 2011. Targeting hypoxia in cancer therapy. Nat Rev 
Cancer 11: 393-410. 
234. Cabarcas, S. M., L. A. Mathews, and W. L. Farrar. 2011. The cancer stem cell niche--
there goes the neighborhood? Int J Cancer 129: 2315-2327. 
235. Levesque, J. P., I. G. Winkler, J. Hendy, B. Williams, F. Helwani, V. Barbier, B. Nowlan, 
and S. K. Nilsson. 2007. Hematopoietic progenitor cell mobilization results in hypoxia 
with increased hypoxia-inducible transcription factor-1 alpha and vascular endothelial 
growth factor A in bone marrow. Stem Cells 25: 1954-1965. 
236. Roesch, A., M. Fukunaga-Kalabis, E. C. Schmidt, S. E. Zabierowski, P. A. Brafford, A. 
Vultur, D. Basu, P. Gimotty, T. Vogt, and M. Herlyn. 2010. A temporarily distinct 
 149 
subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. 
Cell 141: 583-594. 
237. Mathieu, J., Z. Zhang, W. Zhou, A. J. Wang, J. M. Heddleston, C. M. Pinna, A. Hubaud, 
B. Stadler, M. Choi, M. Bar, M. Tewari, A. Liu, R. Vessella, R. Rostomily, D. Born, M. 
Horwitz, C. Ware, C. A. Blau, M. A. Cleary, J. N. Rich, and H. Ruohola-Baker. 2011. 
HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 71: 4640-
4652. 
238. Liang, D., Y. Ma, J. Liu, C. G. Trope, R. Holm, J. M. Nesland, and Z. Suo. 2012. The 
hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. BMC 
Cancer 12: 201. 
239. Espinoza, I., and L. Miele. 2013. Notch inhibitors for cancer treatment. Pharmacology & 
therapeutics 139: 95-110. 
240. Neish, A. S., A. J. Williams, H. J. Palmer, M. Z. Whitley, and T. Collins. 1992. 
Functional analysis of the human vascular cell adhesion molecule 1 promoter. J Exp Med 
176: 1583-1593. 
241. Saha, B., S. Jyothi Prasanna, B. Chandrasekar, and D. Nandi. 2010. Gene modulation and 
immunoregulatory roles of interferon gamma. Cytokine 50: 1-14. 
242. Reis, M., C. J. Czupalla, N. Ziegler, K. Devraj, J. Zinke, S. Seidel, R. Heck, S. Thom, J. 
Macas, E. Bockamp, M. Fruttiger, M. M. Taketo, S. Dimmeler, K. H. Plate, and S. 
Liebner. 2012. Endothelial Wnt/beta-catenin signaling inhibits glioma angiogenesis and 
normalizes tumor blood vessels by inducing PDGF-B expression. J Exp Med 209: 1611-
1627. 
243. Abdallah, B. M., and M. Kassem. 2012. New factors controlling the balance between 
osteoblastogenesis and adipogenesis. Bone 50: 540-545. 
244. Ueno, K., H. Hirata, Y. Hinoda, and R. Dahiya. 2013. Frizzled homolog proteins, 
microRNAs and Wnt signaling in cancer. Int J Cancer 132: 1731-1740. 
245. Wang, Y., and H. S. Sul. 2006. Ectodomain shedding of preadipocyte factor 1 (Pref-1) by 
tumor necrosis factor alpha converting enzyme (TACE) and inhibition of adipocyte 
differentiation. Molecular and cellular biology 26: 5421-5435. 
246. Zhang, J., S. Fukuhara, K. Sako, T. Takenouchi, H. Kitani, T. Kume, G. Y. Koh, and N. 
Mochizuki. 2011. Angiopoietin-1/Tie2 signal augments basal Notch signal controlling 
vascular quiescence by inducing delta-like 4 expression through AKT-mediated 
activation of beta-catenin. The Journal of biological chemistry 286: 8055-8066. 
247. Perez-Cabezas, B., M. Naranjo-Gomez, P. Bastos-Amador, G. Requena-Fernandez, R. 
Pujol-Borrell, and F. E. Borras. 2011. Ligation of Notch receptors in human conventional 
and plasmacytoid dendritic cells differentially regulates cytokine and chemokine 
secretion and modulates Th cell polarization. J Immunol 186: 7006-7015. 
248. Rini, B. I., and M. B. Atkins. 2009. Resistance to targeted therapy in renal-cell 
carcinoma. Lancet Oncol 10: 992-1000. 
249. Chi, N., J. K. Maranchie, L. J. Appleman, and W. J. Storkus. 2010. Update on vaccine 
development for renal cell cancer. Research and Reports in Urology 2010: 125-141. 
250. Siekmann, A. F., and N. D. Lawson. 2007. Notch signalling and the regulation of 
angiogenesis. Cell Adh Migr 1: 104-106. 
251. Maraver, A., P. J. Fernandez-Marcos, D. Herranz, M. Canamero, M. Munoz-Martin, G. 
Gomez-Lopez, F. Mulero, D. Megias, M. Sanchez-Carbayo, J. Shen, M. Sanchez-
Cespedes, T. Palomero, A. Ferrando, and M. Serrano. 2012. Therapeutic effect of 
 150 
gamma-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by 
derepression of DUSP1 and inhibition of ERK. Cancer cell 22: 222-234. 
252. Krebs, L. T., Y. Xue, C. R. Norton, J. R. Shutter, M. Maguire, J. P. Sundberg, D. 
Gallahan, V. Closson, J. Kitajewski, R. Callahan, G. H. Smith, K. L. Stark, and T. 
Gridley. 2000. Notch signaling is essential for vascular morphogenesis in mice. Genes & 
development 14: 1343-1352. 
253. Glomski, K., S. Monette, K. Manova, B. De Strooper, P. Saftig, and C. P. Blobel. 2011. 
Deletion of Adam10 in endothelial cells leads to defects in organ-specific vascular 
structures. Blood 118: 1163-1174. 
254. Bugeon, L., L. M. Gardner, A. Rose, M. Gentle, and M. J. Dallman. 2008. Cutting edge: 
Notch signaling induces a distinct cytokine profile in dendritic cells that supports T cell-
mediated regulation and IL-2-dependent IL-17 production. J Immunol 181: 8189-8193. 
255. Ohishi, K., B. Varnum-Finney, R. E. Serda, C. Anasetti, and I. D. Bernstein. 2001. The 
Notch ligand, Delta-1, inhibits the differentiation of monocytes into macrophages but 
permits their differentiation into dendritic cells. Blood 98: 1402-1407. 
256. Kuijk, L. M., M. I. Verstege, N. V. Rekers, S. C. Bruijns, E. Hooijberg, B. O. Roep, T. D. 
de Gruijl, Y. van Kooyk, and W. W. Unger. 2013. Notch controls generation and function 
of human effector CD8+ T cells. Blood 121: 2638-2646. 
257. Metsuyanim, S., O. Harari-Steinberg, E. Buzhor, D. Omer, N. Pode-Shakked, H. Ben-
Hur, R. Halperin, D. Schneider, and B. Dekel. 2009. Expression of stem cell markers in 
the human fetal kidney. PLoS One 4: e6709. 
258. Takebe, N., P. J. Harris, R. Q. Warren, and S. P. Ivy. 2009. Targeting cancer stem cells 
by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8: 97-106. 
259. Ellisen, L. W., J. Bird, D. C. West, A. L. Soreng, T. C. Reynolds, S. D. Smith, and J. 
Sklar. 1991. TAN-1, the human homolog of the Drosophila notch gene, is broken by 
chromosomal translocations in T lymphoblastic neoplasms. Cell 66: 649-661. 
260. Matsuno, Y., A. L. Coelho, G. Jarai, J. Westwick, and C. M. Hogaboam. 2012. Notch 
signaling mediates TGF-beta1-induced epithelial-mesenchymal transition through the 
induction of Snai1. The international journal of biochemistry & cell biology 44: 776-789. 
261. Palagani, V., M. El Khatib, U. Kossatz, P. Bozko, M. R. Muller, M. P. Manns, T. Krech, 
N. P. Malek, and R. R. Plentz. 2012. Epithelial mesenchymal transition and pancreatic 
tumor initiating CD44+/EpCAM+ cells are inhibited by gamma-secretase inhibitor IX. 
PLoS One 7: e46514. 
262. Xie, M., L. Zhang, C. S. He, F. Xu, J. L. Liu, Z. H. Hu, L. P. Zhao, and Y. Tian. 2012. 
Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired 
resistant lung cancer cells. J Cell Biochem 113: 1501-1513. 
263. Koch, U., R. Lehal, and F. Radtke. 2013. Stem cells living with a Notch. Development 
140: 689-704. 
264. Gu, J. W., P. Rizzo, A. Pannuti, T. Golde, B. Osborne, and L. Miele. 2012. Notch signals 
in the endothelium and cancer "stem-like" cells: opportunities for cancer therapy. 
Vascular cell 4: 7. 
265. Krop, I., T. Demuth, T. Guthrie, P. Y. Wen, W. P. Mason, P. Chinnaiyan, N. Butowski, 
M. D. Groves, S. Kesari, S. J. Freedman, S. Blackman, J. Watters, A. Loboda, A. 
Podtelezhnikov, J. Lunceford, C. Chen, M. Giannotti, J. Hing, R. Beckman, and P. 
Lorusso. 2012. Phase I pharmacologic and pharmacodynamic study of the gamma 
 151 
secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin 
Oncol 30: 2307-2313. 
266. Strosberg, J. R., T. Yeatman, J. Weber, D. Coppola, M. J. Schell, G. Han, K. Almhanna, 
R. Kim, T. Valone, H. Jump, and D. Sullivan. 2012. A phase II study of RO4929097 in 
metastatic colorectal cancer. European journal of cancer 48: 997-1003. 
267. Tolcher, A. W., W. A. Messersmith, S. M. Mikulski, K. P. Papadopoulos, E. L. Kwak, D. 
G. Gibbon, A. Patnaik, G. S. Falchook, A. Dasari, G. I. Shapiro, J. F. Boylan, Z. X. Xu, 
K. Wang, A. Koehler, J. Song, S. A. Middleton, J. Deutsch, M. Demario, R. Kurzrock, 
and J. J. Wheler. 2012. Phase I study of RO4929097, a gamma secretase inhibitor of 
Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J 
Clin Oncol 30: 2348-2353. 
268. Fouladi, M., C. F. Stewart, J. Olson, L. M. Wagner, A. Onar-Thomas, M. Kocak, R. J. 
Packer, S. Goldman, S. Gururangan, A. Gajjar, T. Demuth, L. E. Kun, J. M. Boyett, and 
R. J. Gilbertson. 2011. Phase I trial of MK-0752 in children with refractory CNS 
malignancies: a pediatric brain tumor consortium study. J Clin Oncol 29: 3529-3534. 
269. Wang, N. J., Z. Sanborn, K. L. Arnett, L. J. Bayston, W. Liao, C. M. Proby, I. M. Leigh, 
E. A. Collisson, P. B. Gordon, L. Jakkula, S. Pennypacker, Y. Zou, M. Sharma, J. P. 
North, S. S. Vemula, T. M. Mauro, I. M. Neuhaus, P. E. Leboit, J. S. Hur, K. Park, N. 
Huh, P. Y. Kwok, S. T. Arron, P. P. Massion, A. E. Bale, D. Haussler, J. E. Cleaver, J. 
W. Gray, P. T. Spellman, A. P. South, J. C. Aster, S. C. Blacklow, and R. J. Cho. 2011. 
Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell 
carcinoma. Proc Natl Acad Sci U S A 108: 17761-17766. 
270. Osipo, C., P. Patel, P. Rizzo, A. G. Clementz, L. Hao, T. E. Golde, and L. Miele. 2008. 
ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-
secretase inhibitor. Oncogene 27: 5019-5032. 
 
 
